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Abstract 
 
The rise of bacterial resistance has driven the search for new antimicrobials 
employing not only innovative mechanisms of action, but also new characteristics such 
as high selectivity or multitargeting capabilities, whilst the search for new biological 
targets continues. 
Past work demonstrated the potential of carbohydrate chemistry, with a new 
family of surface-active deoxy sugars showing promising antimicrobial activity and 
surprising selectivity towards the Bacillus genus. These characteristics, and the absence 
of correlation between MIC and CMC values for the most active compound, motivated 
the creation of a small library of compounds with the optimal structural features for these 
alkyl deoxy glycosides. Simultaneously, the referred antimicrobial and surfactant 
characteristics showed remarkable differences when compared to the literature of similar 
alkyl glycosides, hence the study of a possible mechanism of action, independent of the 
expected surfactant effect was undertaken. 
The synthesis of antimicrobial derivatives was target oriented, and the 
methodology applied successfully provided the desired analogs in good yields. The 
evaluation of antimicrobial activity allowed to establish the essential structural features 
of this alkyl deoxy glycoside family, leading to dodecyl 2,6-dideoxy-α-L-arabino-
hexopyranoside (1) as the ideal compound for the biological studies. This compound 
showed to be ineffective in the disinfection of surfaces and lack sporicidal activity, 
however, bacterial mutants resistant to the main families of antibiotics revealed unaltered 
susceptibility (MIC=16 µg/mL), and no resistance development was observed after 
continuous exposure. 
The study of the mode of action was initiated by kinetic characterization of the 
bactericidal action, followed by potential target assessment by measuring the differential 
metabolic response when exposed to compound 1, defining the main metabolic pathways 
affected. By establishing a hierarchical relationship model between them, the most 
probable targets were identified: ABC and PTS transport systems and the amino acyl t-
RNA biosynthesis. The creation of mutant libraries helped to understand that the 
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existence of a specific molecular target is very unlikely, since no significant alteration of 
the susceptibility of all mutant libraries to compound 1 was observed.  
Hence, the importance of the bacterial ultrastructures to the antibacterial activity 
was assessed and the susceptibility of protoplasts and spheroplasts revealed that, for 
Gram-negative bacteria, the ultrastructures enveloping the cytoplasmic membrane are 
responsible for the resistance to this compound, while in Gram-positive bacteria they have 
no effect. This also means that the specificity observed to Bacillus spp., here exemplified 
S. aureus, results from the characteristics of the bacterial membrane. The impact of 
compound 1 in the cellular envelope was achieved using AFM techniques, unequivocally 
demonstrating that these compounds cause alterations of cell surface morphology and 
cellular damage, even at sub inhibitory concentrations. 
Additionally, an opportunity emerged to apply this expertise in carbohydrate 
synthesis to develop new tools for early Alzheimer’s disease diagnosis and possible 
therapeutics, aiming to improve solubility and bioavailability of known bioactive 
molecules while providing additional selectivity. A simple, low-cost synthetic strategy 
was paramount to the challenge proposed: the glucoconjugation of fluorescein, quinolone, 
curcumin and cyclohexylpiperazine derivatives. The methodologies chosen resulted in 
the successful glucosilation, particularly for the latter. 
In summary, the multidisciplinary work here reported denotes the capabilities and 
importance of carbohydrate chemistry for all life sciences. Allowed to successfully 
establish a correlation between the structure and the bioactivity of alkyl deoxy glycosides, 
fully characterized the exhibited bactericidal action and provided essential information 
regarding the peculiarities of the mechanism of action, to be used as guidelines for future 
work. Moreover, it demonstrated potential in assisting the development of new tools 
against AD. 
 
Keywords: multidisciplinary, surfactant glycosides, glycosylation, antibacterial, 
mode of action 
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Resumo alargado 
 
O aumento da resistência bacteriana e o consequente declínio na eficácia dos 
antibióticos disponíveis têm impulsionado o desenvolvimento de novos antimicrobianos 
com mecanismos de ação inovadores. Esta realidade representa um desafio ao nível das 
características antibacterianas pretendidas, como a alta seletividade e a capacidade de 
atuação, simultânea, em múltiplos alvos, paralelamente à contínua procura por novos 
alvos biológicos. 
Trabalhos preliminares permitiram demonstrar o potencial da química dos 
carbohidratos na resposta a essas necessidades, tendo sido criada uma nova família de 
desoxi glicósidos surfactantes, que apresentam atividade antimicrobiana promissora e 
seletividade para as bactérias do género Bacillus. Estas características, bem como a 
ausência de correlação entre os valores de CIM e CMC para o composto mais ativo, 
motivaram a criação de uma biblioteca de compostos para determinar a estrutura 
otimizada desta família de antimicrobianos. Simultaneamente, a bioatividade 
demonstrada e as propriedades surfactantes evidenciaram diferenças notáveis quando 
comparadas com os alquil glicósidos semelhantes, encontrados na literatura. Tal facto 
motivou o estudo de um possível mecanismo de ação para estes compostos, independente 
do efeito surfactante esperado. 
Para além disso, procedemos à aplicação da síntese de carbohidratos no 
desenvolvimento de novas ferramentas para o diagnóstico precoce da doença de 
Alzheimer e para possíveis terapias, com o intuito de melhorar a solubilidade e 
biodisponibilidade de moléculas bioativas. Neste contexto, o presente trabalho teve como 
foco a glicoconjugação de estruturas moleculares quelantes de cobre e moléculas 
indutoras de P-gp. 
As estratégias de glicosilação aplicadas tanto na criação de novos 
antimicrobianos, como na melhoria de moléculas bioativas, foram adaptadas às suas 
especificidades. Assim, a glicoconjugação de derivados de fluoresceína, quinolona, 
curcumina e ciclohexilpiperazina, exigiu uma abordagem exploratória. Para além disso, 
a adoção de uma estratégia sintética simples e de baixo custo foi requisito à elaboração 
deste trabalho, pelo que recorremos ao pentaacetato de glucose como doador de glicosilo. 
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Porém, apurou-se que o método de glucoconjugação com trifluoreto de boro como 
catalisador, produziu rendimentos muito baixos (<10%) para todos os compostos. Para 
tornar o sistema mais reativo, o pentaacetato de glucose foi quantitativamente convertido 
no correspondente brometo de glucosilo, e aplicado numa metodologia de transferência 
de fase conduziu a rendimentos mais elevados, particularmente no caso do derivado de 
ciclohexilpiperazina (η=47%).  No entanto, mesmo após terem sido reunidos esforços no 
sentido da otimização deste sistema reacional, não foi possível obter glucósidos de 
curcumina. 
A abordagem sintética para o desenvolvimento de derivados antimicrobianos 
focou-se na síntese de alquil 2-desoxi-glicósidos, com preferencial obtenção dos 
anómeros α, sendo estes os mais ativos. Diante disso e com base em trabalhos 
anteriormente desenvolvidos, a síntese de tridecil, dodecil, undecil, decil, 1,1-H,H-
perfluorodecil e 2-octildodecil 2,6-didesoxi-L-arabino-hexopiranósidos foi realizada pela 
reação de peracetil L-ramnal (obtido a partir de L-ramnose em três etapas), com os álcoois 
correspondentes. Esta glicosilação foi catalisada por bromidrato de trifenilfosfano e 
subsequente desproteção dos produtos obtidos. Tendo sido conseguida a otimização da 
metodologia para um procedimento one-pot, esta permitiu-nos obter melhores 
rendimentos dos produtos sintetizados em, respetivamente, 69%, 67%, 56%, 71% e 59%.  
Adicionalmente, foi sintetizado o composto dodecil 2,6-didesoxi-2-iodo-α-L-
arabino-hexopiranósido (η=61%), através da utilização de NIS como catalisador para a 
glicosilação, dando origem a um composto capaz de ser marcado radioactivamente para 
estudos biológicos. 
Após ter sido concluída, com sucesso, a síntese dos análogos desejados, a 
avaliação da sua atividade antimicrobiana foi realizada por duas metodologias, diluição 
em ágar e microdiluição, tendo esta última sido escolhida para o apuramento de 
bioatividade de outros compostos.  
Tendo sido obtidos os valores de CIM para todos os compostos sintetizados pelo 
grupo de pesquisa, foram estabelecidas as características estruturais essenciais para esta 
família de compostos. Com efeito, as estruturas e as características associadas à maior 
atividade antimicrobiana foram: (i) dodecil aglicona, (ii) dois grupos hidroxilo livres (iii) 
anómero α e (iv) O-glicósidos ou C-glicósidos. Todos estes atributos estão presentes no 
composto dodecil 2,6-didesoxi-α-L-arabino-hexopiranósido (1), que exibiu um valor de 
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CIM de 16 µg / mL, sendo este o composto ideal para prosseguir com os estudos 
biológicos.  
Adicionalmente à determinação da atividade antimicrobiana do composto 1, 
através de estudos focados nas suas potenciais aplicações, foi possível revelar que este 
composto não é eficaz na desinfeção de superfícies e não possui atividade esporicida. No 
entanto, mutantes bacterianos resistentes às principais famílias de antibióticos revelaram 
suscetibilidade inalterada a este composto (CIM = 16 µg / mL) e, para além disso, não se 
verificou nenhum desenvolvimento de resistência após a exposição contínua ao dodecil 
2,6-didesoxi-α-L-arabino-hexopiranósido.  
O estudo do mecanismo de ação foi iniciado empregando uma metodologia de 
time-kill de forma a avaliar os parâmetros cinéticos da ação bactericida observada. Em 
seguida o impacto do composto 1 na vitalidade bacteriana foi avaliado por citometria de 
fluxo, e foi observada uma população celular refratária, potencialmente resistente a estes 
compostos. Isto motivou a utilização de microscopia de fluorescência, recorrendo a uma 
estirpe bacteriana expressora de GFP, de forma a avaliar o impacto deste composto na 
vitalidade bacteriana ao longo do tempo. Uma vez completamente caracterizada a ação 
bactericida, a procura por potenciais alvos moleculares foi iniciada adaptando a 
tecnologia "Phenotype Biolog® microarray" para medir a resposta metabólica diferencial 
à exposição ao composto 1, fornecendo informações sobre quais vias metabólicas 
potencialmente mais afetadas. Desta forma, o impacto em várias vias metabólicas foi 
determinado e estabelecendo-se um modelo de relação hierárquica entre elas, os alvos 
moleculares mais prováveis foram identificados como sendo os sistemas celulares de 
transporte ABC e PTS, e a biossíntese de aminoacil-t-RNA. 
Assim, estudos genéticos foram iniciados, de forma a confirmar a validar os 
potenciais alvos detetados, com a criação de bibliotecas de mutantes por transposição 
aleatória, bem como uma biblioteca obtida por knockout específico dos sistemas de 
transporte, no entanto, nenhuma biblioteca testada mostrou alteração de suscetibilidade, 
o que indica que a existência de um alvo molecular específico é muito improvável.  
Porém, uma vez que todos os hipotéticos alvos estão associados à membrana 
bacteriana, procurou-se avaliar a importância destas ultraestruturas para atividade 
antibacteriana. Foram criados protoplastos e esferoplastos bacterianos pela aplicação de 
lisozima e a determinação da sua susceptibilidade revelou que, no caso das bactérias 
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Gram-negativas, as ultraestruturas que envolvem a membrana citoplasmática são as 
responsáveis pela resistência à ação deste composto. Pelo contrário, nas bactérias Gram-
positivas, elas não têm efeito, significando que a especificidade observada para Bacillus 
spp., exemplificada pela resistência de S. aureus, resulta das características da membrana 
bacteriana. A observação da ação do composto 1 no envelope celular foi efetuada 
utilizando técnicas de AFM, que demonstraram inequivocamente que estes compostos 
causam alterações na morfologia da superfície celular e danos celulares, mesmo em 
concentrações sub-inibitórias. 
Em resumo, o trabalho desenvolvido permitiu estabelecer uma correlação entre a 
estrutura dos alquil desoxiglicósidos e a sua bioatividade. Complementarmente, foi 
possível demonstrar e caracterizar a ação bactericida que exibem, bem como, obter 
informações essenciais sobre as peculiaridades do seu mecanismo de ação, em particular, 
a aparente seletividade para o género Bacillus. 
Assim, acreditamos que o trabalho desenvolvido e os resultados apresentados 
poderão representar um importante contributo para o desenvolvimento científico nas 
matérias que foram objeto de estudo, tanto no que respeita ao combate à progressiva 
resistência bacteriana, como em resposta à necessidade de novas ferramentas contra o 
Alzheimer.  
 
Palavras-chave: multidisciplinar, glicósidos surfactantes, glicosilação, 
antibacteriana, modo de ação 
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1 Antimicrobial resistance and the path forward 
1.1 Antibiotics and the emergence of resistance 
The discovery of antibiotics was a stepping stone in human evolution, since until 
the middle of the nineteenth century, infectious diseases were the main cause of death in 
the developed world1. The accidental discovery of penicillin in 19292 and the later 
development of sulfonamides3 changed that, and since then, modern medicine has been 
dependent on antibiotics and vaccination as the main weapons in fighting off infection. 
Although the first antibiotic largely used was of synthetic origin, a sulfonamide 
named prontosil discovered in 19323,4, the clear majority of antibiotics discovered were 
obtained from Nature or derived from them. The discovery of natural antibacterial 
compounds began fortuitously with penicillin, but the development of a discovery 
platform by Selman Waksman4, revolutionized the search for antibiotics. This “Waksman 
platform” was widely adopted by the pharmaceutical industry, leading to the golden era 
of antibiotic discovery, where most of the major classes of these drugs were obtained 
from microorganisms, namely, aminoglycosides (streptomycin, from Streptomyces 
griseus in 1943), amphenicols (chloramphenicol, from Streptomyces venezuelae in 1947), 
cephalosporins (cephalosporin, from Acremonium sp. in 1945), glycopeptides 
(vancomycin, from Amycolatopsis orientalis in 1953), macrolides (erythromycin, form 
Saccharopolyspora erythraea in 1952), penicillins (penicillin, from Penicillium 
chrysogenum in 1928) and tetracyclines (chlortetracycline, from Streptomyces 
aureofaciens in 1945)3–6. 
From the 40s to the 60s, a great number of antibiotics were revealed and 
immensely used, but natural product discovery quickly started declining, until it became 
impractical due to the increasing difficulty of identifying new classes of antibiotics 
against the background of known compounds7. 
At the same time antibiotic discoveries were made, bacterial resistance was also 
documented. Resistance to penicillin was detected right after its introduction in 1947, due 
to the emergence of β-lactamase causing the hydrolysis of the drug8. This could be 
recalled as the first call of attention to an emerging problem, that was observed in all the 
early used antibacterial compounds4 and culminating in one of the major modern health 
threats. Since natural selection has provided a stream of bioactive small molecules with 
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antibiotic properties it can be expected that the same natural selection, or evolutive 
pressure, would provide the tools to overcome said molecules. This happens to be the 
truth, as it was later discovered by genetical analysis. Microorganisms always had the 
molecular tools to drive resistance, as shown by surveys from all kinds of environmental 
niches and even from samples found in permafrost9,10. This collection of antimicrobial 
resistance genes was designated resistome and it pre-dates the modern antibiotic era by 
far11. 
The resistome consists of a collection of resistance genes in a given environment 
and encompasses both intrinsic and acquired resistance genes, proto-resistance genes and 
cryptic resistance genes12. 
Intrinsic genes refer to the inherent antibacterial resistance and that is independent 
from previous exposure to antimicrobial compounds. These are present in many bacterial 
species, pathogenic and non-pathogenic, and are most commonly associated to reduced 
permeability of the bacterial envelope and the presence of multidrug efflux pumps. 
Generally, these genes are also associated to other essential biological roles for the 
cellular function13,14.  
Acquired resistance genes refers to the bacterial resistance observed in species 
that were susceptible to the antibacterial drugs, but by being in a dense bacterial 
population with resistant bacteria, they acquire the genetic material necessary to express 
reduced susceptibility. This acquisition is performed by horizontal gene transfer, in which 
by a number of diverse mobile genetic elements (like plasmids, transposons and 
integrons), the genetic material is passed between bacteria, mostly of the same species, 
but also from another genus and even other families. The most common resistance 
mechanisms that can be acquired are the target modification and antibiotic inactivation15. 
Lastly, proto-resistance16 and cryptic12,17 resistance genes are those that do not 
confer antibacterial resistance, but these are genes that through mutation or selective 
pressure can be activated to give rise to an antimicrobial resistant phenotype. Cryptic 
genes are often not expressed or with a very low expression, lacking an obvious 
association to antibiotic resistance, while proto-resistance genes are those that have the 
potential to evolve into resistance genes.  
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Our increasing knowledge of the resistome is also modifying the way we think 
about the emergence of antibiotic resistance and the therapeutic approaches to be 
developed in order to overcome this issue12. 
Meanwhile, antibiotics are hardly exclusively for human use, and it is their 
application in a massive scale in livestock and poultry production that allows this 
enormous number of animals to resist disease in such dense populations18,19. In fact, in 
many countries, antimicrobial compounds are used in larger volumes in the animal 
production industry than for human consumption, and, for this reason, it is considered an 
important factor driving the current antimicrobial resistance crisis18,20,21. This incessant 
use in these industries, as well as in human health care, has created extraordinary 
conditions for the deployment of genetic resistance tools, over time causing the selection 
of evermore drug-resistant bacteria. 
The emergence of resistance is also driven by an vital forgotten fact about 
antibiotic therapy: the drugs employed are mainly effective in rapidly growing bacteria. 
However, during the course of treatment, a fractional population survives to treatment, 
designated as persister cells22,23.  
Persisters are not mutants but phenotypic variants produced stochastically in the 
population, known to be formed by all known pathogens.24 These dormant or non-
replicating bacteria are tolerant to antibiotics, but once the concentration of antibiotic 
falls, they resume growth. The number of persisters in each population varies greatly, 
depending in the age of the bacterial culture, the type of antibiotic, the concentration and 
length of exposure, medium composition and other environmental factors. 
During the course of treatment, antibiotics are used and effectively kill most of 
the bacterial population causing the infection, but the remainder will possibly consist in 
a high number of persister cells. Additionally, the macrophage action that ensues any 
infection was observed to greatly contribute to the formation of persister cells25, and 
persisters that give rise to highly antibiotic resistant descendants. The fact that 
macrophage phagocytosis places the bacteria in a nutrient-deprived, aggressive 
environment seems to potentiate the formation of persister cells and activation of toxicity-
resistance mechanisms. 
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Even though the environmental clues and cellular mechanisms that lead to the 
formation of persisters are poorly understood, the connection between the persister 
population and the emergence of antibiotic-resistant bacteria cannot be denied.23,24 
 
1.2 Past and Future of antibiotic discovery 
 
Antibiotic discovery started with the synthesis of Prontosil, a red dye product of a 
trial-and-error synthetic effort by Bayer26. This drug revolutionized healthcare when 
introduced in 1936 and is responsible for many saved lives during the Second World War. 
This spurred antibiotic research leading manufacturers to produce countless variations of 
the drug, some with dire consequences due the lack of testing requirements. 
Penicillin, that was discovered in 1928, was not used until 1939 and even then, 
treatment was still in a research setting, since its isolation in large quantities was difficult 
and supplies were scarce. Challenges to its mass production and subsequent application 
continued until mid-40s27. 
Nonetheless, the pharmaceutical industry was increasingly interested in 
discovering new antimicrobial compounds and several compounds of natural origin 
emerged as a response. The development of tools like the “Waksman platform”, allowed 
a systematic study of samples, a very different approach from the fortuitous discovery as 
in the case of penicillin. This platform consisted in the screening of soil samples for 
microorganisms that showed antimicrobial activity against a test organism by detecting 
areas of growth inhibition on an overlay plate28. Its introduction and vast application by 
the pharmaceutical industry lead us to the golden age of antibiotic discovery, as referred 
before. 
As soon as new antibiotics were discovered, a new problem was raised with 
resistance starting to be observed for all of them (Figure 1), thereby motivating the 
development of synthetically modified derivatives of the original scaffolds. The most 
successful cases of drug development were indeed obtained by creating synthetic 
analogues to natural scaffolds from the golden era of discovery, but even if these 
derivatives proved to be very successful when they were developed, by the end of the 
20th century, the escalating bacterial resistance was a clear indicator that the race was 
lost29. 
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Figure 1. Representative time-line of the year of discovery and application (in green) and detection of 
resistance (in red) for the first discovered antibiotic of each main class. 
Additionally, the number of large pharmaceutical companies actively researching 
novel antimicrobial compounds is in decline since the 80’s30,31, possibly a major factor in 
the lack of appropriate response to such developing issue. The development of therapies 
for other clinical indications that demand longer therapy times and the increased 
profitability that is associated are a major driving force of this trend.  
After the gold age of antibiotic discovery, a stale period ensued, despite several 
different approaches being undertaken, but the truth is that from the 70’s to the  90’s very 
few successful new antibiotics have been introduced in the market5. 
The methods utilized for natural product screening have evolved, but the most 
commonly produced antibacterial compounds have already been identified. Nonetheless, 
a continuous effort exists in searching for potential new sources of antimicrobial natural 
compounds, such as from marine invertebrates and uncultured bacteria5,32, as well as by 
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the modification of previously known compounds to analogues capable of overcoming 
the antibacterial resistance. This rational synthetic effort is supported by the increasing 
knowledge of the antimicrobial mechanism of action and respective mechanisms of 
resistance. In fact, natural products or their derivatives still constitute a substantial part of 
compounds in clinical trials33. 
However, this approach has another profound issue associated: while Nature can 
provide an enormous variety of molecules, the fact is that these compounds may not 
provide an answer to the problem we are facing, if they do not act under novel 
mechanisms of action. This is of critical importance due to the well-known phenomena 
of cross resistance between compounds of the same class of antibiotics5,34. 
The development of genetics and biotechnology allowed the establishment of new 
platforms for drug research29,35. Likewise, developments in high-throughput synthesis 
allowed the creation of large chemical libraries, which could be subjected to 
computational methods of analysis and high-throughput biochemical screening assays. 
But most of the research has been predominantly guided by metrics such as the Lipinski 
rule of five, for orally available drugs36, optimizing them to the human biology, even 
though most antibiotics in clinical use do not conform to those parameters37. At the same 
time, genomics searched for conserved essential proteins, as the major targets to focus 
high-throughput synthesis and rational design, but even if and when inhibitors were 
identified, the access to those targets was not achieved or ineffective. In fact, these 
approaches produced very poor results.38 
Nowadays, some new tools are emerging in the fight against bacterial resistance, 
but instead of being guided by technological advancement, but rather by a new way of 
looking to old approaches. The idea of a single small-molecule that interacts with a single 
target has been mostly abandoned, since the most successful drugs are actually multi-
targeted, and combinatorial and adjuvant approaches offer many advantages over the 
traditional methodologies39. Likewise, instead of a broad-spectrum approach, a species-
selective could have a very favourable outcome in many diseases, being capable of 
preserving microbiota, as well as diminishing some of the selective pressure in non-
pathogenic bacteria.5,40 
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1.2.1 New antibiotic discovery methodologies 
Although today there is a renewed interest in antibiotic discovery and increased 
activity in this field, the past 30 years were of low outputs41. One of the already referred 
reasons for this was the diminishing interest in the search for natural compounds, in 
favour of synthetic discovery, with the screening of large compound libraries. But the 
ineffectiveness of this approach is pushing the research back to natural products, and new 
techniques were developed to allow the study of previously unculturable 
microorganisms42,43. 
Likewise, advances in biotechnology, namely in genomics and metabolomics, 
gave rise to new tools to obtain information about possible biological relevant secondary 
metabolites, without the need for the microorganism growth, compound production and 
isolation, relying instead mainly in in silico approaches34,44. 
1.2.1.1 Methodologies for the discovery of new natural compounds 
These new sources of natural compounds became available due to the 
development of several new discovery platforms and methodologies, a revival of the 
“Waksman platforms”. One of these techniques is in situ cultivation, which involves the 
growth of microorganisms in the presence of a simulated natural environment. In one of 
the earlier accounts of this method, Kaeberlain et al. (2002)45 used diffusion chambers to 
mimic the marine environment and were able to culture two new bacteria. This 
technology developed into the iChip (isolation chip), a high-throughput screening system 
of miniaturized diffuse chambers, that by being placed in the natural environment allow 
for naturally occurring compounds to freely diffuse in the growth media, serving as 
nutrients for the target microorganism, imitating its natural environment in a single 
colony format. Such methodologies already enabled the discovery of new antibiotics, 
namely, lassomycin and teixobactin43,46,47. 
Another emerging approach is co-culture of microorganisms, where the co-
cultivation of two or more microorganisms will lead to an influence in growth and the 
activation of new biosynthetic pathways, from the presence of signaling bioactive 
molecules in the media. Using this method, a new alkaloid, aspergicin, was isolated by 
Zhu et al. (2011)48. (a current overview of this technique was performed by Beppu in 
201749, detailing the specific variables and promotive factors for the co-cultivation of 
several microbial strains.) 
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These approaches must also be paired with suitable identification technologies, 
that are also showing important evolution. Advances in analytical methods such as 
nuclear magnetic resonance (NMR) and mass spectrometry (MS) allow for database-
associated comparison between possible new compounds and the ones already 
discovered, providing at least a reasonable guess to the novelty of a compound. 
This rediscovery problem can also be avoided by taking in silico approaches in 
the selection of microorganisms or compound discovery. One main approach receiving 
important attention is genome mining34. This poses an alternative to the microorganism 
production and posterior analysis of secondary metabolites by directly looking at the 
sequenced genome and determining if any biosynthetic gene clusters involved in the 
production of new antibiotics can be found. A number of bioinformatic tools were already 
used in the discovery of new secondary metabolites: DECIPHER, antiSMASH or 
BAGEL are just examples50–52. Nonetheless, an important limitation to the methodology 
is that it is based in the comparison to known biosynthetic pathways, meaning it will fail 
to detect completely new ones, and is also limited to the effectiveness of its prediction 
capabilities. Still, novel approaches emerge to overcome the limitations and the 
development of metagenomics as of other culture-independent methods show promise in 
their capabilities53.  
Metabolomics, with the development of associated analytical methodologies such 
as UHPLC, FTICR or LC-NMR-MS, is also of growing importance, being ideal for the 
screening and subsequent comparison of secondary metabolites produced by 
microorganisms43,54. Such techniques provide structural information of compounds in 
trace amounts making them useful in identifying potentially valuable biomolecules. This 
capability associated with the database structural comparison allows for rapid 
discrimination against previously known metabolites, preventing redundant analyses. 
1.2.1.2 Sources for new natural compounds 
The increased interest in the discovery of new antimicrobial compounds resulted 
from the recognition of the existence of numerous untapped potential sources of bioactive 
molecules. 
The marine environment is full of microorganisms and its exploration is a very 
recent development, but already provided results as already described before. Marine 
actinomycete species are considered an important source of novel bioactive secondary 
Chapter I 
9 | P a g e  
 
metabolites. Marine sponges and corals are also on the spotlight, providing a plethora of 
secondary metabolites, many of them originated from bacteria colonizing these 
animals55,56. 
Another realm of microorganism with rising popularity are endophytes, 
microorganisms, mainly bacteria and fungi, living symbiotically with plant species for at 
least some of their life cycles. The relationship between these microorganisms is not yet 
well understood, but recent reports57,58 show endophytes as a rich reservoir of natural 
products with antimicrobial activity. Since this is a vastly underexplored realm of 
microorganism, the probabilities of uncovering novel antimicrobials are promising. 
Other sources such as fungi or plants, traditional sources of important bioactive 
compounds, are also relevant and their study continues, but many newly discovered 
compounds are toxic also to eukaryotic cells, derived from the broad antimicrobial 
activity these organisms use as a defense mechanism5. 
1.2.1.3 Other approaches to antibiotic development 
Synthetic methodologies are also observing important advances, since new natural 
compounds represent new scaffolds capable of synthetic improvement. In fact, such 
remarkable improvements in the discovery of novel natural compounds and their 
biosynthesis lead to the development of a new synthetic approach: combinatorial 
biosynthesis.  
Using this approach, instead of a very laborious and costly development of a 
complete synthesis, either by chemical or chemoenzymatic routes, genetic tools are used 
to modify the genes involved in the biosynthesis of the natural products, leading to the 
production of non-natural compounds in vivo. This technique has already seen some cases 
of success, for example with telavancin59, and its application to sugar-containing 
antibiotics is a recent focus60. 
1.2.1.3.1 Combinatorial and adjuvant approaches 
An increasing understanding that the most successful antibiotics interact with multiple 
biological targets has motivated the study of possible combinatorial approaches. The 
combination of antibiotics that is used nowadays was mainly a product of clinical 
experimentation and focused in acting against a broader spectrum of pathogens, when 
facing an unknown infectious agent, a synergetic activity or to suppress the emergence of 
resistance. What has gained increased interest is the study of possible combinations that, 
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although not necessarily synergistic, will act in multiple cellular targets, increasing the 
effectiveness of therapy and reducing the resistance emergence.41,61 
Adjuvants are another type of combinations, where a non-antibiotic compound inhibits 
some enzymatic target or biological process, effectively potentiating the activity of an 
antibiotic with which it is combined. A good example of this is the combination of 
amoxicillin with clavulanic acid, which inhibits the b-lactamase drug resistance enzymes. 
With our increasing knowledge of the antibiotic resistance mechanisms, such approaches 
will be of increasing value, by developing molecules capable of returning antimicrobial 
activity to known drugs39,62. 
1.2.1.4 Species-selective antibiotics 
A narrow spectrum of activity has been traditionally considered a big 
disadvantage in antibiotic discovery, and narrowly selective compounds identified using 
high-throughput screening platforms, were mostly discarded do to this same 
characteristic, in favor of wider-spectrum alternatives. Nonetheless, the study of the 
mechanism of action of some species-selective compounds revealed that they tend to 
focus metabolic targets well-conserved within the species or group63,64.  
However, species-selective compounds are now considered to be the future of 
antibiotic discovery5,65, due to the many, now considered, advantages this approach 
contains. Firstly, the search of selective compounds eliminates nuisance compounds as 
the pan-assay interference compounds (PAINS), which by their surfactant or DNA 
intercalating properties have a broad spectrum of activities66. At the same time, such 
compounds of narrow-spectrum of activity are also not likely to be toxic to humans, since 
the hypothetical targets present in a strict group of microorganisms are very unlikely to 
be present in humans.  
Resistance development is also hindered by a species-specific approach, because 
when using broad spectrum antibiotics, if one species develops a resistant mechanism, it 
can pass it onto others by lateral gene transfer. Such processes would be inviable with  
such antibiotics.40,67 
Another very important advantage of a species-selective therapy is the 
preservation of our microbiota during the course of treatment. Our gut microbiome is now 
recognized as a major player in human health, both physically and mentally, and so its 
preservation is paramount to future therapies. Additionally, specific antibiotics would 
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allow not only to protect the microbiome but also to manipulate it. This is of major 
interest, since nowadays the best methodology to positively impact an unhealthy 
microbiome is by fecal microbiota transplantation. With the development of selective 
antimicrobials, the suppression of unfavorable species could be achieved, leading to a 
cure for a number of gastrointestinal diseases and even neurological conditions68,69. 
1.2.2 Alternatives to antibiotics 
With the difficulties presented by the development of new antibiotics, other 
approaches have emerged with growing interest. One of such approaches is the 
development of antivirulence methodologies either using antibodies or small-molecule 
inhibitors of virulence mechanisms. Since this approach poses little or no selective 
pressure in the microorganisms, the emergence of resistance should be much lower than 
with traditional therapy.70,71 
Another emerging possibility is the utilization of RNA-guided nucleases of 
CAS/CRISPR (clustered regularly-interspaced short palindromic repeats). Such systems 
that recognize unique DNA sequences could target and kill specific pathogens or inactive 
resistance mechanisms. The main limitation for this approach resides in a suitable 
delivery method, generally involving bacteriophage vectors.72 
 
1.3 Biological Targets 
Traditional antimicrobial compounds resulted from screening efforts, and so, their 
target was studied after proven efficacy. But in the past decade, with the development of 
genetics, the possibility of finding possible targets first, and then develop molecules 
capable of interacting with them became the main paradigm in antibiotic research. 
Genomics and the essential gene search were acclaimed as the tools that would provide 
us with an abundance of new antibiotics, but, as was already discussed, such approach 
was a failure. Certainly, multiple factors are responsible for this, and overcoming this 
issue will most likely require a paradigm shift in the way we use modern tools and a 
redefinition of what we consider druggable targets. 
The fact remains that current antibiotic therapy targets only a small subset of 
microbial essential processes, and most new antibiotics developed are focused in 
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incremental modifications of known drugs, and so, focusing on the same targets.73 In 
recent years, only a single new target has emerged with impact in antibiotic research: a 
cell-wall synthesis component, lipid II74. 
 
 
 
 
 
 
 
 
 
 
 
Nonetheless, the search in the genome for essential genes has provided numerous 
new antibacterial targets of potential utility33, however it is evident that the idea that any 
gene required for microbial growth creates a plausible drug target is incorrect. The 
successful prioritization of the new “possible targets” is one of the major necessities for 
the successful implementation of these tools. At the same time, the conditional context of 
gene essentiality is being overlooked, possibly neglecting valuable targets as well38,73. 
Since the search for new antimicrobials is focused in in vitro activity, without 
consideration for the host-pathogen context, this also represents an opportunity for 
possible new targets related to host-pathogen interaction and bacterial infection. 
Additionally, broad-spectrum activity is also preferred and screened for, resulting in the 
discard of new narrow spectrum antimicrobials with possibly new mechanisms of action, 
due to highly specific targets. 
With the current abundance of possible targets and no well-defined method of 
prioritization, several studies and literature reviews are emerging aiming to sort out this 
problem73,75–77.  
Figure 2. The major targets of antibiotic action 
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One transversal issue to most of the “new targets” resides in the fact that they are 
present in the cytoplasm and many small-molecule inhibitor hits fail to enter the bacterial 
cell, possibly because the “Lipinski rules” that heavily influenced the physicochemical 
profiles of most industrial chemical libraries are not optimized for antibiotics. This was 
noted by Lipinski himself78, since antibiotics were outliers from the orally active 
compounds used to formulate the rule. Given this, a compilation of rules or exceptions 
could be derived from studying known antibiotics, and it would be a better guide to 
bacterial permeation. 
1.3.1 The bacterial cell envelope 
The bacterial cell envelope is the gateway to the cell for all exogenous compounds 
and, as such, is one of the main factors impacting the success of antibiotic therapy. These 
structures are fundamentally different from thouse of animal eukaryotic cell cells (that 
consists of only a plasma membrane), providing good inherent specificity to drugs that 
target them. 
Bacteria are generally classified in two main groups, the Gram positive and Gram 
negative, depending on their Gram-stain retention properties, a classification based in the 
marked differences in their ultrastructures. 
Gram positive bacteria have a simpler bacterial envelope, consisting of a 
cytoplasmic membrane (CM) surrounded by the cell wall. This outer layer is comprised 
mainly of peptidoglycan (a polymer constituted by a carbohydrate backbone and amino 
acid residues) forming a thick mesh, anchored to the membrane by lipoteichoic acid 
(LTA) strands.79,80 Between these two ultrastructures exists a small periplasmic space 
(Figure 3). 
The more complex Gram-negative bacteria possess two membranes, an outer 
membrane (OM) and an inner membrane (IM), and the periplasmic space in between 
them, where a small cell wall is present, also constituted by peptidoglycan (Figure 3). The 
OM is an asymmetric lipid bilayer, with the outer leaflet being constituted mainly by 
lipopolysaccharides (LPS)81, and the inner leaflet by glycerophospholipids. The LPS 
content is responsible for the low permeability of the membrane and is one of the main 
obstacles to the passage of drugs. Passage through this membrane is mostly mediated by 
the presence of porins.80,82 
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The IM is constituted mainly by phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG) and cardiolipin (CL), much like the CM, apart from the 
presence of LTA in the latter. In these membranes, the lipids’ proportion vary greatly 
according to the bacterial species (as well as the lipid composition, with some species 
having unique lipids), but generally Gram-negative bacteria are richer in PE83. 
 
 
Figure 3. Schematic presentation of the membrane architecture of Gram-negative and Gram-positive 
bacteria. 
1.3.1.1 Membranes as antimicrobial targets 
Antimicrobial agents targeting the cell wall are widely used, as all β-lactam 
antibiotics act by inhibiting cell wall synthesis, but bacterial resistance to these antibiotics 
is widely spread and quickly acquired4. That is why pursuing other biological targets is 
essential. Additionally, for the activity of most drugs and their access to the bacterial 
cytoplasm, the peptidoglycan does not represent a barrier, and so, the membrane emerges 
as an attractive target. 
Some drugs exploit the presence of anionic lipids on the surface of bacterial 
membranes, specially Gram-negatives, as means of displaying increased selectivity, for 
example, aminoglycosides, that display multiple cationic moieties in physiological 
conditions, and are even actively transported into Gram-negative bacteria80. Many 
membrane-active antibiotics display the same strategy83,84, whether by specifically 
targeting certain lipids (like daptomycin, that exhibits an PG-dependent insertion on the 
membrane) or by using electrostatic interactions to guide their surfactant action to the 
bacterial membrane (e.g. polymyxins, that link to the LPS and then their aliphatic moiety 
destabilizes the bacterial membrane). 
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The factors that affect the action of membrane-active antibiotics are not limited to 
bacterial surface charge, covering also the more general amphiphilicity of the membrane, 
as well as other physical properties like fluidity/packing, curvature and clustering of 
lipids83. Since these are core properties of bacterial membranes, they are associated to the 
multiple phenomena that can lead to bacterial death when under the action of surfactant 
agents. The disruption of the cell membrane bulk biophysical properties, by altering the 
lipid packing, clustering or curvature, leads to membrane reorganization and/or 
permeability alteration, and consequently an alteration of the proton motive force (PMF), 
and even the destabilization and/or loss of function of membrane embedded proteins. 
Given the properties discussed, membrane-active antimicrobials present several 
benefits, such as the fact that their target is essential and preserved among various 
bacterial species, with various degrees of similarity, possibly allowing for selectivity 
tuning. Also, they can be active against slow-growing or dormant bacteria (persisters for 
example) as well as in biofilms and display a low potential for the development of 
resistance, probably resulting from the multi-targeted mode of action. In general, they 
possess a favourable pharmacokinetic profile, and have displayed a great potential to 
serve as chemosensitizer, increasing the activity of other antibiotics80,83. 
However, the same properties represent some drawbacks of this type of approach, 
with the accessibility of the bacterial membranes and selectivity over animal cells 
representing some major concerns, and the reason why surfactant compounds are known 
and feared for their promiscuity that leads to undesired secondary effects.80,83 
Nonetheless, the interest in developing compounds active by membrane-
associated interactions or targets is growing and several new compounds are showing 
promising results80,85. Additionally, membrane-active antibiotic classes like lipopeptides, 
lipoglycopeptides and polymyxins (non-ribosomal peptides) are already in use, and the 
study of the mechanism of action of several members of this type of antibiotics revealed 
that many possess other targets in addition to the bacterial membrane (examples are 
daptomycin that also inhibits several biosynthetic pathways86, or telavancin that also 
inhibits the transglycosylation of peptidoglycan cell wall synthesis87). 
The introduction of amphiphilicity in already known antibiotics and the 
development of derivatives with a membrane-active moiety is an approach that can aid in 
overcoming antibiotic resistance, telavancin being one great example of success 
(resulting from the conjugation of vancomycin with a lipid moiety), but it is still an 
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underexplored approach. Lipid conjugation to aminoglycoside antibiotics is one of the 
emerging tendencies of this approach80,88. 
1.4 Carbohydrate contribution to antibiotic therapy 
Most carbohydrate-based antimicrobial drugs in use nowadays are of natural or 
semisynthetic origin, and constitute some of the major classes of antibiotics, such as 
aminoglycosides or macrolides. Nonetheless, most highly successful antimicrobial drugs 
like erythromycin, vancomycin or gentamycin, even if they represent different antibiotic 
classes, they have the same general mechanism of action: antimicrobial effect due to 
inhibition of protein synthesis. This can be interpreted as a sign that these compounds 
contain a vast untapped potential, since the single mechanism of action does not translate 
the enormousness of diverse biological roles associated to carbohydrates. 
The design of new carbohydrate-based antimicrobials has received special 
attention in drug discovery due to the increasing need of novel antibiotics, with novel 
mechanisms of action.89,90 The exploration of other cellular structures as potential targets, 
such as the bacterial cell wall or membrane has gained increasing relevance for this 
reason. 
Carbohydrates also display important therapeutic roles, not as a drug but as a 
potentiating system for available antibiotics. One example of this are host-guest 
complexation strategies, capable of enhancing the solubility, stability permeability and 
bioavailability of a guest drug91,92. These host-guest complexation methodologies rely in 
the non-covalent bonding between two molecules, and carbohydrates such as 
cyclodextrin are a prime example of the capabilities of this technique with applications in 
sensor, biomedical and pharmaceutical technologies93,94. Additionally, by applying these 
systems to antibiotic delivery it is possible to counteract the antibiotic resistance 
mechanisms, such as enzymatic degradation or efflux systems and even raise the affinity 
for modified targets by altering antibiotic conformation95. 
But carbohydrates and their ubiquitous in living organisms are also being studied 
as possible tools aiding the fight on antimicrobial resistance in multiple of ways: from 
wound dressing technology, since the risk of wound infection96 is a major concern in 
multiple cases, to the use of cell-surface carbohydrate recognition as an infection 
diagnostic tool97. Also, therapeutic alternatives already referred such as vaccines and anti-
adhesion therapies are highly reliant in carbohydrates. 
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1.4.1 Alkyl glycosides and their antimicrobial potential 
Since the 70’s the antimicrobial properties of saturated fatty acids and fatty 
alcohols are well known and were already in use98,99. Most of the early efforts to improve 
their application potential via conjugation were promoted by the oil industry, as a possible 
expansion on the use of oleochemicals as antimicrobial agents100. 
 
Figure 4. Exemplar structural representation of glycerol (A) and glucose (B) conjugates 
The most abundantly studied conjugates were with glycerol and glucose (Figure 
4), but also with other mono- and oligosaccharides. These conjugates were used as 
surfactants in cleaning solutions and cosmetics but also played roles as preservatives and 
emulsifiers101–104. Another important role of an alkyl glycoside (more specifically octyl 
glucoside) was in the solubilization of membrane proteins while retaining their 
activity105,106. 
The antimicrobial and surfactant capabilities of alkyl glycosides gained renewed 
notoriety in the 90’s, with the increasing environmental concern, since such compounds 
are generally of low toxicity and biodegradable and both the sugar moieties and the alkyl 
chains could be obtained from renewable sources107. 
Several studies on their surfactant and antimicrobial properties show the great 
potential of these compounds and will be discussed in greater detail in chapter 3.1. Alkyl 
glycosides have been continuously used in cosmetics, as preservatives and in cleaning 
and disinfection solutions, but also in drug formulations showing the potential as 
druggable compounds103,108,109. 
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2 Carbohydrate chemistry as an answer 
Carbohydrates are a class of compounds with the unique feature of exhibiting 
multifunctionalization, being one of the most abundant types of compounds in Nature. 
They are ubiquitous in the biological processes of all forms of life and their presence 
helped fuel traditional medicine with natural compounds, as well as providing valuable 
scaffolds for synthetic drug discovery. In fact, carbohydrates are regarded as important 
sustainable raw materials, and the increasing knowledge of their involvement on 
biological processes demonstrates the vast chemical space that is available for further 
exploration89. 
Carbohydrate chemistry is a promising area of research in the forthcoming years, 
as the role of carbohydrates has become more relevant specially in signaling and 
recognition, leading to important advances in immunotherapy and protein therapeutics. 
2.1 Carbohydrate fundamentals 
The term 'carbohydrate' (French 'hydrate de carbone') was applied originally to 
monosaccharides, in recognition of the fact that their empirical composition can be 
expressed as Cn(H2O)n. However, the term is now used generically in a wider sense. The 
generic term 'carbohydrate' includes monosaccharides, oligosaccharides and 
polysaccharides as well as substances derived from monosaccharides by reduction of the 
carbonyl group, by oxidation of one or more terminal groups, or by replacement of one 
or more hydroxy group(s) by a hydrogen atom, an amino group, a thiol group or similar 
heteroatomic groups. It also includes derivatives of these compounds. The term 'sugar' is 
frequently applied to monosaccharides and lower oligosaccharides110. 
Carbohydrates are subjected to a functional isomerization when in solution 
(Scheme 1). This isomerization from acyclic monosaccharide to the heterocyclic ring can 
be interrupted, if the anomeric position (the hemiacetal marked 1 in scheme 1) is 
conjugated to any other molecule, since the acetal functionality then formed is not 
converted into the corresponding ketone or aldose. In nature, carbohydrates are often 
found in this glycoside form, in which the sugar residues are stable maintaining its 
multifunctional potential111. 
 
Chapter I 
19 | P a g e  
 
 
Scheme 1. Acyclic and cyclic forms of D‐glucose in water at pH 7 
 
Carbohydrates are also stereochemically rich molecules and all ring carbon atoms 
of a cyclic saccharide are chirality centers, presenting one of the two configurations (R, 
S). Given this asymmetry, several isomers exist, e.g. 16 for a carbohydrate having 4 
chirality centers, all of them being stereoisomers. Additionally, all have several 
conformers possible, for example, for pyranose the most common are the chair (1C4 and 
4C1) and boat conformations, but many more exist
112. 
Monosaccharides are classified in two series, designated by the symbols D or L. 
Assignment of a monosaccharide to any of these series relies on the orientation of the 
projection of the bond linking the chirality center furthest from the carbonyl group to the 
hydroxy group, in the Fischer projection. If that hydroxy group is on the right, the 
molecule belongs to the D series, and accordingly if it is oriented to the left, the molecule 
belongs to the L series. The new chirality center, generated by the cyclization, also gives 
rise to two diastereoisomers, called anomers. In hexopyranosides, anomeric α- or β-
configuration is defined by a trans or cis orientation of the anomeric OR group in relation 
to the hydroxymethyl group linked to C-5, respectively. 
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All these characteristics of carbohydrate core structures, with defined three-
dimensional orientation of their substituents, provide them with unique capabilities in 
biological recognition systems113,114. 
2.2 Glycosylation 
Sugar moieties in Nature are typically found as oligo- and polysaccharides or 
glycoconjugates comprising a variety of biological molecules. The most frequent linkage 
between monosaccharide residue and aglycone is designated glycosidic bond, an acetal 
functionality that can be obtained by a glycosylation reaction115. In Nature these 
glycosidic bonds are formed in highly regulated systems using enzymes, ensuring this 
way a high selectivity and efficiency. Chemists, on the other hand, must rely on extensive 
multi-step procedures in order to obtain glycosylated derivatives with the desired 
anomeric configuration, often at the cost of efficiency (if total yield is taken as an 
efficiency marker for starting material / product transformation). Such studies nonetheless 
gave rise to numerous procedures that can be used to achieve an impressive variety of 
products116,117. 
Despite the enormous variety of systems, all glycosylation reactions involve a 
glycosyl donor with a leaving group in its anomeric position that will react with a glycosyl 
acceptor in the presence of an activator, often with the formation of an oxacarbenium 
ion118 (Scheme 2). One could be fooled by the simplicity of such description, but several 
imperative factors must be taken into account. Regarding the glycosyl donor, one of the 
most important factors is the protection of any unsubstituted hydroxy group, in order to 
obtain selectivity to the chosen acceptor, since its own -OH groups are in most cases also 
nucleophiles, competing in the reaction and leading to mixtures. One of the few examples 
where this can be desirable, is the formation of polysaccharides of a single monomer.  
This regioselectivity issue has caused the continuous development of efficient 
protection/deprotection systems, capable of resisting to the reaction conditions, until 
deprotection is desired119,120. 
 
Scheme 2. General glycosylation mechanism 
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Under certain conditions, these protecting groups can also aid in the formation of 
a desired monomer, due to the neighbouring group effect. This effect is present when an 
electron rich protecting group is used in the neighbouring position (position 2) to the 
anomeric position, leading to the stabilization of the formed glycosyl cation by the 
delocalization of the positive charge, stabilized by resonance (Scheme 3). Several groups 
have been studied as capable of influencing the result of the glycosylation reaction, and 
a broad range of effects can be obtained121,122. Most of the compounds bearing acyl groups 
in position 2 lead to the formation of 1,2-trans glycosides (Scheme 3), that are 
stereochemically less hindered, but in the absence of neighbouring group participation, 
most of the systems generate the α anomer, due to the anomeric effect.  
 
Scheme 3. Mechanistic representation of the neighbouring effect in a glycosylation reaction. 
 
This general preference for the α anomer, the anomeric effect, can be explained 
by two models, since no consensus exists123–125. The first interpretation to emerge, with 
its roots in the discovery of the anomeric effect123, is based on the electrostatic interaction 
of the dipoles formed by the endocyclic oxygen and the polar bond between the exocyclic 
heteroatom and the anomeric carbon (C1) (Figure 5a), a dipole-dipole interaction that 
does not exist in the case of an equatorial substituent, and better explains the reverse 
anomeric effect. The other popular model is based in the electron delocalization from the 
oxygen lone pairs to the vacant antibonding orbital σCY* (Figure 5b), a n → σ* 
hyperconjugative interaction that better explains the observed variations in bond lengths 
and angles around the anomeric position124,125. The aforementioned reverse anomeric 
effect consists in the preference of an equatorial position, occurring in positively charged 
anomeric substituents126. Additionally, the lone pair from an exocyclic heteroatom can 
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stabilize a preferred anomeric position, by interaction with the endocyclic C-O pair, 
giving rise to the exo-anomeric effect127. 
 
Figure 5. Most common models explaining the anomeric effect. a - electrostatic model; b - 
hiperconjugation model 
 
Another factor that can influence the outcome of a glycosylation reaction is the 
solvent. Many studies were also carried out testing this effect, and the most studied 
solvent for this is acetonitrile, for its largely reported beta orienting effect in several 
reaction systems. Nonetheless, it is also known that it is not a determinant factor for the 
outcome of the reaction, and major alfa anomer can be obtained depending on the 
selection of activators and/or donor/acceptor systems. 
Of course, the outcome of a glycoconjugation reaction depends on a careful 
selection of its two mainly intervening parts, the glycosyl donor and the acceptor. 
Glycosyl donor halides have been quite used, possibly for its relatively easy preparation 
and good glycosylation results.116 Since then, several improvements ensued and a number 
of diverse glycosyl donor systems were developed, that far surpassed the results of the 
glycosyl bromide/chloride, as it is the case of glycosyl trichloroacetimidates. 
Nonetheless, since the preparation of glycosyl iodide and fluoride became more easily 
accessible, this class of glycosyl donors has remained one of the most utilized. Many 
other methodological advances have brought forward the expansion to other glycosyl 
donors specially tailored for an activator, or that suit the specific needs of the acceptor115. 
All these developments aim to provide a solution to one of the greatest issues in 
carbohydrate chemistry, which is the stereoselectivity in the formation of the glycosidic 
bond, and the impact of all the effects here discussed are still under debate117,118. 
2.3 Synthesis of alkyl glycosides 
The synthesis of alkyl glycosides goes back to the beginning of carbohydrate 
chemistry and the work of Emil Fisher115,128. By refluxing a solution of a saccharide in an 
alcohol, in the presence of acid, acting as catalyst, provided the first alkyl glycosides, but 
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quickly a number of glycosylation techniques and/or variations emerged, providing better 
yields and stereochemical control over the resulting glycosides. These techniques made 
use of new catalysts and/or glycosyl donors, like glycosyl halides in Koenigs-Knorr115,129 
reaction or the much later developed thioglycosides by Ferrier130.  
Given this, the initial synthesis of medium chain alkyl glycosides (with 8 to 14 
carbon atoms comprising the aliphatic chain) relied in acid-catalysed131 or Koenigs-Knorr 
type reactions102. With the evolution of glycosylation reactions several other 
methodologies have emerged for the synthesis of alkyl glycosides132. 
At the same time, as our knowledge of biosynthetic pathways evolved, the 
development of enzymatic catalysis has been of major importance since it allows precise 
control over the stereoselective formation of glycosidic bonds. Even though this would 
allow the synthesis of enantiomerically pure glycosides, their in vitro application poses 
some challenges, like the solvent mixture used, that is a compromise between reagent 
solubility and enzyme activity, or the fact the enzymes need to be produced, isolated and 
immobilized for their correct use133. One of the most successful glycosylation 
methodologies employs trichloroacetimidates as donors, mainly for the formation of 1,2-
trans-glycosides134. One main advantage of this technique is the fact that it yields 
glycosides even with weak nucleophilic aglycones. 
Although the discussed strategies can be used for a variety of glycoside donors 
and acceptors, several methodologies were developed, tailored to obtain specific end 
products or families thereof. One example is the use of glycals when intending to obtain 
2-deoxy glycosides135. 
Direct glycosylation making use of glycals relies on a number of activators such 
as gallium (III) chloride135 to obtain 2-deoxy glycosides in good yields (>70%) and not 
only O-glycosides but also their S- and N-analogues. Activators can also be selected 
according to the desired stereochemistry, for example, when using triphenylphosphane 
hydrobromide or similar systems, a pronounced α-stereoselectivity is obtained. 
There are a number of diversified systems and synthetic pathways leading to the 
desired products, and in the growing field of carbohydrate chemistry, the number of 
stereochemically selective strategies is finally coming to pair with the vast chemical space 
that carbohydrates represent. 
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3 Alkyl glycosides as antimicrobials 
3.1 What is known about alkyl glycosides and where to 
improve 
Previous work by the research group lead to the synthesis of the first compounds 
of a new family of deoxy glycosides136,137 and their surfactant properties as well as their 
antimicrobial potential were studied, and this work came to constituting an important 
starting point for the work further developed.  
The compounds described consist of a 2-deoxy or 2,6-dideoxy sugar moiety, 
conjugated with an aliphatic alcohol, forming octyl or dodecyl glycosides, easily accessed 
by employing a glycal as a glycosyl donor and the corresponding saturated alcohols as 
acceptors, and using triphenylphosphane hydrobromide as a promoter; a simple 
methodology that yields the alfa anomer as the major product and in reasonably high 
yields138.  
Then, the properties of these compounds were preliminarily assessed, namely their 
antimicrobial activity, surfactant activity and cytotoxicity137. The results of antimicrobial 
activity by paper disk diffusion methodology have shown bioactivity towards Gram-
positive bacteria and no activity towards Gram-negative bacteria and fungi. The study of 
its surfactant properties revealed that the aggregation tendency, described as critical 
micellar concentrations (CMC), and adsorption are promoted by the deoxygenation 
pattern, but the same overall behavior is observed on the literature data reported for 
structurally related surfactants. Unfortunately, these compounds also show toxicity 
towards lymphocytes. 
From these results, summarized in table 1 and 2, one compound emerged with 
unexpected selective antimicrobial activity towards the genus Bacillus, and this 
pronounced activity does not correlate with any difference in adsorption properties 
between similar compounds, both in the same study and in available literature107,139. 
Hence, the dodecyl 2,6-dideoxy-α-L-arabino-hexopyranoside was considered the core 
molecule and the target of several structural modifications in an attempt to optimize the 
antimicrobial activity observed, while maintaining the specificity to the genus Bacillus, 
and also to lower the toxicity of this type of compounds, in order to achieve a suitable 
therapeutic window.  
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Table 1. Antimicrobial activity expressed by the diameter of the inhibition zones ± standard 
deviation (mm) for dodecyl deoxyglycosides. 
*Data adapted from Silva et all (2008)137 
 
Table 2. Adsorption properties of dodecyl glycosides at the air–aqueous solution interface. 
*Data adapted from Silva et all (2008)137 
 
Compound 
Name 
Dodecyl 2-deoxy-
α-D-arabino-
hexopyranoside 
Dodecyl 2-deoxy-
β-D-arabino-
hexopyranoside 
Dodecyl 2,6-
dideoxy-α-L-
arabino-
hexopyranoside 
Dodecyl 2,6-
dideoxy-β-L-
arabino-
hexopyranoside 
B. cereus <6.4 10 ± 0 27 ± 5 <6.4 
B. subtilis 9 ± 0 10 ± 0 25 ± 3 <6.4 
E. faecalis <6.4 17 ± 2 13 ± 2 <6.4 
E. coli <6.4 <6.4 <6.4 <6.4 
L. 
monocytogenes 
10 ± 1 <6.4 12 ± 2 <6.4 
P. aeruginosa <6.4 <6.4 <6.4 <6.4 
S. enteritidis <6.4 <6.4 <6.4 <6.4 
S. aureus <6.4 <6.4 9 ± 1 <6.4 
A. niger <6.4 <6.4 <6.4 <6.4 
C. albicans 9 ± 0 10 ± 1 <6.4 <6.4 
P. oryzae <6.4 <6.4 <6.4 <6.4 
Compound Name 
CMC   
(mol kg-1) 
γCMC  
(mNm-1) 
pC20 
Dodecyl 2-deoxy-α-D-arabino-hexopyranoside -- -- -- 
Dodecyl 2-deoxy-β-D-arabino-hexopyranoside 2.2 x 10-5 32.5 5.1 
Dodecyl 2,6-dideoxy-α-L-arabino-hexopyranoside 1.1 x 10-5 28.4 5.7 
Dodecyl 2,6-dideoxy-β-L-arabino-hexopyranoside -- -- -- 
Dodecyl-β-D-gluco-hexopyranoside 1.9 x 10-4 39.1 4.2 
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3.1.1 Analysis of the available literature 
As previously referred, alkyl glycosides are known since the end of the nineteenth 
century, but the available literature is not as extensive as one could expect. Examples of 
such compounds can be found107,140–142, and most of them consider their surface activity 
and adsorption capabilities, but not many of them refer to their biological activities. So, 
a comprehensive study on the structural features important for their biological activity 
could not be found. Nonetheless, the relationship between activity and structure with the 
available reported data was studied in order to trace a profile of which structural features 
can be of most importance in our lead moleculeand to establish which characteristics of  
the compounds under study  are unique or in compliance with the literature. 
Data reported in the literature related to alkyl chains with less than 8 carbon atoms 
and more than 16 was included only throughout a small number of representative 
structures, since, in general, their biological properties are worse than between these 
values and they are out of the range desired for this work. Likewise, other substituents 
like amines in the sugar moiety were placed only as representatives, since the compounds 
under study are non-ionic surfactants and any amine residues can become protonated 
under physiological media, implying a different mode of action143, and so, not the focus 
of the study. 
Collected data was organized and normalized (Annex 1139,142–146). One of the most 
relevant information obtained from this analysis is a clear relationship between the length 
of the aliphatic chain and the biological activity. For all the compounds found in the 
literature, antimicrobial activity raises with length of the aliphatic chain until an optimal 
range of 11-13 carbon atom length. This is also in accordance to the activity of the simple 
corresponding alkyl alcohol. Both the α and β anomers display very similar bioactivities, 
although the β anomer shows better activities toward fungi. The limited modifications on 
the configuration of the sugar moiety reveled a slight improvement in antimicrobial 
activity for the mannoside residue. Finally, the protection of hydroxy groups causes an 
increase in the minimal inhibitory concentration (MIC) values observed. 
 By comparing what was known about the compound lead and the conclusions 
obtained by literature analysis, two main differences were observed: firstly, the 
antimicrobial action of the compound lead was more pronounced against the genus 
Bacillus, and generally these surfactant compounds present a broad spectrum of activity; 
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secondly, the bioactivity of the α and β anomers are very similar in all the examples 
observed, but the β anomer of the lead compound shows no bioactivity. 
In the face of such divergences from the traditional profile of biological activity, 
it is plausible to consider the hypothesis that such compound is exhibiting its 
antimicrobial activity by a new mechanism of action, other then the surfactant action 
expected of alkyl glycosides, or at least in addition to it. 
3.2 Objectives of the work proposed 
 Incorporating all the information discussed, the present work was outlined has 
having two main objectives: 1) the creation of a small library of derivatives to the lead 
compound, aiming at optimizing bioactivity / toxicity and enabling the structure-activity 
relationship study; 2) the study of the mode of action for these compounds, despite their 
surfactant properties. 
These objectives were then further developed and the work to be performed 
subdivided. In order to achieve the first objective, the modification of the starting 
scaffold, compound 1 (Figure 6), were divided into: i) modifications of the aliphatic 
portion, the aglycone; ii) modifications on the sugar moiety; iii) modifications of the 
glycosidic bond. By modifying each feature independently, we could observe the 
relationship between each structural modification and its impact in antimicrobial and 
toxicological properties. 
 
Figure 6. Lead compound: Dodecyl 2,6-dideoxy-α-L-arabino-hexopyranoside (1) 
Regarding the second main objective, in order to study if, apart from a surfactant 
action, we can observe additional modes of action, several steps were postulated: i) 
detailed study of the antimicrobial action and its kinetic parameters; ii) the study of the 
metabolic impact, where the surfactant activity would lead to a non-specific impact and 
any other putative targets would impact specific metabolic pathways; ii) a genetic 
approach in order to confirm any target discovered. 
Such objectives provided the guidelines for the work here presented. 
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4 Glycoconjugation towards molecular entities with 
potential in Alzheimer’s disease 
Infection is reemerging as a worldwide concern due to the growing bacterial 
resistance, with the elderly having the higher mortality rates. This population segment is 
also the most affected one by a number of age-related non-curable diseases147. In the 
context of an European project focusing on the Alzheimer’s disease (AD), the 
collaboration with the partner Biofordrug allowed to evaluate compounds’ toxicity with 
Caco 2 cells and to investigate the synthesis of new glycoconjugates, expected to improve 
aglycone bioactivity and bioavailability. A brief introduction to the subject and the 
presentation of the objectives of the work developed are presented below. 
 
4.1 Brief introduction to Alzheimer’s disease and available 
therapy 
4.1.1 Alzheimer’s disease 
Alzheimer’s disease is a chronic neurodegenerative disease and the prevailing 
cause of dementia. It is a slow progressing disease and the absence of perceptive 
symptoms in the first stages makes it very difficult to detect, only with specialized 
examination. It’s only when symptoms like memory impairment or other cognitive 
dysfunctions are perceptive that the closest relatives begin to notice changes, but even 
then they can be mistaken by normal aging.148–150  
The symptoms for Alzheimer’s are very difficult to distinguish in a pre-clinical 
stage, but upon close examination a sort of global cognitive deficit can be observed, with 
slight impairments in episodic memory and executive function.149 At its clinical stages 
there are clear signs of disease progression, specially associated with the memory, and 
several biomarkers that can be used to understand its severity and progression. Finally, in 
the late stages, dementia onsets and even the everyday and most basic functions are 
impaired.150,151 
Biologically, AD is characterized by the accumulation of intra- and extra-neuronal 
β-amyloid (Aβ) as well as intra-neuronal Tau (leading to plaque/tangle formation), factors 
that drive a cascade of biological processes leading to inflammatory processes and 
ultimately to neuronal degeneration.152,153 The factors that cause this accumulation and 
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ensuing processes are still not fully understood, despite the prolonged efforts that 
provided insight on many of the biological mechanisms associated with it. This 
knowledge is essential to the development of new therapeutic options to effectively cure 
AD.153 
Presently, the potentially most successful approach, and the major focus of 
interest, relies in the prevention and successful delay on the most damaging stages of this 
disease is its detection in a pre-clinical stage, where several precautions can be taken in 
order to minimize the suffering of the patient and the patient’s family.154,155 For this 
purpose, several methodologies were applied aiming at finding possible biomarkers in 
preclinical AD, like structural and functional imaging, and analysis of cerebral fluid 
amyloid and tau proteins.155–160 Nevertheless the type of assays necessary to detect these 
biomarkers are costly and hard to use in a large screening-based manner. Hence, the 
development of blood-based biomarkers is of great importance for its cost- and time-
efficiency and studies have been carried out based on detection of proteins and lipids in 
the blood, autoantibodies and micro-RNA.161–167 
It is in this last category that the present research is inserted, but focused in a new 
and different type of biomarker: metallic ions, namely, copper168,169. 
4.1.2 Current therapeutic approach 
Nowadays, after diagnosis of Alzheimer’s disease, probably already in the 
symptomatic stages, the therapeutic intervention can only provide relief of the symptoms, 
without being able to effectively treat the underlying causes or stopping the evolution of 
the disease170. 
Most of the available drugs are acetylcholinesterase inhibitors (donepezil, 
rivastigmine and galantamine) and one N-methyl-D-aspartic acid (NMDA) and glutamate 
receptors antagonist (memantine)171. The latter, being the last approved drug, goes back 
to 2003, and although some new drugs with diverse targets reached clinical trials, many 
were discontinued due to safety and/or effectiveness concerns172. 
One of the issues for AD therapeutic development, is that the clinical trials are 
performed with patients with already advanced pathophysiological signs of the disease, a 
factor impairing the true assessment of potential drug effectiveness and success rate172. 
Chapter I 
30 | P a g e  
 
Therefore, the development of reliable early detection tools for AD and effective 
biomarkers to evaluate the progression of the disease are still a primary necessity. 
 Nonetheless, as currently available drugs fail to alter the primary pathological 
processes that underlie AD, new therapeutic agents are emerging, targeting Aβ production 
(namely γ- and β-secretases)173–175, Aβ clearance (Aβ-degrading proteases)176,177, protein 
aggregation (specially Tau)178 and neuroinflammation (microglia modulators)179,180. 
4.1.3 The role of copper ions in AD 
The link between metals and AD or other neurodegenerative diseases is becoming 
better understood and it is known that they play an essential role in protein aggregation, 
making them possible biomarkers.181,182 Copper (II) and zinc (II) ions are indicated as the 
best candidates for the formation of the first fibrils in protein aggregation, which becomes 
then an autocatalytic process. Thus, once a certain concentration of free ions in the blood 
is detected, there is a corresponding probability of these aggregates to be formed in the 
brain, the beginning of AD.183,184 Even though research in the role of these ions in AD is 
quite new, the connection is already indisputable.185 
Given this association, the possible application of metal chelating compounds as 
an important early-Alzheimer’s biomarker or even as a therapeutic approach, is of 
growing interest186,187. 
4.1.4 ABC transporters and AD 
ATP-binding cassette (ABC) transporters are a superfamily of active transporter 
systems formed by multiple subunits, one transmembrane domain and an ATP-binding 
cassette domain. They perform various functions and can be importers or exporters. 
The relation between this type of transporters and AD has been discovered in the 
last decade and only recently these transporters are looked at has a viable therapeutic 
target. But, nonetheless, a relationship between various subfamilies of ABC transporters 
and AD has been established, mainly for ABCA, ABCB and ABCG.188–191 
P-glycoprotein (P-gp) is an ABC transporter (also called ABCB1) and has been 
correlated with the rate of accumulation of amyloid protein in the brain, becoming a 
possible therapeutic target for the treatment of AD. It is highly present in the blood-brain 
barrier (BBB) and several studies indicate that an overexpression or “over-activation” of 
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this protein is correlated with decreased Aβ brain load.192–196 Because of this, the 
investigation of improved pharmacokinetics in inducers of P-gp has become a secondary 
goal of the work performed. 
An important note is that P-gp is not a transporter system exclusive to the BBB, it 
is greatly expressed in the intestinal epithelium, liver and kidney, and its overexpression 
in several cancer types is associated to multidrug-resistance, all of which has an important 
impact in the potential applications of modulator compounds. 
4.1.5 Improving with carbohydrate conjugation 
The incorporation of a sugar residue by a glycosidic bond in bioactive molecules 
is a commonly employed strategy to improve compound solubility, bioavailability and, 
in general, the pharmacokinetic profile197,198, as discussed before.  
Nonetheless, in the specific case of metal chelating molecules, this approach is of 
increased value, since one of the main advantages of such glycosylated compounds is the 
masking of their chelating function, leading to the prevention of side effects due to 
systemic chelation. Hence, such compounds can function as a prodrug, since the 
hydrolysis by glycosidases will increase the chelating capacity only in targeted 
tissues.187,199  
Additionally, a glycoconjugate approach in order to enhance the selectivity 
towards the central nervous system (CNS) has been successful in other cases, once the 
BBB has a high density of hexose transporters, named GLUTs, responsible for the intake 
of glucose to the brain, and some glycoconjugates have shown an equally positive brain 
uptake.199–201  
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5 Alkyl glycosides as antimicrobials  
5.1 Synthesis of antimicrobial alkyl glycosides 
Alkyl glycosides as antimicrobials From the past study previously discussed, 
several conclusions provided insights into the advantageous structural features for this 
family of compounds. For example, the alkyl 2-deoxy-D-arabino-hexopyranosides 
exhibited no significant antimicrobial properties, except with Enterococcus faecalis that 
was susceptible to the beta anomers, and so, 2,6-dideoxygenation patter was deemed 
important to bioactivity.  
Regarding the alkyl 2,6-dideoxy-L-arabino-hexopyranosides, the octyl glycosides 
showed an unremarkable broad spectrum of inhibition, but regarding the dodecyl 
glycosides, interesting and striking differences arise. The dodecyl 2,6-dideoxy-β-L-
arabino-hexopyranoside showed no biological activity to any of the species tested, while 
the dodecyl 2,6-dideoxy-α-L-arabino-hexopyranoside exhibited a marked antimicrobial 
activity to both Bacillus species tested (MIC = 7.8 μg mL-1), rivalling the antimicrobial 
potency of the control drug, chloramphenicol (MIC = 3.1 μg mL-1 and 6.3 μg mL-1, 
against B. subtillis and B. cereus, respectively)137. 
Additionally, some activity regarding E. faecalis and Listeria monocytogenes was 
observed, but not as strikingly different from most of the compounds used in the study. 
Actually, E. faecalis sp. appears to be quite susceptible to this type of compounds since, 
looking to the paper disk screening, 75% of the compounds demonstrated at least a small 
inhibition diameter. This is indicative that it is especially susceptible to the surfactant 
capacity of these compounds. 
As referred before, merging this information with the conclusions obtained from 
the literature examples (section 3.1.1), the antibacterial results observed were surprising, 
not only due to the singular activity towards Bacillus spp. of one compound against very 
similar analogues, but also by the outstanding difference of bioactivity between the α and 
β anomers. Such observations do not fit the established bioactivity profile for surface 
active compounds reported in the literature. 
This apparent antimicrobial specificity to Bacillus species, and α/β disparity 
instigated the further study of this compound and it was considered the scaffold structure 
for further studies (Figure 6). 
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5.1.1 Defining a synthetic strategy 
Regarding further compound development, the need of developing compounds 
that would allow us not only to overcome the observed toxicity but mainly that could help 
us to establish a mode of action for this type of compounds was the driving force. So, a 
library of analogues to this compound was generated, attempting to provide insight into 
the essential molecular characteristics for this profile of bioactivity. 
The target glycosides were designed intending to explore the importance of the 
aglycone in the bioactivity, and if a direct relationship between the surface activity and 
the antibacterial properties could be observed. So, maintaining the sugar moiety, a 
number of aglycones were conjugated. 
 Firstly, a range of glycosides comprising saturated aglycones ranging from 10 to 
13 carbon atoms were synthesized, in order to establish if a linearity in the relation 
between chain length and antibacterial activity exists, as it could be expected based on 
the literature information about the bioactivity of the saturated alcohols98,202. 
Also, modifications to the nature and type of packing of the aglycone were 
attempted by employing a highly fluorinated saturated aglycone. By introducing this 
modification, the amphiphilic molecular character is altered by reducing the lipophilicity 
of the aliphatic chain. At the same time, an opposing modification was performed, by 
testing the behaviour with a branched saturated chain. This modification can drastically 
increase the aliphatic portion, altering profoundly the hydrophilic head – lipophilic tail 
proportion. Such structural changes modify the packing structure of the lipids and may 
affect the type of interaction with biological membranes.  
Regarding the glycon (glycosyl group) of this type of molecules, the information 
gathered from the literature and our previous studies encouraged modifications of the 2-
deoxy position, once the 6-deoxy position was regarded as pivotal to the biological 
activity observed. 
So, in an alignment of interests, a derivative capable of being radioactively 
labelled was synthesized, by introduction of a halogen atom in position 2. The reasons 
driving a possibility of radioactive labelling were related to the fact that labelling this type 
of compounds with fluorophores or other types of labelling techniques would, 
theoretically, profoundly modify their amphiphilic character. In order to preserve the 
structural features of the lead compound as much as possible, a 2,6-dideoxy-2-iodo-
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glycoside was prepared, since a radioactive iodine isotope (125I or 131I) can be easily 
prepared from the “cold” form, by nucleophilic exchange, where halogen-halogen 
exchange happens in solution203. 
 
5.1.2 Synthetic effort and results obtained 
As stated above, the initial modifications to the core compound 1 (Figure 6) were 
performed focusing on the aliphatic portion, aiming to understand the impact of the chain 
length in compound activity, and to check if the activity profile follows the expected 
pattern, according to the literature. 
In order to perform the synthesis of these compounds, the glycosyl donor had to 
be prepared as well. Since the donor is a glycal, more specifically the 6-deoxy-3,4-di-O-
acetyl-L-glucal (2) (systematic name:  3,4-di-O-acetyl-1,5-anhydro-2,6-dideoxy-L-
arabino-hex-1-enitol), synthetic strategies were tested using L-rhamnose as a starting 
material, one of the few natural sugars belonging to the L-series.  
Several techniques are available from the literature116,204 for the preparation of 
glycals. In scheme 4 is depicted the reaction pathway carried out via an intermediate 
glycosyl bromide. However, reaction optimization was required to improve compound 
isolated yield. 
 
Scheme 4. Glycal synthesis via glycosyl bromide formation. 
The first reaction conditions tested used hydrobromic acid in acetic acid solution, 
but this methodology to form the intermediary bromide was not very successful, as 
revealed by the average bromide final yield of 39 %. Using the method applying acetyl 
bromide for the in-situ formation of hydrobromic acid, the results obtained were much 
more reproducible and the yield increased to 70%.  
After obtaining the glycosyl donor, the next step consists in the conjugation which 
was performed by following the known methodology already highly studied in the 
2 
L-rhanmnose 
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research group. A suitable glycal reacts with the alcohol in the presence of 
triphenylphosphane hydrobromide (TPHB) as shown below (Scheme 5).137,205 
 
Scheme 5. Schematic representation of the glycoconjugation reaction. 
 
When using glycals as starting materials, glycoconjugation by acid catalysis 
(Scheme 6A), as it is the case, can also give rise to secondary products due to Ferrier 
rearrangement, upon the formation of an allyloxycarbenium ion (Scheme 6B).  
 
Scheme 6. General mechanism for acid-catalyzed glycoconjugation reaction and the formation of Ferrier 
rearrangement products. 
Which of these reactions is more predominant in the glycoconjugation procedure 
can be controlled by the choice of catalyst, hence our catalyst of choice for obtaining 2-
deoxy glycosides was TPHB, that is known to prevent Ferrier rearrangement by 
promoting the protonation of the softer C-2 position138,206. Additionally, the choice of 
catalyst was also due to the fact that it gives rise to the α anomer as the major product, 
which is the most desired anomer, since in the preliminary study only the α anomers have 
shown significant bioactivity (section 3.1 & 4.1). 
The two-step methodology applied involved the purification of the intermediary 
acetylated compounds (yields for the major intermediary compounds in table 1), but 
further optimization to a one-pot methodology (section 9.1.4) gave rise to the best yields 
for all compounds. Yields and stereoselectivity of the one-pot, glycal reaction with 
saturated alcohols with chains of different lengths are summarized in table 3. 
2 
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Table 3. Yield of alkyl glycosides with different alkyl chain length 
 
 
The same methodology was employed to obtain two other derivatives, where the 
nature of the aliphatic chain was modified. The first derivatives synthesized (9,10) 
contained a highly fluorinated chain, aiming at understanding the impact in bioactivity of 
a reduction in the lipophilicity of the aliphatic portion, maintaining nonetheless the 
chemical nature of the glycoside, since fluoride is a well-known bioisostere to hydrogen 
atoms207. A branched aliphatic chain aglycone was also used, in order to evaluate the 
impact of increasing lipophilicity, resulting in the compounds 11 and 12. 
Also, since the 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-nonadecafluorodecanol 
presented poor solubility in dichloromethane, for the reaction solvent a mixture of 
dichloromethane and acetonitrile (1:1) was used instead. The results are presented in table 
4. 
 
 
 
 
 
 
Compound Name Compound No. Structure Yield 
Tridecyl 3,4-di-O-acetyl-2,6-
dideoxy-α-L-arabino-
hexopyranoside 
3 
 
57 % 
Dodecyl 3,4-di-O-acetyl-2,6-
dideoxy-α-L-arabino-
hexopyranoside 
4 
 
59 % 
Decyl 3,4-di-O-acetyl-2,6-
dideoxy-α-L-arabino-
hexopyranoside 
5 
 
61 % 
Tridecyl 2,6-dideoxy-L-
arabino-hexopyranoside 
α: 6 
β: 7  
α: 69 % 
β: 23 % 
Dodecyl 2,6-dideoxy-L-
arabino-hexopyranoside 
α: 1 
β: 8  
α: 67 % 
β: 14 % 
Undecyl 2,6-dideoxy-L-
arabino-hexopyranoside 
α: 9 
β: 10  
α: 56 % 
β: 13 % 
Decyl 2,6-dideoxy-L-
arabino-hexopyranoside 
α: 11 
β: 12 
 
α: 71 % 
β: 15 % 
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Table 4. Yield of glycosides embodying a fluorinated and a branched alkyl chain 
 
5.1.2.1 Impact of the solvent in α:β ratio 
As referred before (section 2.2) the choice of solvent in a glycosylation reaction 
can also have an important impact in the reaction products, namely the α/β ratio. When 
employing acetonitrile as a solvent, there is the possibility of it participating in the 
reaction, following the mechanism represented in the following scheme, leading to the 
formation of the β anomer as the major product, instead of the α125,208. 
 
Scheme 7. General mechanism of the role of acetonitrile in leading to the major formation of β anomer. 
Since there was the need of using both dichloromethane and acetonitrile as 
solvents, for example in the synthesis of compound 13, their impact in this reactional 
system was assessed. In order to maintain the reaction conditions as similar as possible 
for the synthesis of dodecyl 2,6-dideoxy-L-arabino-hexopyranosides (1,8) and dodecyl 
2-deoxy-D-threo-pentopyranosides (18,19), the procedures were performed in parallel, in 
both solvents, according to scheme 8. 
 
 
 
Compound Name Compound  No. Structure Yield 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,
10,10,10-
Nonadecafluorodecyl 3,4-di-
O-acetyl-2,6-dideoxy-L-
arabino-hexopyranoside 
13 
 
50% 
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,
10,10,10-
Nonadecafluorodecyl 2,6-
dideoxy-L-arabino-
hexopyranoside 
α: 14 
β: 15 
 
α: 59 % 
β: 17 % 
2-octyldodecyl 2,6-dideoxy-
L-arabino-hexopyranoside 
α: 16 
β: 17  
α: 33 % 
β: 19 % 
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Scheme 8. Reactional system for the study of the impact of solvent in α:β ratio 
The analysis of reaction mixtures by 1H NMR spectrometry was performed to 
detect, in the most unaltered state possible, the proportion of reaction products formed 
(Figure 7 and Annex 2). 
 
Figure 7. NMR comparison of reactional mixtures and corresponding α:β ratios. A – NMR from 
reactional system a, in CH2Cl2; B – NMR from reactional system a, in CH3CN; C – NMR from reactional 
system b, in CH2Cl2; D – NMR from reactional system c, in CH3CN  
In order to observe the corresponding ratios α and β ratios, for the reactional 
system a (scheme 6a; Figure 7 A and B), the integration of peaks corresponding to the 
anomeric H-1 were used, with H-1α appearing around 4.85 ppm and H-1β around 4.51 
ppm. For reactional system b (Scheme 6b; Figure 7 C and D), the integrations used were 
of peaks H-3α appearing around 5.25 ppm and H-1β around 4.60 ppm. 
α: 1 
β: 8 
α: 18 
β: 19 
a) 
 
 
 
b) 
2 
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It was found that there was a higher proportion of the α anomer in both solvents, 
but with significant difference between the ratios in different solvents, in accordance to 
the reported137. 
5.1.2.2 Microwave-assisted synthesis 
Microwave-assisted synthetic methodologies can benefit numerous reaction 
systems, since microwave-heating is known to greatly increase reaction kinetics, while 
also displaying specific and non-thermal microwave effects, whose existence is still 
widely debated209. Nonetheless, microwave-assisted methodologies seem to have a clear 
advantage over traditional heating methodologies210, and with additional benefits to 
specific reactional systems, our synthetic methodologies were adapted to explore their 
potential optimization under microwave-assisted reactional conditions (Table 5). 
 
Table 5. Comparing yields and reaction times of microwave-assisted synthesis with the 
conventional method 
Compound 
Traditional Microwave-assisted 
Yield Time (min) Yield Time (min) 
1 67 % 
50 
63 % 
10 
8 14 % 24 % 
11 71 % 
40 
56 % 
10 
12 15 % 18 % 
14 59 % 
180 
55 % 
30 
15 17 % 24 % 
 
As shown, the reaction times of the microwave-assisted synthesis were 
significantly lower, however, yields obtained were lower compared to those obtained by 
the traditional methodology due to an increase in the formation of side products, in 
particular Ferrier rearrangement products. In the case of compounds 14/15, the least 
reactive by the traditional methodology, there was a slight increase in overall yield, but 
due to an increased formation of the β anomer (15). This increase of β anomer formation 
was registered for all the compounds, causing a variation in the α:β ratio and, since the 
alpha anomer is the compound of interest, microwave-assisted synthesis methodologies 
proved to be less appropriate than traditional methods. 
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5.1.2.3 Radioactive isotope labelling 
Other modifications to the aliphatic chain were performed, namely having a 
terminal functional group (compound G9, Figure 18), capable of further 
functionalization. The idea behind this development was the possible functionalization 
with a fluorophore, as a mechanism of tracing and visualizing the compound in the 
biological media. However, preliminary results showed that any modification in the 
terminal position of the aliphatic portion of these compounds would lead to a complete 
loss of measurable bioactivity (Table 5 and/or Figure 18). Although unfortunate, such 
results could be expected since bioactivity of this type of compounds relies on their 
amphiphilic character and such a variation would hinder its capacity to access its potential 
biological target211. 
Given these results, an alternative methodology to label the compounds was 
proposed, one that would alter as little as possible the aliphatic character. A possible 
solution is radioactive labelling, and to test this hypothesis, an iodine radioactive isotope 
was planned. 
The synthesis of compound 1 iodinated analog was performed with the same 
glycosyl donor and acceptor but employing N-iodosuccinimide (NIS) has a catalyst for 
the glycoconjugation212,213 (Scheme 7)  
Scheme 9. Reaction scheme for the synthesis of dodecyl 2,6-dideoxy-2-iodo-α-L-arabino-hexopyranoside 
 
Employing this methodology, compound 21 (Dodecyl 2,6-dideoxy-2-iodo-α-L-
arabino-hexopyranoside) was obtained with 61 % yield, and only the alfa anomer of this 
compound was isolated, as expected by the mechanism of this reaction (Scheme 8). 
 
Scheme 10. Mechanism for the glycosylation reaction catalysed by NIS.  
20 21 
2 
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5.2 Establishing a compound library and its antimicrobial 
efficacy 
The synthesis previously described was part of the development of alkyl L-
arabino-hexopyranosides, but the synthetic effort of the entire research group produced 
other families of compounds as well, such as alkyl D-arabino-hexopyranosides, D-threo- 
and L-threo- pentopyranosides. The summary of the most relevant compounds obtained, 
presented in figure 18, provides an overview of the structural diversity of the compounds 
synthesized and the functionalization capabilities of such structures. Alongside the 
development of such compounds, the determination of their antimicrobial capabilities 
allowed for a rational design of further structures and provided guidance to the work 
performed. 
A compounds antimicrobial activity is assessed via the determination of the 
Minimal Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration 
(MBC). While MIC values indicate the lowest concentration of antimicrobial agent that 
inhibits observable bacterial growth, MBC values indicate the lowest concentration 
necessary to kill the bacteria, which makes them two complementary results, essential to 
the correct determination of the antimicrobial potential associated to any compound. 
When a bacterial culture is submitted to an antibacterial agent and no bacterial 
growth is observable, it is not possible to know if the bacterial growth was simply 
inhibited by the presence of this compound (bacteriostatic effect) or if the bacteria were 
in fact rendered non-viable or killed (bactericidal effect). That is the reason why, after the 
MIC determination, the bacterial culture submitted to the compounds’ action is then 
transferred to growth media devoid of antimicrobial compound, where any surviving 
CFUs (Colony Forming Units) will resume growth. After 16-24 hours, the MBC results 
are obtained. 
The determination of bacterial susceptibility in previous studies was performed in 
using solid media agar dilution136 as a methodology, and for experimental reasons, the 
microdilution methodologies would be much more favorable for all the studies planned. 
So, a comparison between both techniques was done to validate the results obtained. 
These methods were applied according to the standards provided by the Clinical and 
Laboratory Standards Institute214. At the same time, using microdilution methods 
provided the possibility of obtaining high resolution microbial growth curves, that allow 
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not only the determination of the susceptibility to the compounds, as well as the 
observation of the impact on bacterial growth and its evolution over time, including at 
sub-inhibitory concentrations. 
Based in the previous results137, the bacterial strains for the antimicrobial 
susceptibility determination were selected. Firstly, there was no bioactivity detected in 
Gram-negative bacteria, fungi and yeast cells, so, they were not focused in the assays 
performed. Regarding the Gram-positive bacteria, as previous results show bioactivity 
specially towards Bacillus genus, several strains were selected, in order to observe if this 
activity was the same in amongst other strains of Bacillus, so, B. cereus ATCC 14579, B. 
cereus ATCC 11778 and B. subtilis ATCC 6633 were selected. 
In addition to the Bacillus strains referred above, two reference bacterial species 
were added: Staphylococcus aureus ATCC 29213 strain, a Gram-positive bacteria, and 
Escherichia coli ATCC 8739 strain, a Gram-negative bacteria, and both widely used as 
representatives of their respective Gram classification. Also, the lack of bioactivity of 
these alkyl glycosides to S. aureus has become a hallmark in the bioactivity profile, since 
it was unexpected according to the literature, as discussed before. 
Results for the susceptibility assay in the bacterial strains described as well as the 
results for the comparison between both methodologies used are summarized in the 
following table. 
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Table 6. Comparison of the results obtained for susceptibility determination.* 
 MIC (µg/mL) 
Compound 
B. cereus 
ATCC 
14579 
B. cereus 
ATCC 
11778 
B. subtilis 
ATCC 
6633 
S. aureus 
ATCC 
29213 
E. coli 
ATCC 8739 
 
   1 
16(8) 16(8) 16(8) 
>128 
(>128) 
>128 
(>128) 
8 
128(128) nd nd nd nd 
 
G1 
16(16) 16(16) 16(16) 
>128 
(>128) 
>128 
(>128) 
      
11 
32(32) nd nd nd nd 
        
12 
128(128) nd nd nd nd 
      
18 
16(8) 16(8) 16(8) 
>128 
(>128) 
>128 
(>128) 
       
G2 
>128 
(>128) 
>128 
(>128) 
>128 
(>128) 
>128 
(>128) 
>128 
(>128) 
*Values inside parentheses refer to solid media assays results and outside to microdilution 
liquid media assays 
 
Both methodologies provided very similar results and the microdilution 
methodology was used for the remainder of the work developed and the results were 
comparable to those obtained using solid media. 
Additionally, the microdilution methodology, by using an automated plate reader, 
provides additional information to the determination of MIC values, providing bacterial 
growth curves in all the conditions tested (Annex 3). This allows for the complementary 
acquisition of the profile of bacterial response to the action of all compounds tested. It 
was this additional information that allowed the observation of the unexpected effects of 
compound 14, subject discussed in section 8.2 (Annex 4). 
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In order to simplify the screening technique for the remainder of the compounds 
tested, only a single bacterial strain was selected. The strain B. cereus ATCC 14579 was 
selected as being representative of the genus Bacillus, since its genome has been 
completely sequenced and extensively studied215–218, a fact that will help during the search 
for the mechanism of action, where this will also be the selected strain. Also, compound 
1 was also used as inter-experimental control once it has shown the most promising 
bioactivity in the previous studies as well as in the present screening studies. The results 
are summarized in table 7. 
 
Table 7. Antimicrobial activity over B. cereus ATCC 14579 determined for all the compounds 
synthesized by the research group* 
Compound structure and No. MIC MBC Compound structure and No. MIC MBC 
 
1 
16 16 
 
G1 
16 16 
 
4 
>128 >128 
 
G3 
32 32 
 
5 
>128 >128 
 
G4 
32 32 
 
6 
64 64 
 
G5 
16 16 
 
8 
128 128  
G6 
>128 >128 
 
9 
16-
32 
32 
 
G7 
16 16 
 
11 
32 32 
 
G8 
128 128 
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12 
128 128 
 
G9 
>128 >128 
 
13 
>128 >128 
G10 
64 128 
 
14 
>128 >128 
 
G11 
 
64 128 
 
15 
>128 >128 
 
G12 
128 128 
 
16 
>128 >128 
 
G13 
>128 >128 
 
18 
16-
32 
32 
 
G14 
32 32 
 
19 
16-
32 
32 
 
G15 
32 32 
 
21 
16 16  
G16 
32 32 
* Compounds designated as G were synthesized by other members of our research group. Antimicrobial 
activity expressed by MIC (µg/mL) and MBC (µg/mL), determined by microdilution methods (section 
9.3.2) 
Since B. anthracis is one of the most important pathogens in the Bacillus genus, 
especially since its weaponization and use in bioterrorism219, a selected group of 
compounds was tested against B. anthracis strains, but the study of this species is 
restricted to level 3 biosafety laboratories, which I could not operate, and so such studies 
were performed at the National Institute of Health Instituto Dr. Ricardo Jorge. Results 
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obtained for 3 different B. anthracis strains are presented in table 8 and were already 
published205.  
 
 
Table 8. Antibacterial activity expressed in MIC (µg/mL) 
Compounds 
B. 
anthracis 
sterne 
B. 
anthracis 
pathogenic 
B. 
anthracis 
ovine 
E. faecalis B. cereus 
 
1  
8 8 8 >16 8 
 
18 
8 16 16 >16 16 
 
19 
8 8 16 16 16 
 
G3 
8 8 8 >16 8 
 
G4  
8 8 16 16 n.d. 
 
G8  
8 16 16 >16 16 
 
G1 
16 16 16 16 8 
 
G14 
8 8 >16 >16 16 
 
G15 
8 16 16 16 n.d 
 
G16 
8 8 16 16 n.d. 
 
G17  
8 16 16 >16 8 
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G18 
16 8 16 16 8 
 
G19 
8 16 16 >16 16 
 
G20 
8 8 8 16 8 
 
G21  
8 8 8 >16 8 
aAgar dilution method following CLSI guidelines, compound concentration ranging from 8 to 16 µg/mL. 
5.2.1 Evaluation of the cytotoxicity of alkyl deoxy glycosides 
Evaluation of compound biological activity is as relevant as the determination of 
its cytotoxic effects for applications in human health. This is especially true to the studied 
family of compounds, since their surfactant properties are associated to promiscuous 
interaction to all kinds of biological membranes, including eukaryotic cell membranes. If 
similar levels of bioactivity are detected to both prokaryotic and eukaryotic organisms, 
this would be an indicator that only the surface activity is responsible for the effects 
observed, and possible applications of this type of compounds would be limited to 
cleaning and disinfection formulations108,220,221. 
Evaluating the toxicity of a selected group of compounds was possible by applying 
the MTT assay, a colorimetric assay allowing the visualization of cellular metabolic 
activity with and without exposure to any agents. In this methodology, the desired cellular 
culture is exposed to the action of the compounds in study, and after, a tetrazolium dye, 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in this case, is 
added. This dye, in the presence of metabolic active cells, can be reduced by 
oxidoreductase enzymes dependent of NADH and/or NADPH. This dependence means 
that only metabolic active (NADH/NADPH producing) cells, will reduce MTT to 
formazan, a purple, insoluble dye. This dye is accumulating in live cells, and upon cell 
lysis, it can be spectroscopically quantified, this way allowing the direct correlation 
between MTT absorption values and cellular vitality. 
For this assay, Caco2 cells were selected as a model for human tissue, since they 
are human epithelial cells derived from a colon carcinoma. The cytotoxicity was 
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evaluated in Caco2 cells grown in supplemented DMEM high glucose media, in a 
humidified incubator at 37 °C with a 5 % CO2 atmosphere. After the established 
incubation time with the desired compounds, MTT (0.5 mg/mL) was added to the cell 
suspension, leading to the formation of formazan crystals. 
The results were obtained by measuring the absorbance of said crystals in a 
solution of DMSO/EtOH (1:1), in a microplate reader. The graphical representation of 
the variation of cell viability with the compounds concentration (Figure 8), allowed the 
determination of the IC50 values (Concentration at which a 50% inhibition in a biological 
process is observed in vitro), and the results are shown in the following table (Table 9). 
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Table 9. Cytotoxicity over Caco 2 cells determined using the MTT method. 
Compound Structure Nº IC50 (μM [µg/mL]) MIC (µg/mL) 
 
1 59.0 [18.7] 16 
 
18 142.1 [43.0] 16-32 
 
19 87.9 [26.6] 16-32 
 
G1 58.3 [18.5] 16 
 
G3 56.3 [17.8] 32 
 
G8 58.5 [19.5] 128 
 
G14 62.0 [20.7] 32 
 
G15 115.9 [35.0] 32 
 
G17 121.8 [36.6] 8* 
 
G20 103.0 [29.5] 8* 
 
G21 139.0 [41.8] 8* 
*Results obtained by dilution in solid media at National Institute of Health Dr. Ricardo Jorge 
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Figure 8. Graphical representation of the cytotoxicity assay of a group of compounds selected according 
to the results obtained for bioactivity in B. anthracis spp. 
Unfortunately, as we can see, these compounds present similar values of MIC and 
IC50, meaning that these compounds are toxic to human cells, and that the structures 
synthesized did not successfully presented an answer to this issue, nonetheless the C-
glycosides are, generally, the least toxic compounds. 
Also, no obvious correlation between antimicrobial activity and toxicity was 
found, hence the mechanism of these two biological effects could be unrelated. 
 
5.2.2 Surface disinfection and antibacterial activity 
Several patented applications of similar compounds (alkyl glycosides) show that 
the emulsifying and surfactant properties of this type of compounds are generally 
desirable for disinfectant and cleaning formulations108,220–222, but there are also examples 
of its use in pharmaceutical formulations as well as in cosmetics109,223–225. Hence, 
considering the potential applications of this type of compounds, its use in the disinfection 
of surfaces was evaluated. 
The European standard methodology provided by the OECD "Guidelines for the 
Testing of Chemicals" - "Quantitative Method for Evaluating Bactericidal Efficacy of 
Biocides Used on Hard Surfaces"226, was adapted in order to test the effectiveness of 
compound 1 in the disinfection of various surfaces: PVC, low density-fiberboard (LDF), 
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metal (aluminum) and fabric (pure cotton and cotton 65% / polyester 35%). Several 
variations to the determination of surface sterility after treatment were attempted, and the 
most reproducible results were obtained by performing a swab sampling of the surface 
and placing it in growth media. Likewise, diverse methodologies of surface disinfection 
were tested, apart from the standard methodology. Spray application of the compound 
solution was tested, since it would be an optimization to its practical application, and the 
results did not differ from the standard methodology. 
The most robust results are also based on observation of bacterial growth at 48 
hours, once at 24 hours the reproducibility required for validation could not be obtained. 
This signify a great reduction of the bacterial load in the tested surfaces, but its complete 
disinfection could not be achieved. These results compromise the effectiveness of the 
application of the compound to surfaces contaminated with B. cereus ATCC 14579. 
The methodologies applied are described in detail in Methodologies, and the 
results obtained are summarized in the following table: 
 
Table 10. Study on the efficiency of compound 1 in the disinfection of surfaces contaminated 
with B. cereus ATCC 14579 
Material PVC LDF 
Metal 
(aluminium) 
Fabric 
(cotton) 
Fabric 
(cotton : polyester) 
Method 1 ir >256 ir >256 >256 
Method 2 >256 nd nd >256 >256 
Method 3 >256 >256 >256 >256 >256 
Method 4 1000 1000 ir >1000 >1000 
Method 5 1000 nd nd 1000 1000 
*MBC values here presented (μg/mL) are the result of observation at 48h. Results were not 
determined (nd) due to methodology limitations and inconclusive results (ir) due to lack of 
reproducibility. All experiments were performed with a total of 5 replicates. 
 
The fact that it was not possible to achieve the complete sterilization of surfaces 
at the expected concentrations may be related to the spore form of bacterial cells produced 
under harsh conditions217,227. It is plausible to assume that bacterial cells devoid of any 
growth medium when on a surface, begin to produce endospores. The fact that a 
significant reduction in bacterial load was achieved also supports this hypothesis because 
only a small amount of the bacterial population would have time to produce endospores. 
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Also, it would be in accordance to the fact that the most reliable results would be achieved 
at 48h, due to the lag phase of spore germination and growth to visible colony. 
5.2.3 Efficacy against bacterial spores 
Bacillus genus is reported as a spore-producing strain, in face of the previous 
results and in order to evaluate the validity of our hypothesis, the susceptibility of B. 
cereus spores to compound 1 was studied. 
The production of spores from strain model was carried out by incubation at 37 
ºC in sporulation medium (CCY) for 48 hours228. After the purification of the spores by 
centrifugation, the susceptibility assays to compound 1 were performed. Comparing the 
susceptibility observed for vegetative cells and for spores, over diverse stages of the 
germination procedure, the results presented in table 11 were obtained. 
 
Table 11. Susceptibility to compound 1 of diverse cellular forms of B. cereus ATCC 14579 
*AGFK buffer – germination inducer buffer (30 mM L-asparagine, 5,6 mM D-Glucose, 5,6 mM 
D-Fructose, 20 mM KCl and 50 mM Tris-HCl, pH 8,4) 
The results show that compound 1 is bioactive only in vegetative cells, but it is 
important to note that the spore solution after thermal activation and germination becomes 
susceptible to the action of the compound. These results could justify the difficulties in 
surface sterilization, once there’s indication that the spore coat limits the access to any 
important structural component of vegetative cells, and only as soon as they become 
available, the bactericidal action occurs. Also, this is indicative that access to the 
cytoplasmic membrane or its constituents is imperative for antibacterial activity.  
  
B. cereus ATCC 14579 MBC (μg/mL) 
Vegetative cells 32 
Spores > 256 
Vegetative cells suspended in 1 mM PBS and 0.01 % tween 20 16 
Spores suspended in 1 mM PBS and 0.01 % tween 20 >256 
Vegetative cells after heat treatment at 70ºC for 30 minutes 8 
Spores after heat treatment at 70ºC for 30 minutes 16 
Vegetative cells in AGFK buffer* at 37ºC for 20 min 8 
Spores after germination, achieved in AGFK buffer* at 37ºC for 20 min 16 
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6 The study of the mode of action 
No literature was found with a suitable methodology stating the intention of 
studying the mechanism of action for this type of compounds. Most of the studies 
approached these compounds strictly as surfactants, where only the surfactant 
characteristics were addressed. Furthermore, these studies assumed the observed activity 
to be solely due to their surfactant capacities and not much discussion was found on the 
subject.142,145,146,229 Some of the presented studies discussed a mechanism of action, but 
analysis was based on their capacity to de-organize the membrane, and this would be 
causing the cellular lysis observed230. 
The interaction between alkyl glycosides and biological membranes is largely 
known, and such compounds can be used, for example, as protein solubilizing 
agents231,232. Effects in biological membranes are to be expected for all surfactant 
compounds, affecting the organization and thermotropic properties of lipids but not all 
disruptive effects are associated to a negative biological impact: alkyl glycosides can act 
as permeability enhancers on human cell lines allowing improved cell recovery233. 
Since this new type of alkyl glycosides is associated with a biological activity 
profile that differs from the traditional, as described before, in order to study its mode of 
action, a logic course of methodologies was decided upon, exploring the possibility of a 
non-surfactant effect to be present. Some limitations to the experimental design were 
imposed by a lack of labelling capability for these compounds. Early experiments with 
compound G9 (Table 7) where the aliphatic chain was substituted in the terminal position, 
a complete loss of bioactivity was observed, a result in agreement with the literature211. 
The first approach taken was aimed at better understand the type of antimicrobial 
activity, as well as characterize it, employing a time-kill assay. At the same time, with 
this study we attempted to establish a suitable methodology for comparing the bioactivity 
of potential candidates to lead compounds, where standard susceptibility assays do not 
provide the necessary sensibility. 
Finally, a multiphasic approach was used in an attempt to unravel the mechanism 
of action for these compounds, while trying to go beyond the traditional assumption that 
the biological activity is only due to the surfactant capacity, since the observed microbial 
specificity at specie-level does not correlate to the bibliography data on other alkyl 
glycosides, as discussed before. With the consideration that a species-selective biological 
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activity could become important for drug development in the future40, understanding the 
mechanisms behind the bioactivity profile is important. 
 
6.1 Establishing the mechanism of action  
The first objective of this study was to verify the type of the antibacterial activity 
observed and determine a set of parameters to allow the selection of the best lead 
compound, in the presence of several structures leading to the same MIC and MBC 
profiles. To achieve this, a time-kill assay methodology was decided upon, since the 
information on the kinetic parameters obtained through this type of assay could be a 
strategy to differentiate very similar compounds. 
6.1.1 Bactericidal or bacteriostatic action? 
In order to evaluate the antimicrobial effectiveness of any lead compounds, a time-
kill assay was performed. Cell concentrations (106, 107 and 108 CFU / mL) of the 
reference strain Bacillus cereus ATCC 14579 were exposed to a range of concentration 
of the desired compounds for determination of time exposure on the number of colony 
forming units (CFU). The tests were made for each concentration at 35 °C in microplate 
(liquid medium) in 2 biological and 6 technical replicates. Tests were performed with a 
temporal resolution of 10 min during the initial 6h of incubation followed by an endpoint 
reading after 11h of incubation. 
 This method was firstly applied to compound 1, the lead chosen from past studies 
as referred before. For this reason and for being readily available, it was the compound 
selected for all the mechanist studies, allowing a better integration of results, considered 
to be a representative of this new family of compounds. The most relevant measurement 
of antibacterial action kinetics is the T99.9, which is the time necessary for a certain 
compound to achieve a 99,9% reduction in the bacterial population, a measurement of the 
cellular impact of a compound widely used in research234. 
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Figure 9. Graphical representation of the variation in B. cereus ATCC 14579 bacterial vitality with time 
of exposure to the action of compound 1 (starting inoculum: A – 106 CFU/mL; B - 108 CFU/mL) 
 
Compound 1 showed a very fast kinetic of bacterial death for the concentration 
above the MIC, [32 µg/mL], achieving T99.9<10 min. (the smallest time interval allowed 
by the experimental procedure) (Figure 9). This denotes a highly efficient bactericidal 
action for this compound, since no viable CFUs could be detected after this very short 
time of exposure, while if it was a bacteriostatic effect number of CFUs would remain the 
same after exposure. 
The efficacy of this bacterial action is remarkable, once even testing a 100X higher 
concentration of initial cells than standard conditions resulted in a T99.9 value of  < 40 
minutes. 
6.1.2 Comparison of bactericidal efficiency 
The time-kill assay allowed to establish the kinetic parameters of bactericidal 
activity, so, a comparison assay was performed between compound 1 and a second 
compound with a similar nature, that exhibited a lower toxicity profile (compound 18), 
which made this compound a suitable lead candidate. The tables below contain the 
bacterial death kinetic data obtained for both compounds 1 and 18. As an example of the 
bacterial time kill curves obtained, figure 10 shows the time kill curves for the standard 
initial bacterial concentration (106 CFU / mL). 
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Table 12. Study on the bacterial death kinetics for B. cereus ATCC 14579 in the presence of 
compounds 1 and 18 (16 µg/mL) 
[CFU/ml]ini Compound 
T99.9 
(min) 
ΔLog 
(CFU/h) 
ΔLog 
(CFU/24h) 
MBC 
(µg/mL) 
106 
1 <10 6 6 16 
18 >24h 0.5 0 32 
107 
1 180 2 7 16 
18 >24h 0.5 0 32 
108 
1 40 4 4 32 
18 >24h 0 0 32 
 
Table 13. Study on the bacterial death kinetics for B. cereus ATCC 14579 in the presence of 
compounds 1 and 18 (32 µg/mL) 
[CFU/ml]ini Compound 
T99.9 
(min) 
ΔLog  
(CFU/h) 
ΔLog  
(CFU/24h) 
MBC 
(µg/mL) 
106 
1 <10 6 6 16 
18 90 1 6 32 
107 
1 <10 7 7 16 
18 90 2 7 32 
108 
1 10 8 8 32 
18 90 1 8 32 
 
 
Figure 10. Graphical representation of the variation in B. cereus ATCC 14579 bacterial vitality with time 
of exposure to the action of compound 18. 
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Compound 1 had been showed to be more effective bactericidal than compound 
18, presenting lower T99.9 values, either at MIC or supra-MIC concentrations. 
Regardless, both compounds demonstrate the same break-point behavior in the time-kill 
assays, meaning that at the concentrations that the compound is active, we can observe a 
complete cellular death, otherwise the presence of the compound does not have an effect 
in bacterial growth. This could be indicative of similar mechanisms of action. 
6.1.3 Bacterial viability  
In order to verify and further characterize the bactericidal nature of the bioactivity 
displayed by compound 1, a viability assay was devised using flow cytometry, where a 
single-cell resolution was achieved by hydrodynamic focusing. Cellular viability was 
determined by using the DNA intercalating agent SYTOX green235, which can only be 
incorporated in the bacterial cells once the membrane integrity is compromised. In this 
way there is a direct correlation between the fluorescence intensity and cellular leakage, 
as a marker of cellular viability, or the lack thereof. The results obtained are shown in 
figure 11 and table 14. 
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 B. cereus ATCC-14579               B. cereus ATCC-14579 with compound 1 
 
Figure 11. Impact of compound 1 (256 mg/L) in the cell morphology and viability of B.cereus ATCC-
14579. FSC - Forward Scatter Channel. FL1 – Fluorencence Level Channel 1. Logaritmic scale 
(calibration: 1um = 10 FSC Units; 3um = 30 FSC Units). Calibration performed with solution of SYTOX 
in growth media; 
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Table 14. Parametric evaluation by flux cytometry of compound 1 impact in the physiology 
(FSC) and cellular viability (FL1-SYTOX) of B. cereus ATCC-14579 
FSC: Foward Scatter Channel; CV = Covariance; GM = Geometric Mean 
 
The analysis of cellular viability comes from SYTOX fluorescence (channel FL1 
– 536/40nm) allowing the identification of the sub-populations considered as viable cells, 
shown in gate RN3 (1 – 22 FL1 Units), and as non-viable cells, show in gate RN4 (25 – 
160 FL1 Units).  
Firstly, the average size of the particles analyzed in the exponential growth B. 
cereus sample, without the presence of compound, was of 2.1 µm (geometric average: 
21.42 FSC units  CV = 41.2%), an expected size for this bacterial specie, while in the 
presence of compound there is a non-normal distribution of particles with much lower 
size, probably resulting from cellular debris, causing the low-intensity fluorescence 
observed in FL1-RN1, as well as possibly micellar or vesicular ultrastructures formed by 
compound 1. 
The analysis of the particle size (FSC) versus cellular viability (FL1 -SYTOX) 
has revealed the almost total absence of cells when submitted to the compounds action, 
leaving only a small refractory population (R1 (1,87%), that could be constituted by death 
cells that retained their features or cells in lysis process. This data supports the 
microscopic observations, confirming the bactericidal effect and consequent complete 
bacterial cell lysis, not allowing any further visualization. 
 
Sample 
FSC 
geometric 
mean 
(FSC; CV) 
RN3 Viable 
subpopulation 
(GM; CV) 
RN4 Non-viable 
subpopulation 
(GM; CV) 
RN1 sub-
cellular 
events 
(GM; CV) 
Number of 
events 
analyzed 
B. cereus  
ATCC 14579 
21.42; 
41.2% 
80.5%  
(5.76; 68.05%) 
16.47%  
(4.35; 45.69%) 
- 1.6X106 
B. cereus  
ATCC 14579 
+ compound 1 
6.86; 
130.34% 
1.87%  
(5.59; 71.5%) 
0.12%  
(38.11; 36.37%) 
98.01% 
(0.26; 
52.72%) 
5.5X106 
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6.1.4 Bacterial vitality of a refractory population 
6.1.4.1 Defining cellular vitality 
Although the definition of cellular viability is generally well defined as the ability 
of a cell to grow and multiply236, the definition of cellular vitality less well defined. 
Nonetheless, vitality is regularly associated to cellular fitness or metabolic activity236,237.  
So, for the purposes of this work, cellular viability will be considered de capacity 
of a cell to grow and multiply and can be determined by assays that assess cellular 
integrity, since if this characteristic is lost it is impossible for these cells to regain 
viability. Vitality on the other and will be considered as an indicator of cellular metabolic 
activity, and so, determined by metabolic markers. 
6.1.4.2 How alive is a refractory population? 
The observation of a refractory cellular population by flux cytometry, after the 
action of compound 1, raised the question if it consisted of dead bacterial cells that simply 
retained their bacterial structure or if it is indeed a population of cells putatively resistant 
to compound 1. Hence, a better understand of the impact of this compound in bacterial 
vitality at the single cell level, in real time and independent of their cellular integrity is 
needed. 
With this objective, an in-situ real-time fluorescence microscopy approach was 
employed, where Bacillus subtillis 3A40 was used since it expresses GFP (Green 
Fluorescent Protein) and this expression is controlled thru a promotor inducible by IPTG 
(Isopropyl β-D-1-thiogalactopyranoside) in a constitutive manner. This way, the protein 
expression is independent of external factors, constant and an indicator of active 
metabolic processes and cellular fitness. With this approach, the visualization of GFP 
fluorescence should provide a reliable and prompt measurement of cellular vitality at 
single cell level in real-time. 
Another determining factor to the success of this approach, in order to obtain the 
single-cell real-time sensitivity, is cellular immobilization, and to that end, several 
methodologies were tested, namely: immobilization in agar matrix and chemical 
immobilization. 
Relating to the latter, immobilization with polydopamine238 and 
polyethylenimine239 were tested, but it was observed that both these systems 
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compromised bacterial integrity or, at least, altered their susceptibility and, for this 
reason, they could not be used. 
Regarding the immobilization in agar matrix, it was used a low melting agar and 
whether by immobilizing the bacteria in an agar matrix240,241 and then expose them to 
compound 1 or by previous integration of the compound in the matrix and further 
inoculation of the matrix, this alkyl 2-deoxy glycoside has demonstrated some issues in 
exhibiting its bactericidal action in this environment.  
Efforts to optimize such methodologies to the compounds action proved 
unsuccessful, and so, observation of the compounds’ action without the presence of an 
immobilization device was performed. These results remained diverse from the expected, 
so, it was postulated that being in a microscope preparation fundamentally changed the 
compound’s bactericidal capacity. Such effects could be due to a necessary 
“surface:solution” ratio in order to fully express their biological activities. This could be 
indicative of a necessity of this type of compounds to create ultrastructures and, these are, 
at least, partially responsible for the bioactivity observed.  
Given the inability to observe the in loco action of the compound in real time, a 
bacterial culture was submitted to the action of compound and hourly samples 
microscopically observed, resulting in a reproducible and consistent methodology. Even 
if real-time observation could be achieved, the approach taken produced the proposed 
results. Examples of the images obtained are shown below. 
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Figure 12. Images obtained from different temporal points, in 3 experimental 
conditions: a) bacterial culture b) Bacterial culture with DMSO 6% c) bacterial 
culture with compound 1 [256 µg/mL] 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
These images show a clear loss of cellular vitality over time, with exposure times 
over 2 hours showing GFP expressing cells only survive in clusters (detailed image in 
Annex 5). For a better statistical analysis of the data obtained, automated total cell count 
and GFP expressing cell count was performed and the results are presented in table 15 
and in the graphic below (Figure 13). 
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Table 15. Impact of compound 1 in cellular vitality, observed by GFP fluorescence. 
Time (h) 
Control Compound 1 
Total cells* 
Metabolically 
active cells** 
Vitality 
rate 
Total cells 
Metabolically 
active cells 
Vitality 
rate 
0 196 ±43,8 189 ± 39,3 96,4% 397 ±139,7 372 ±124,2 93,7% 
1 292 ±53,9 277 ±53,6 94,9% 328 ±65,4 292 ±54,1 89,0% 
2 147 ±51,7 127 ±44,4 86,4% 91 ±36,5 60 ±28,3 65,9% 
3 387 ±138,3 358 ±113,4 92,5% 140 ±44,9 50 ±15,3 35,7% 
4 235 ±46,7 216 ±38,1 91,9% 226 ±100,2 56 ±16,7 24,8% 
5 362 ±68,1 304 ±52,8 84,0% 167 ±54,0 13 ±13,9 7,8% 
24 250 ±39,0 237 ±31,3 94,8% 97 ±33,2 1 ±1,3 1,0% 
*Median of total cell number (n=5) observed using DIC field ± Variance 
** Median of the cell number (n=5) expressing GFP (Excitation/emission = 495/517 nm) ± Variance 
 
 
Figure 13. Impact of compound 1 in cellular metabolic activity with time, as observed by fluorescence 
microscopy. Compound 1 – bacteria exposed to compound 1; Control conditions – bacteria exposed to 
similar concentration of DMSO 
 
The attempt to observe the bactericidal effect of this type of compounds in real 
time proved to be unfruitful, but, despite of that, the data obtained confirmed the type of 
effect compound 1 has on bacterial cells and the visualization of the loss of vitality over 
time was achieved. 
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6.1.5 Efficacy against antimicrobial-resistant mutants 
When two substances have similar or related modes of action, the emergence of 
resistance to one of them will lead to a reduction of susceptibility to the other. This is 
known as cross-resistance, and it allowed the search for an association between the 
mechanisms of action of the main antibiotic families and the mode of action of compound 
1. Positive or negative variations of susceptibility to this compound would provide 
important guidelines in the search of the molecular target of its bactericidal action. 
Thus, a set of spontaneous mutants from B. cereus ATCC 14579 bacterial strain 
were created by subjecting the parental strain to increasing concentrations of chosen 
antibiotics for about 15 days or, until a minimum increase in MIC values of 10 times was 
observed, using a daily serial passaging methodology with gradient plates (Table 16). 
The same procedure was applied with compound 1, to assess the capacity for the 
B. cereus strain to acquire resistance by natural mutagenesis. After 15 days of serial 
passaging in gradient plates supplemented with the compound, no significant resistance 
was observed, with MIC values remaining the same by the end of the experiment. This 
result represents a major advantage of alkyl deoxy glycosides, since after the same time 
of exposure in the same experimental conditions, it was possible to obtain resistant 
mutants to all the antibiotic classes but not our compound. 
The bacterial resistant strains susceptibility to compound 1 was then determined, 
and the results obtained are presented in the following table: 
 
Table 16. Susceptibility of resistant strains. 
 Compound 1 
Antibiotic Resistant Mutant 
MIC 
(µg/mL) 
MBC 
(µg/mL) 
Erythromycin      (20 µg/mL)* 16 16 
Penicillin             (20 µg/mL)* 16 16 
Vancomycin        (5 µg/mL)* 16 16 
Ciprofloxacin      (50 µg/mL)* 16 16 
Tetracycline        (50 µg/mL)* 16 16 
* () final MIC values of the resistant mutants obtained 
The values of MIC and MBC obtained were equal to the values determined for the 
standard strain showing that there is no correlation between the mechanism of action of 
these drugs (and the classes they represent) and the mode of action of the compound 1. 
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6.1.6 Main metabolic pathways affected by alkyl deoxy glycosides 
In order to obtain a number of possible directions regarding possible molecular 
targets while also considering the possibility of a general surfactant effect, an experiment 
was designed based in the differential analysis of a phenotypic microarray assay, focused 
mainly in different carbon sources available to B. cereus ATCC 14579 bacteria. 
To assess the phenotypic cellular response to the presence of the compound in 
study, the "Phenotype Biolog® microarray" technology, was adapted to evaluate the 
impact of compound 1 in the metabolism of 95 different carbon sources. The 95 different 
carbon sources selected to the assay were the ones designed as PM1 according to the 
Biolog technology (Annex 6). Four replicates of this plate were used and after the 
assembly of the used media according to the manufacturer’s instructions242, the media of 
each plate was supplemented with increasing concentrations of compound 1, namely 0 
μg/mL, 4 μg/mL, 8 μg/mL and finally 16 μg/mL, the MIC value obtained. Thus, this 
system allowed not only to observe the effect of the compound in the metabolism, but 
also if the effect occurred in a concentration-dependent manner. 
The evaluation of the bacterial metabolic fitness was assessed by NADH reduction 
via a dye mixture supplied by the manufacturer, that function as tetrazolium dye, 
meaning, an indirect measure of cellular capacity to oxidise NADH to NAD+, causing a 
reduction of the dye resulting in the emergence of coloration in solution243. 
This coloration was measured by OD590, in a microplate reader, hourly, and the 
results obtained were treated and plotted in order to better visualize the impact of 
compound 1 (Annex 7). 
For each different carbon source, we observe the differential response to the 
compound 1, and so, in order to understand what carbon sources were significant to the 
bioactivity, analysis of the data obtained was performed as described in the methodology 
section, and the results were classified according to 5 categories: 1) highly inhibitory 
effect (above 5σ diminution in OD values), 2) inhibitory effect (under 5σ but above 2σ 
diminution in OD values), 3) no effect (under 2σ variation from the OD values of the 
control condition), 4) growth potentiation effect (with a rise of more than 2σ in OD 
values), and finally 5) no growth condition, when the OD values for the control condition 
and all the concentrations were similar to the no inoculation condition. It was this no 
inoculation condition, where the OD variations resulted solely from abiotic reduction of 
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the dye, that allowed for the normalization of the values, and the definition of the cut-off 
σ values, since it provided a cross-experiment stable control and so using these standard 
variation values (2σ and 5σ) would provide suitable confidence intervals. 
After this classification, the carbon sources associated to inhibitory effects 1) and 
2) were associated with the respective metabolic models and information processing 
systems, known for the model strain used (B. cereus ATCC 14579) and available in the 
database "Kyoto Encyclopedia of Genes and Genomes" (KEGG). A simple rating system 
was used, where the metabolic pathways were ordered according to the number of 
associated carbon sources that produced an inhibitory response. 
 Using this database, we determined the metabolic pathways and other systems 
with a measured response associated with the action of compound 1 (Table 17), revealing 
as the most promising molecular target candidates the environmental information 
processing systems (ABC and phosphotransferase transport systems) and the metabolic 
pathways of starch and sucrose. 
 
Table 17. Main cellular systems associated to the results obtained by deferential phenotypic 
microarray data analysis 
Metabolic pathway Number of compounds associated 
ABC transporters 13 
Starch and sucrose metabolism 7 
Phosphotransferase system (PTS) 7 
Aminoacyl-tRNA biosynthesis 6 
Methane metabolism 5 
Two-component system 5 
Pyruvate metabolism 4 
 
These results provided a general and integrated idea of what cellular targets could 
be disrupted and form a theory for the mechanism of action, and since most of the systems 
referred are an initial step in the intake of nutrients and information from the environment, 
a disruption of these systems could lead to impairment of all the metabolic pathways 
dependent on them, leading to cellular death. 
Also, for each different carbon source, we observed a differential response to the 
compound 1: for the same concentrations of compound, depending on the carbon source, 
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we can observe total inhibition of bacterial growth, no effect at all or even potentiation of 
growth at subinhibitory concentrations of this type of compounds. Such responses have 
provided more meaning to the search of a molecular target, since if a simple surfactant 
effect was present, changes to the potency of this unspecific effect could be expected but 
not the complete inactivity of the compound. This diversification of the results also 
suggests that this compound acts on a main cellular system that may or may not be 
activated depending on the environment. 
In order to understand the hierarchical relationship between the aforementioned 
pathways as well as the existence of cellular, molecular or metabolic global connections, 
the data obtained was treated and a reconstruction model of the molecular pathways 
(metabolic and others), designed based on the determination of non-parametric 
association between the consumption of the various carbon sources previously analyzed. 
Metabolic reconstruction was performed through the application of graph theory with 
hierarchical superimposition of nonparametric coefficients determined previously. With 
this methodology, an extensive map was obtained (Annex 8) that represents the 
association between the impact of compound 1 and several molecular pathways, as well 
as, associations between them and other cellular structures. 
It was observed the convergence of the hierarchical routes obtained to a main node 
classified as ABC transporters systems, also surrounded by other secondary hubs (PTS 
systems and amino acyl t-RNA biosynthesis for example), but that are in accordance to 
the data presented before. Cellular transporters as well as most of the other possible 
targets are described by the used model and by literature as present in the bacterial 
cytoplasmic membrane, suggesting that compound 1 primary targets are one or more 
constituents of the cell membrane. Inactivation of these primary targets may lead to 
malfunction or inactivation of various metabolic pathways, resulting in the cascade of 
effects observed and ultimately in cell death. However, we must also consider that the 
observed effects could be the result from a non-specific interaction with the cytoplasmic 
membrane, which results in a similar cascade reaction, even if it does not explain all the 
characteristics observed for this alkyl glycoside bactericidal action. 
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6.1.7 Investigating the mode of action by genetic dissection  
Genetic studies are an essential tool in the discovery of a mechanism of action and 
allow the definitive confirmation of any specific molecular target. The development of 
mutants resistant to the molecules in study is one of the strongest proofs that their 
biological activity is dependent of the modified molecular targets244. Once the modified 
genes are determined, which translates to a modification in the potential molecular target, 
several new studies can be performed. The overexpression or modification of that target 
allows the complete understanding of the interaction of the small molecule with the target, 
thus permitting the rational design and optimization of said small molecules. 
With this in mind, a genetic approach was decided upon. Since the results from 
the differential metabolomic study provided various possible targets and reconstruction 
model indicated a number of different hubs affected by the presence of compound 1, a 
mutant library by random transposition was created, introducing multiple modifications 
across the entire genome, as an attempt to discover possible genetic modifications that 
can lead to the emergence of resistance or diminishing susceptibility to the small 
molecules in study. 
Also, since the cellular transport systems (ABC and PTS) were the main targets 
obtained from the approaches described earlier, a specific knockout mutant library with 
selective inactivation of these various transporter system proteins was obtained, in order 
to clearly establish the relevance of these systems to the bactericidal action observed. 
For the creation of a mutant library by random transposition, we used the reference 
strain B. cereus ATCC 14579 and the plasmid pLVT1, carrying the transposon Tn917. 
Upon electroporation and mutant selection, 2 mutant libraries were obtained with a 
significant number of mutants, of about 9.8x108 total mutant cells, amounting to 106 
mutants per ORF and representing a transposon mutagenesis yield of 98%. 
Regarding the specific knockout mutant library, firstly, a study on the conserved 
genome and proteome of the selected Bacillus species was carried out, aiming to identify 
which proteins were associated to the transport systems that were the most relevant targets 
from the metabolomic study. From these proteins, a list of specific mutants was selected, 
both from ABC transporter and PTS systems, and the knockout mutant library was 
obtained, with the parent strain Bacillus subtilis 168. The susceptibility of all the mutant 
libraries was evaluated, and the results are presented in the table 18.  
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Table 18. Obtained mutants and susceptibility to compound 1. 
Strain / Library Description 
MIC 
(µg/mL) 
MBC 
(µg/mL) 
Bacillus cereus ATCC 
14579 
Parental isogenic strain 16 32 
Mutant Library 1 
Mutant library generated by random 
transposition using pLTV1 system 
16 16 
Mutant Library 2 
Mutant library generated by random 
transposition using pLTV1 system 
8 8 
Bacillus subtilis 168 Parental isogenic strain 16 32 
Bacillus subtilis ΔygaD 
Putative ABC transporter (ATP-binding 
protein) 
16 16 
Bacillus subtilis ΔyjdD 
PTS mannose-specific enzyme IIBCA 
component 
16 16 
Bacillus subtilis ΔyhcJ 
Putative ABC transporter (binding 
lipoprotein) 
16 16 
Bacillus subtilis ΔyhaQ 
Na+-efflux ABC transporter (ATP-
bindingprotein) 
16 16 
Bacillus subtilis ΔykfD 
Putative cell wall oligopeptide ABC 
transporter(ATP binding protein) 
16 16 
Bacillus subtilis ΔykoD 
Thiamine-related ABC transport system 
ATP-binding protein, thi-box regilon 
16 16 
Bacillus subtilis ΔywhQ 
ABC transport system ATP-binding 
protein, subtilosin production 
16 32 
Bacillus subtilis ΔyknU 
Putative ABC transporter (ATP-binding 
protein) 
16 32 
Bacillus subtilis ΔykpA 
Fructose-1-phosphate kinase(similar to 
ABC transport system ATP-binding 
protein) 
16 32 
Bacillus subtilis ΔyheH 
Multidrug ABC transporter (ATP-binding 
protein), involved in the signalling 
pathway that activates KinA during 
sporulation initiation 
16 32 
Bacillus subtilis ΔyvcC Multidrug ABC transporter 16 32 
Bacillus subtilis ΔywbA 
Putative phosphotransferase system 
enzyme IIC permease component 
16 32 
Bacillus subtilis ΔyxdM 
ABC transporter (permease); efflux of 
cationicpeptides 
16 32 
Bacillus subtilis ΔyybL Putative integral inner membrane protein 16 32 
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Bacillus subtilis ΔybbF 
Putative sugar phosphotransferase 
enzyme II 
16 16 
Bacillus subtilis ΔmtlA 
Phosphotransferase system (PTS) 
mannitol-specific enzyme IICB 
component 
16 32 
Bacillus subtilis ΔexpZ 
ABC transport system ATP-binding 
protein, export of virginiamycin M and 
lincomycin 
16 32 
Bacillus subtilis ΔydhO 
PTS oligo-beta-mannoside-specific 
enzyme IIC component 
16 32 
Bacillus subtilis ΔyfmR 
Putative ABC protein involved in RecA-
independent precise excision of 
transposons 
16 16 
Bacillus subtilis ΔtreP 
Phosphotransferase system (PTS) 
trehalose-specific enzyme IIBC 
component 
16 16 
Bacillus subtilis ΔyfiB ABC transporter ATP-binding protein 32 32 
Bacillus subtilis ΔyfiM Putative ABC transporter (permease) 16 16 
Bacillus subtilis ΔyflF 
PTS N-acetylglucosamine-specific 
enzyme IICB component 
16 32 
Bacillus subtilis ΔyfiC 
Putative ABC transporter (ATP-binding 
protein) 
16 16 
Bacillus subtilis ΔyfiN putative ABC transporter (permease) 16 32 
Bacillus subtilis ΔybdB 
Exporter of cell killing factor, ABC 
transport system permease protein, the 
mutation exhibited highly 
oligosporogenous phenotypes 
16 32 
Bacillus subtilis ΔybdA 
Exporter of cell killing factor, ABC 
transport system ATP-binding protein, the 
mutation exhibited highly 
oligosporogenous phenotypes 
16 32 
The MIC and MBC values obtained lack of biologically significant difference (a 
difference in values >log2) when compared to the parent strains, or the general biological 
activity observed for Bacillus species. These results are indicative of the absence of a 
specific molecular target for the mechanism of action, or at least one that is not essential, 
since these methods cannot evaluate essential targets, once mutations in them do not 
produce viable mutants.  
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6.1.7.1 The impact of ATP-dependent systems 
The genetic study previously described showed no correlation between the 
bioactivity of compound 1 and any non-essential molecular targets, including from the 
main clusters resulting from the metabolic correlation map obtained previously. 
Nonetheless, several other metabolic pathways were indicated as putative targets, as 
stated in section 6.1.5, as well the fact that only non-essential targets could be evaluated 
by the genetic methodology applied, and so a complementary approach was devised. 
By employing a proton motive force (PMF) inhibitor, an agent that causes the 
decoupling of proton gradient, the inactivation of all membrane ATP-dependent systems 
is caused. In order to achieve this, CCCP (carbonyl cyanide m-chlorophenyl hydrazone) 
was used, since it is well known as a PMF inhibitor as well as capable of impairing the 
ATP production in the cell, by inhibiting oxidative phosphorylation238,245. This way all 
cellular transport systems were inactivated, and their effect in the action com compound 
1 could be determined. 
So, firstly, the susceptibility of the strain B. cereus ATCC 14579 to CCCP was 
evaluated, and then, several mixtures with compound 1 were used, aiming to observe a 
synergistic or antagonistic effect. MIC values for CCCP were determined at 0,625 µg/mL, 
hence ½ MIC was used in the synergistic study (0,3 µg/mL). 
Results show that the MIC values obtained for the control condition (only 
compound 1 with a MIC of 32 µg/mL) were unaltered by be the presence of CCCP, 
showing that compound 1 effect was neither positively nor negatively affected by the 
presence of CCCP. Since no correlation was found between both compounds, this is a 
strong indication that none of the transport systems, or any other ATP dependent system, 
interfere with the antibacterial activity observed. 
Putting together all the results just presented, we concluded that in fact the 
transport systems were unlikely to be the target of the action of the compounds here 
presented, even though they represented the most promising target according to the 
metabolic assay. Not only that but, since the genetic dissection was the strongest tool for 
the determination of a possible target, or at least provide a clue to what cellular systems 
were associated to the compounds’ action, the results obtained are a strong indication that 
the mechanism of action of such compounds is devoid of a molecular target. 
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Thus, the most prominent hypothesis for the mechanism of action focuses on a 
physicochemical interaction with the cytoplasmic membrane, destabilizing it and leading 
to cell lysis, even though a suitable explanation to the selectivity observed cannot be 
achieved within this traditional point of view. 
6.1.8  Bacterial envelope and bactericidal activity 
The information obtained by the metabolic reconstruction and the aforementioned 
genetic studies suggest that most of the results obtained in the phenotypic analysis are 
associated to a single structural component: the bacterial membrane. For this reason, a 
study was devised in order to better understand if the bioactivity observed for compound 
1, and maybe more importantly the resistance to it, is influenced by other cellular 
structures or is only associated to the bacterial membrane. 
To this end, the evaluation of the importance of certain bacterial ultra-structures, 
including wall and cell membrane, was performed recurring to protoplasts and 
spheroplasts and determining their susceptibility to compound 1. By using this 
methodology, it is possible to deconstruct the bacteria, at least its most exterior layers, 
and assess the impact of said structures in the bioactivity. 
 Protoplasts and spheroplasts were produced using lysozyme to digest the cell wall 
of Gram positive and Gram-negative bacteria, exposing the respective cytoplasmic 
membrane. This way, if any hypothetical targets were present in the outermost layers, 
higher MIC values should be expected. According to the previous results this should not 
be expected, instead, since the access to the bacterial membrane is immediate, a reduction 
of MIC values to the susceptible species is expected. 
The bacterial species selected to this assay were two Gram-positive bacteria (the 
susceptible control strain B. cereus ATCC 14579 and the resistant S. aureus ATCC 
29213) and one Gram-negative (resistant strain E. coli K12). With these selected bacterial 
species, we intended to gain any insight into the mechanisms of resistance of the 
unexpectingly resistant Gram-positive S. aureus, and what causes the general Gram-
negative resistance, of which E. coli is a representative species (Table 19). 
 The results of the test carried out are shown in the following table and figure: 
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Table 19. Activity of compound 1 on E.coli, B. cereus, S. aureus, and corresponding 
spheroplasts and protoplasts, expressed in MIC, compared with the activity of a control drug 
(polymyxin B). 
Strain MIC (g/mL) Polymyxin B 
E. coli K12  256 8 
E. coli K12 spheroplasts 4 >1 
B. cereus ATCC 14579 16 128 
B. cereus ATCC 14579 protoplasts 16 16 
S. aureus ATCC 29213 256 128 
S. aureus ATCC 29213 protoplasts 256 >1 
 
 
 
Regarding Gram negative bacteria (E. coli K12 in this case), the structure 
responsible for the resistance to this family of compounds is probably the cell wall or its 
external membrane, since compound 1 is not active in the vegetative cell but to its 
spheroplasts has a MIC value of 4 μg/mL. Such observation denotes that, probably, for 
most Gram-negative bacteria the main mechanism of resistance is the inaccessibility of 
the inner membrane to this type of compounds. At the same time, this result also 
reinforces the idea that the bioactivity is due to the interaction with the cytoplasmic 
membrane. 
As for the results obtained with the Gram-positive bacteria, a conclusion that holds 
true to both the susceptible and the resistant species is that the external cell wall does not 
Figure 14. Representation and summary of the results obtained and relation with the bacterial 
ultrastructures. PE-phosphatidylethanolamine; PG-phosphatidylglycerol; CL-cardiolipin 
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influence the bioactivity of this compound since the MIC values for were the same for 
the vegetative cells and their respective protoplasts. This same observation regarding the 
S. aureus strain, shows that the resistance mechanism in this case is not the inaccessibility 
to the bacterial membrane, but possibly some of its constituents or even its composition 
that somehow inhibit the supposed surfactant action of these compounds.  
This information only adds to the strangeness of the selectivity that is present for 
these alkyl deoxy glycosides, even though a molecular target for its mechanism of action 
was not found and the predominant theory relies in a non-specific effect, probably 
associated to the bacterial membrane. One important hypothesis to take into consideration 
is the possibility of the specificity of bactericidal action being correlated to the membrane 
lipid composition (Figure 14). Although similar specificity characteristics are known, as 
mentioned in section 1.3.1.1 for daptomycin, further studies most be performed in order 
to confirm this. 
 
6.1.9 Morphologic changes of the cellular envelope by the action of 
compound 1 
Atomic Force Microscopy (AFM) is a suitable technique for precise three-dimensional 
mapping of microbial cell surfaces and the detection of very subtle changes in their 
surface morphology and structure246. This highly sensitive technique has been 
demonstrated to be a proficient tool for the assessment of the mechanism of action of 
bactericides247,248. Employing tapping mode provides nanometer-scale resolution in 
topographic imaging, while also allowing for phase imaging, that can be used to map 
compositional variations in heterogenous samples. As phase imaging is impacted by 
factors like viscoelasticity, elasticity and adhesion, it allows to observe the alteration of 
bacterial surface by action of membrane active compounds.  
Hence, such methodologies were employed as means to evaluate and observe, 
possibly in real time, the impact of compound 1 in the bacterial surface and its 
morphology, in order to confirm its impact in the bacterial membrane and bacterial cell 
damaging capabilities. 
In order to visualize the desired bacterial surfaces, two methodologies were tested, 
designated "in situ" and "ex situ"249. The technique "in situ" allows to visualize in real 
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time the cell envelope and any morphological changes caused by the presence of the 
compound, once it is performed in liquid media. 
This would be the best candidate for an assessment of the compounds action, since 
the observation in real-time would provide an unequivocal proof of the bactericidal effect. 
However, it was not possible to obtain consistent data once compound 1 was added, and 
the experiment results varied independent from all the factors verified. 
One of the main issues in “in situ” analysis is the need for a fixating agent250, in 
order to immobilize the bacteria. The fixating agents tested did not provide reproducible 
results, possibly by modifying the bacterial susceptibility or compromising the viability 
and/or vitality as well as possible interactions with the compound or its ultrastructures. 
Due to this, an "ex situ" approach provided the best results allowing a good 
comparison between the observation of bacteria exposed to the action of the compound 1 
and a control condition, of healthy cell culture. In this manner, a characterization of the 
morphological differences caused by the presence of this compound was possible, as 
shown in figure 15. 
 
 
 
 
Figure 15. Observation by AFM of bacterial morphology after exposure to compound 1 at a sub 
inhibitory concentration [8 µg/mL] (B and E) and comparison to control condition (A and D). Cellular 
lysis observed at MIC values [16 µg/mL]. 
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Bacterial suspensions were subjected to the action of the compound for 2 hours, 
then analyzed by AFM TappingTM mode. Compound 1 was tested at sub-inhibitory, at 
MIC value and super inhibitory concentrations. It was observed complete cell lysis at 
MIC concentrations and higher, without structures that resemble bacterial cells, 
predominating cell debris (C). 
At concentrations below the MIC, there are changes in the morphology of the 
bacterial surface when compared to the control, however neither the shape nor the 
morphology of the cell envelope seems to indicate loss of viability. For better observation 
of the surface, acquisitions with the dimensions 2x2 μm2 were performed (Figure 15, D 
and E). 
The phase images (right images of D and E), derive from a change in the phase of 
the vibrating tip. The information in this type of images reflects differences in surface 
stiffness/softness and adhesion to the tip. In this case, changes in the adhesion due to the 
release of cellular contents could give rise to the observed contrast at sub-inhibitory 
concentrations of compound (white arrows). These modifications are evident and most 
likely correspond to damage of the cell wall in the form of cracks and possible release of 
cytoplasmic contents. 
With these observations, it is clear that a bactericidal action is present and that 
compound 1 causes damage to the cellular envelope, even at leading to cell lysis. 
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Figure 16. Proposed bioactive sugar acceptors 
7 Carbohydrate chemistry as an important tool 
against Alzheimer’s disease 
Given all the advantages of introducing glucose moieties in bioactive molecules, 
already discussed before in section 3.2, a glycoconjugation approach was employed to 
important molecules acting as copper (II) chelators or P-gp inducers. 
7.1 Target compounds and synthetic approaches 
The primary goal is the synthesis of copper chelating molecules and their 
glycoconjugates in order to find an alternative for early AD diagnosis via blood testing, 
a technology patented and under use by Biofordrug, and at the same time develop possible 
therapeutic alternatives to the treatment and prevention of AD. Three main moieties were 
selected as potential selective copper chelating molecules with functional groups 
susceptible to glycoconjugation (Figure 16).  
 
 
 
 
 
Fluorescein hydrazide derivatives (L1), are well known for their copper chelating 
capacity and application as a fluorescent probes251,252. It is also a very interesting moiety 
regarding its selectivity towards copper, making its glucoconjugate a very attractive 
molecule with a high potential for therapeutic application. 
Compound L2 is also the scaffold for a number of derivatives developed by 
Biofordrug with copper chelating properties, but generally with low solubility in aqueous 
media. Hence, linking a sugar moiety to the chelating molecule is expected to solve this 
problem, amongst other advantages. 
Regarding compound L3, curcumin, is a very interesting compound with various 
known biological activities described, including antimicrobial and anticancer, many of 
them linked to its capacity to chelate copper and iron. This compound integrates the class 
of PAINS and has been reported to have the capacity to regulate a number of cellular 
L1 L2 L3 
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Figure 17. P-gp expression promoter molecule 
processes and modulate transport systems like P-gp. This broad range of biological effects 
is also a double-edge blade, because several interactions with other drugs are known. 
Meanwile, any uses are limited by a low bioavailability and solubility in biological media, 
so, a glucoconjugate derivative could represent very interesting solution to the problem, 
allowing its use for the desired goals. 
The transport system P-gp possibly plays a very important role in AD as discussed 
before in section 3.1.4, and so it represents an interesting therapeutic target. Even though 
the real mechanism of transport of P-gp is not completely understood, several compounds 
have been found to promote the expression of P-gp or increase its activity.39,40 Compound 
L4 (Figure 17) is one of those compounds, found to be a potent promoter of P-gp 
expression, and capable of penetrating the BBB, a necessary characteristic for 
Alzheimer’s therapeutics. 
 
 
 
 
 
 
A glucoconjugate of this compound was proposed in order to improve its poor 
solubility in water and physiological media, while at the same time promoting its 
selectivity to the BBB. 
 
  
L4 
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Scheme 11. Synthesis of fluorescein hydrazide (23) 
7.2 Explored synthetic approaches and results obtained 
Firstly, one of the main copper chelator moieties was prepared from the 
commercially available fluorescein. The desired compound was readily obtained by 
heterocyclization of fluorescein, as depicted in scheme 11: 
 
 
 
 
 
  
 
The yields obtained were similar to those given in the literature251,253 (58%) and 
compound 20 was purified by chromatography column and/or recrystallization in ethanol. 
7.2.1.1 Glucose pentaacetate as a glycosyl donor 
For the preparation of glycosylated analogues, it was necessary to synthesize the 
glycosyl donor intermediates. The first glycosyl donor synthesized was the 1,2,3,4,6-
penta-O-acetyl-α-D-glucopyranose (24), which was described as an effective donor in 
glycoconjugation to phenolic compounds116,204. The peracetylation of glucose with acetic 
anhydride in pyridine in the presence of catalytic amount of dimethylaminopyridine 
(DMAP) (Scheme 12) is a reaction with a quantitative yield. 
 
 
 
Scheme 12. Synthesis of peracetylated glucose (24) 
 
Using this donor, the conjugation to several acceptors was attempted, according 
to the reactions presented in the scheme 13: 
 
 
 
22 23 
24 
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Scheme 13. Glycoconjugation reactions using peracetylglucose as glycosyl donor. 
 
a)  
 
 
 
 
 
b)  
 
 
 
 
 
c) 
 
 
 
 
 
 
 
d)  
 
 
 
 
The aglycone chosen for the first reaction (a) is fluorescein hydrazide (23). For 
this type of reaction, since the fluorescein derivative 23 was poorly soluble in 
dichloromethane (DCM), several reaction conditions were tested, but all the yields 
obtained were very small (under 7%) or even just traces detectable by MS. 
24 23 25 
26 27 
L3 
24 
24 
28 
24 
L4 
29 
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Scheme 14. Synthesis of fluorescein hydrazide with spacer; R=CH2CH2OH (30) or R=(CH2)4CH2OH (31) 
 
Besides the solubility issue, the low yields were likely associated to the low 
nucleophilicity of the free OH groups present in the fluorescein derivative. So, in order 
to improve the likelihood of obtaining a good yield of conjugated derivative, the 
introduction of a spacer was tested, since this type of conjugation reactions are known to 
work better for non-aromatic alcohols.116 
So, the reaction depicted in scheme 14 was tested with a short C2 chain and a 
longer C5 chain: 
 
 
 
 
 
 
In both cases, the yields obtained were not good enough to proceed with the 
glycosylation, but, as expected, the longer chain spacer resulted in a better yield (23%) 
than the shorter C2 linker (10%). Attempts of optimization varying the temperature of the 
reaction to 50˚C and 80˚C produced even lower yields. 
For the second aglycone, compound 26 shown in the scheme 11 b), the same 
reaction system was attempted, expecting that once the aromatic system was smaller, and 
with higher electronic density available, it would be more nucleophilic, translating into 
better results for that same reaction system, but, either at room temperature, or when 
heated to reflux, only a trace amount of the products could be observed after mass 
analysis. 
The synthesis of curcumin glucoconjugates (Scheme 11 c) was attempted under 
the reaction conditions previously used, but products formed and detected by TLC were 
not the desired analogues, has shown by mass analysis. Modifications to the protocol 
showed that the use of BF3.OEt2 with curcumin resulted in side reactions forming 
undesirable products, so this reactional system could not be used for this compound. 
All the previous glucosyl acceptors were moieties capable of chelating copper, but 
compound L4, shown in scheme 11 d), is a P-gp inducer already studied by Biofordrug. 
Since its solubility in physiological media is very low, a conjugation with glucose would 
23 
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Scheme 15. Preparation of the glucosyl bromide 16 as an intermediate; 1) acetic 
anhydride, acetic acid, hydrobromic acid (33%)102; 2) DCM, acetic anhydride, 
hydrobromic acid (33%)260; 3) hydrobromic acid (33%)102; 4) AcBr, AcOH, MeOH 
not only improve its pharmacokinetic properties, but also provide selectivity towards the 
BBB, where it is desirable to induce the P-gp activity, as discussed before. 
The reaction was attempted using the methodology described, but once again, the 
yields obtained were very low (9%). 
7.2.1.2 Employing glucosyl bromide as a glycosyl donor 
Since the use of glucose pentaacetate as a glycosyl donor did not produce 
satisfying results, a different, more reactive donor was prepared according to scheme 13: 
 
 
 
 
 
 
Regarding the anomeric bromination, several methodologies were tested, but only 
the methodology 4 provided suitable results, as can be seen in table 20. The results 
registered are not intended to be a methodological comparison, as such disparities can be 
result of the quality of the hydrobromic acid available. 
 
Table 20.  Yields for the glucosyl bromide synthesis 
Methodology 1 2 3 4 
Yield 18% 29% 22% 100%* 
*quantitative – by TLC only one product was observed, so the crude was used in the next 
reaction steps. The other yields were obtained after purification by recrystallization. 
 
From the glycosyl halides used in the aromatic glycoconjugation, glycosyl 
bromides are by far the most commonly used, providing the best results. In the case of 
aromatic glycosylation, the reaction system represented in scheme 14 is the most used 
and provides the best yields:116 
  
24 32 
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Scheme 16. Schematic representation of the glycoconjugation of fluorescein hydrazide (23) with glucosyl 
bromide (32) 
 
 
 
 
 
 
This reaction system consists of a phase-transfer system, where a basic aqueous 
solution is added to an organic phase, ideally containing our reagents, and the presence 
of a phase transfer catalyst, like tetrabutylammonium bromide. 
Attempting this system in the reaction described above (Scheme 14) was not a 
good option, once the solubility of the fluorescein derivative is very low in DCM, so, only 
a small quantity was dissolved, and only traces of the desired product were obtained. 
 
7.2.2 Curcumin as a copper chelator and its glucoconjugates 
Curcumin is a hydrophobic polyphenol and it has been identified as the active 
principle of turmeric, the rhizome of the herb Curcuma longa, associated with a wide 
spectrum of biological and pharmacological activities. 
Chemically, curcumin is most commonly called diferuloylmethane (Figure 17), 
which exhibits keto–enol tautomerism having a predominant keto form in acidic and 
neutral solutions and stable enol form in alkaline medium.  
 
Figure 18. Chemical structure of curcumin and the tautomeric equilibrium 
7.2.2.1 Isolation of curcumin 
 For all the methodologies employed above, the “curcumin” used was not a 
purified compound, as could be observed by TLC, but probably turmeric, since 
commercially it is the most common source of curcumin. Do to the unsuccessful results 
obtained in while using this mixture, extraction and purification of curcumin was 
performed. 
32 23 25 
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 The extraction of curcumin was performed using dichloromethane or acetone as 
a solvent, where the turmeric powder was suspended, under agitation, for long periods of 
time (at least 1 hour). It was found that using acetone for the extraction provided better 
yields. After the desired time, the solvent was filtrated, evaporated, recuperated and added 
again to the turmeric powder, for at least 4 cycles. Then, curcumin was isolated from this 
crude extract by chromatographic column. The yield of extraction and purification was 
5-10%. 
7.2.2.2 Synthesis of curcumin glucosides 
For the synthesis of curcumin derivatives, most of the recent literature describes 
enzymatic or chemoenzymatic approaches254,255. Since a purely synthetic approach is 
preferred, the most widely use method, is a phase-transfer reaction system256–258, as 
described for the synthesis using compound 32 as a glycosyl donor.  
The general methodology used (Scheme 15) was similar to the one described 
above, supported by literature256, which was further modified in an attempt to optimize 
the results obtained. 
 
Scheme 17. Schematic representation of the general synthetic pathway 
 
For this system, several phase-transfer catalysts and bases can be used, and since 
the replication of the reaction conditions observed in the literature did not provide suitable 
results, several modifications were attempted. These variations are presented in table 21, 
but no pure compound yields can be presented, since no positive verification of the 
desired compounds was obtained, after the purification by chromatographic column. 
 
Table 21. Methodological variations applied to the phase-transfer system. 
Base Phase-transfer catalyst Organic solvent Temperature 
NaOH Bu4N
+Br- CH2Cl2 Rt 
KOH Bu4N
+Br- CH2Cl2 Rt 
KOH Bu4N
+Cl- CH2Cl2 Rt 
Na2CO3 Bu4N
+Br- CH2Cl2 Rt 
KOH Bu4N
+Cl- CH3Cl Rt 
KOH Bu4N
+Cl- CH2Cl2 40 ºC 
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Additionally, better yields have been reported in similar reaction systems that 
were adapted to microwave-assisted or ultrasound-assisted synthesis257,259. With this 
information, the most promising system, represented in scheme 16, was also used in a 
microwave assisted synthesis, as well as tested under ultrasound. 
 
 
Scheme 18. Reaction system submitted to microwave and ultrasound assisted synthesis. 
 
The methodologies here described were chosen based in the good yields presented 
in the literature as well as the simplicity of the reaction system and simple preparation of 
the glycosyl donor and acceptor moieties. Unfortunately, the results described in the 
literature could not be duplicated, but the several optimization steps performed allowed 
to better understand the reaction system and infer why the desired outcome could not be 
achieved.  
Firstly, an important observation is the chemical sensitivity of curcumin to this 
reaction system, a fact that it is not mentioned in the literature. Curcumin in the presence 
of base rapidly starts forming possibly degradation products, as observed by TLC, and it 
is a favored process to the glycoconjugation. Regardless, curcumin remains the 
predominant compound, and only after very long reaction times of 72 hours, curcumin 
could not be observed. Unfortunately, with such a long time of exposure to the reaction 
mixture, probably most compounds come from decomposition products. 
For this reason, increasing the temperature, and using the assisted methodologies 
should shorten the necessary reaction time, and in this way result in less decomposition 
products, but what was observed is that decomposition products became the majority 
compounds in the reaction mixture, even with the shorter reaction times of 5-10 hours. 
Another important observation is that even if possible products could be detected 
by TLC, the attempt of purification by chromatographic column revealed that only small 
quantities of compound were obtained and none of the compounds tested revealed to be 
the desired curcumin derivatives, neither mono-glucoside nor di-glucosides. 
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Scheme 20. Deacetylation of compound 29. 
7.2.3 Synthesis of glucosides of a cyclohexyl piperazine derivative 
The phase-transfer system used before was also employed for compound L4 
(Scheme 17), since this compound did not suffer from the stability issues from curcumin. 
The initial results motivated the optimization of the reactional system, resulting in the 
reaction conditions used and corresponding yields are presented in table 22. 
 
  
 
 
 
 
 
Table 22. Reactional systems and corresponding yields 
System nº Reaction system Yield 
1 Bu4N
+F-, NaOH, DCM/H2O, rt 23% 
2 Bu4N
+Br-, NaOH, DCM/H2O, rt 41% 
3 Bu4N
+Br-, K2CO3, DCM/H2O, rt 47% 
 
The desired product 29 was successfully obtained, proof of the effectiveness of 
this approach, and we proceeded with the de-acetylation of the glycoconjugate, according 
to the Zémplen procedure (Scheme 18): 
 
 
 
 
 
This reaction was quantitative, resulting in the desired glycoconjugate capable of 
being used in biological assays. 
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Scheme 19. Scheme of general synthesis of P-gp inducer 29 
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8 General Discussion 
The multidisciplinary work presented in this thesis reflects the importance of 
carbohydrate chemistry and demonstrates its usefulness in multiple branches of life 
sciences. The contribution given to the development of new antimicrobial compounds, as 
well as new diagnostic and/or therapeutic options to Alzheimer’s disease, praise the 
relevance of such chemistry as an essential tool for the improvement of biomedicine with 
subsequent impacts of social relevance. 
Hence, this work remains as a personal standpoint expressing my wish for 
increasing multidisciplinary and cooperative relationships in science. Chemistry provides 
a unique vision towards modification of available tools, by their adaptation and 
optimization to address problem-solving approaches, while benefiting greatly from 
constant feedback as a guideline for further developments. I believe this is especially true 
in the area of carbohydrate chemistry, due to its ubiquity and intrinsic relation to 
biological systems and, as such, one of the most beneficial tools for the understanding 
and tuning of said systems. 
The chemistry employed was simple and objective-focused, as an expression of 
what I take as one of the guidelines of my life: use the simplest tool you can to solve even 
the most complex problem you have. Complicated and intricate paths should be taken as 
a requirement but not as an option.  
As such, the methodologies employed in the synthesis of the antimicrobial 
compounds (Section 4.2.2) have proven to be highly efficient and produced the desired 
results, while allowing further optimization with the development of the one-pot 
methodology, leading to the products obtained in good overall yields (Section 9.1.4). As 
a result of this work, important conclusions were taken regarding the importance of some 
structural features of the alkyl glycosides family, in particular the aglycone structure. 
Furthermore, these methodologies were also used by our research group for the generation 
of a small compound library to further establish other essential features to the pursued 
antimicrobial activity (Section 8.1).  
Regarding the design and synthesis of compounds addressing AD, the initial 
methodology chosen (Section 7.2.1), using pentaacetate glucose as a glycoside donor, 
was the simplest one reported in the literature, that provided suitable yields. Unfortunately 
these results could not be translated into the type of compounds under study. Hence, a 
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more reactive donor, glucosyl bromide (Section 7.2.2), was investigated, leading to much 
better results. Nonetheless some of the target compounds were not obtained in 
quantity/purity required to progress to biological studies, especially in the case of 
curcumin derivatives. In particular the latter, despite extensive literature as proof of 
suitable methodology and extensive optimization attempts, no suitable products were 
identified. But, as an example of the suitability of the chosen methodology, the P-gp 
expression promoter (compound 32), was successfully synthesized.  
The work developed at Biofordrug constituted an innovation in the research 
performed in the company, with the first incorporation of sugar moieties leading to 
biocompatible candidates, improving the properties of previously studied molecules, and 
establishing important methodological guidelines. 
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8.1 Important structural features of alkyl glycosides 
The joint synthetic effort of several members of the research group allowed for 
the generation of a great diversity of structural analogues to the starting scaffold, 
compound 1. The study of bacterial susceptibility to this small compound library made it 
possible to establish a relationship between the different structural features and their 
impact in compounds’ antimicrobial activity, as summarized in figure 18. 
Two main structural groups were modified separately: i) the alkyl chain that 
constitutes the most lipophilic part of the molecule and which modification was the main 
focus of the presented work; ii) the sugar moiety, the most hydrophilic portion of the 
molecule. Both are essential to the amphiphilic character of the studied compounds, and 
so both will be discussed. 
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Figure 19. Visual summary of the structural diversity of compounds obtained and their corresponding 
bioactivity. Label: number of compound : MIC value; *MIC value obtained in NIRJ (Table 9); 
compounds labelled G were obtained by other group members 
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As expected from the literature analysis (Section 4.1), the aliphatic chain is one of 
the key factors to the biological activity under study, since any modifications to its single 
saturated chain or its lipidic character showed a decrease in biological activity, observed 
by comparing the bioactivity of compounds 14, 16, G9 and G10 with that of compound 
1, probably due to the need of good membrane intercalating properties. The length of the 
aliphatic chain is also a crucial factor to bioactivity, with the ideal number of carbon 
atoms being 12. By changing this number, a decrease in antibacterial activity has been 
observed, as shown when comparing compounds 6, 9 and 11 to 1, and/or the respective β 
anomers (7, 10 and 12 to 8). These results are in agreement with data given in the 
literature, as referred in section 4.1. 
Modifications to the lipophilicity of the alkyl chain were also tested. By 
comparing compounds 11 to 14 and 16 to 1, we can conclude that its decrease or increase 
leads to inactive compounds, possibly due to the modification of the intercalating 
capabilities of these alkyl glycosides, resulting in an ineffective interaction with the 
bacterial membrane. 
Finally, attempts at functionalizing the alkyl chain showed that any modification 
of the amphiphilic character leads to less active analogues (G10, comparing to 1) and the 
more drastic the modification, the less active the compound, with compound G9 
representing the extreme case of introduction of a polar group in the aliphatic chain 
terminal. 
As a result of the analysis above described, the C12 alkyl chain was deemed 
essential and optimal to the bioactivity observed and a non-functionalizable portion of the 
molecule. 
Analogues where the glycosidic bond was modified (compound 1 vs G5 or G8 
and 18 vs G18 or G20)  show that the atom linking the dodecyl chain to the sugar induces 
a decrease in biological activity in the case of the sulphur atom (C-O vs C-S bond) but 
showed no significant alteration of the MIC values when linked by a carbon atom (C-O 
vs C-C bond). 
Regarding the study of the sugar moiety, the hydrophilic portion of these 
molecular structures revealed a further potential to optimization and functionalization. 
Firstly, demonstrating the importance of the hydrophilic character and the polarity of the 
sugar moiety, when the hydroxy groups are protected by acetyl groups, all the bioactivity 
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observed is lost as observed by comparing compounds 1 and 4, 5 and 11, 18 and G2 and 
even 13 and 14 (this last is a special case to be further discussed). 
Structurally speaking, the deoxygenation pattern of such compounds was a 
cornerstone for the development of this family of glycosides, and, as such, its 
investigation was essential. 
Considering the deoxygenation at the 6-position, it was found to be essential to 
the biological activity observed, by comparing compounds G12 and G21, but also when 
the sugar moiety is a xyloside derivative, devoid of this position, a slight decrease in 
bacterial activity was observed, by comparing compound 1 with G15, but not detected 
between compounds G1 and 18, although compound 1 was shown to be more effective 
than compound 18 (Section 6.1.2). 
 The deoxygenation at the 2-position was shown not to be essential to the 
bioactivity, since compounds G4 and G14 retained some bioactivity although less than 
the corresponding 2-deoxy analogues (compounds 1 and G1). On the other hand, a 
halogen substituent in that position gives rise to compounds showing bioactivity similar 
to their non-halogenated derivatives (compound 1 vs 21 and G5). 
Regarding the remaining hydroxy groups, when comparing compound 1 and G3, 
it can be mentioned that chirality center configuration is important to the bioactivity, 
being preferential the configuration with the substituent in. equatorial position  
Comparing compounds 1 and G1 (as well as 18 and G15), we can infer that the 
D- and L- configurations do not have significant impact in the bioactivity of these alkyl 
glycosides, although the xyloside derivative shows preference for the D- configuration. 
Comparison of the bioactivity of α/β pairs provided some interesting and 
unexpected results. The MIC values of compound pairs 1 and 8, 6 and 7, 9 and 10, 11 and 
12 show that a major difference in bioactivity is present with at least a 4-fold increase in 
MIC values for the β-anomer. This is not in accordance to the literature data and 
previously described (Section 4.1), where α/β pairs showed very similar bioactivity, 
normally within a 2-fold difference. Equally interesting is the fact that when we analyse 
the xyloside derivatives (compounds 18 and 19, G15 and G16, G18 and G19), this 
difference is no longer present, and the compounds behave much more in accordance to 
the literature, showing no biologically relevant difference in bioactivity. 
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Concluding this analysis, we have established the optimal structural features to 
the antimicrobial activity of this group of compounds, with compound 1 containing all 
these essential features, while allowing the further functionalization of its position-2. 
Noteworthily, one of the structural modifications resulted in some unexpected 
unrelated biological effects. Compound 14 has shown no antimicrobial effects and, 
actually, has demonstrated an opposing effect, causing an increase in the bacterial 
population in stationary phase (Annex 4). This unexpected biological effect is not 
observed in compound 13, showing that it depends on the presence of free hydroxy groups 
and possibly on the specific amphiphilic character of this molecule. Although similar 
potentiating effects can be observed in bacterial growth under stress conditions, such 
effects are normally not so pronounced (compound 14 caused a 30% increase in bacterial 
growth) and also cause a lag phase in bacterial growth, what was not observed for this 
compound. Nonetheless, since such effects were not the focus of the present study and no 
supporting literature to such effects was found, a new and extensive research effort was 
not initiated. 
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8.2 The profile of biological activity 
From the bacterial growth curves (annex 3) obtained for all the compounds tested 
by the microdilution methodology we observed that the behavior, or bacterial response, 
demonstrated to all the biologically active compounds was of a similar profile to that 
observed for compound 1, with no noteworthy differences such as much shorter or longer 
action times, lag phases or other bacterial growth characteristics. This fact can be 
considered as a strong indicator that the mechanism of action of these compounds is the 
same or closely related. 
 Additionally, the fact that MIC and MBC values are equal or similar in all the 
compounds tested (Tables 7 to 9) indicates that the observed biological activity is 
bactericidal in nature and not bacteriostatic, or, in the case of two distinct mechanisms of 
action being present, the bactericidal action is predominant to the bacteriostatic activity. 
Also, this bactericidal action was shown to be very fast, at least for compounds tested by 
time-kill assays 1 and 18 (Section 6.1.1). This fast-acting bactericidal effect is one of the 
main goals in the development of new antimicrobial compounds, since it reduces the time 
necessary for a viable bacterial population to be exposed to the antimicrobial compound 
until its complete destruction, leaving less time to phenotypic adaptations and other 
resistance-conferring strategies. 
  While a correlation between many structural features and the antimicrobial 
activity of these compounds was demonstrated, the same correlation was not observed 
with the toxicity of studied compounds (Section 4.3.1). The cytotoxicity of all compounds 
was very similar (within a log2 variability of IC50 values), even though some structures 
showed remarkable differences in bioactivity (compound 1 compared to G8). 
Nonetheless, a tendency of C-glycosides to exhibit less toxicity without a significant 
difference in antimicrobial activity was observed. Such observations are an important 
indication that the mechanism of antibacterial activity is diverse from that of cytotoxicity. 
8.3 Alkyl glycosides, an answer to a problem? 
Several studies were performed aimed at evaluating the applicability of these 
compounds to uses granted to compounds of a similar structure (Section 5). Firstly, one 
of the most important results of such studies was the assessment of the capability of these 
compounds to counteract the pressing resistance problem (Section 5.1). Here we showed 
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that not only the mechanism of action of these compounds is unrelated to any of the main 
classes of antibiotics used, and so no cross-resistance effects are to be expected, as 
bacteria exhibiting resistance to all the denoted classes have remained susceptible to the 
action of compound 1 with no detectable variation in MIC values. More important is the 
fact that even after extensive exposure to compound 1, the bacterial culture was unable to 
acquire any measurable resistance to the action of this compound, overcoming many of 
the major hurdles in current antibiotic therapy as discussed in section 1.1. 
Since other similar compounds are applied in surface cleaning and disinfection, 
studies of similar application were performed, but with unexpectedly poor results. As 
later shown, this was probably due to their ineffectiveness against bacterial spores, 
consequence of their inability to overcome the thick spore coat. Possibly such issues could 
be overcome in a formulation with other sporicidal agents, which is probably what 
enables the application of other similar compounds to the ends above mentioned. 
8.3.1 Peculiarities of the mechanism of action 
The decision to study the mechanism of action of these compounds besides the 
expected surfactant action was promoted by a number of factors associated to the 
disparities between the available literature and what was observed for the studied 
compounds. Examples of this are the difference between the bioactivity of α and β 
anomers and the lower MIC values obtained as well as the apparent selectivity to bacteria 
of the Bacillus genus. 
After the determination and characterization of the bactericidal activity observed 
for compound 1, evaluation of its impact in bacterial viability revealed the previously 
undetected presence of a persister sub-population. Bacterial vitality studies have 
confirmed this but have also shown that the persister population resulting from the very 
fast reduction of metabolic active bacteria caused by the action of compound 1 was also 
declining with time, a very important factor to take into account, since compounds 
capable of acting in persister populations are in demand once, this population represents 
one of the major drivers of resistance (Section 1.1). 
The search for a possible metabolic target for compound 1 was initiated by a 
differential metabolomic study (Section 6.1.4) and the diversification of biological effects 
observed, dependent on different carbon sources, was a major factor considering possible 
molecular targets, since such variation of results was not expected in the case of a non-
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specific surfactant effect. The analysis of the results obtained lead to the creation of a list 
of possible targets, but, unfortunately, upon target evaluation by creation of mutant 
variants and their susceptibility, no positive target identification was achieved. 
Nonetheless, a target in common with all results obtained in the metabolic analysis 
emerged as a suitable alternative, the bacterial membrane. 
After the assessment of compound 1 activity against active and resistant bacterial 
species and their spheroplast and protoplasts we were able to show that the main factor 
leading the inactivity of such compounds to Gram-negative bacteria is the outer bacterial 
membrane (at least in the case of E. coli K12), and more importantly, that the unexpected 
specificity of this compound to Bacillus spp. was probably associated to the bacterial 
membrane composition, since the resistance observed of S. aureus ATCC 29213 
remained unaltered, with only its membrane exposed to the activity of compound 1. This 
was one of the most surprising results obtained, since no similar examples of such 
specificity exist in the literature for structurally related compounds. If such selectivity 
could be fine-tuned these compounds could be of a major therapeutic advantage for the 
reasons already explained in length in section 1.2.1.4. The activity over the bacterial 
membrane was finally verified using AFM and registering all the morphologic 
modifications associated to membrane damage induction and permeabilization, even at 
sub-inhibitory concentrations. 
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8.4 Final remarks 
The objective of the work performed was the determination or better 
understanding of the mechanism of action for the family of compounds and this was 
achieved. Our compounds demonstrated some characteristics not found in the literature 
for alkyl glycosides, namely their apparent selectivity. This phenomenon was then further 
studied by computational and fluorescence studies, trying to validate a hypothesis: the 
selectivity towards a type of lipid composition in the bacterial membrane. 
From the results obtained we could conclude that the mechanisms involved in 
these interactions were indeed most relevant in the presence of neutral lipids in the 
bacterial membrane, as were found to be the ones most prone to suffer lipid phase 
transitions when exposed to the compound in study. 
Such results could explain the ineffectiveness of these compounds regarding the 
S. aureus spp. while having notable activity against the E. coli spheroplasts, showing that 
its activity is not due to the Gram-positive/Gram-negative metabolic differences, but due 
to their physical barriers and membrane composition. 
When addressing the mechanism of action, various results point to a mechanism 
devoid of molecular target and associated to the referred interaction of a physical 
chemical nature with the cytoplasmic membrane, leading to a destabilization and 
consequently to cell lysis.  
With the high number of compounds created and tested, we were able to derive 
some structure-activity relationships for these types of compounds, granting us the 
capacity to understand the impact of further modifications in its biological activity. It was 
also observed that all the tested compounds, generally, follow the same bactericidal action 
profile, being defined as a family of compounds with the same mechanism of action. 
Furthermore, the methodologies developed have proven to be of great value and 
consisted of a relatively quick pathway to characterize and provide important insights on 
the mechanism of action of any type of compounds, since their application was totally 
devoid of any specificity to the compound, once no labeling was used nor necessary. 
These aspects constitute a great increase in the knowledge available in the 
literature, not only for these types of compounds, to which not much biological relevance 
was given until now, as well as methodologically, since the highly interdisciplinary work 
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performed showed that, with proper coordination of efforts, we could largely increase the 
amount of biologically relevant compounds with previously unknown mechanisms of 
action, since most of the methodologies applied are translatable to other fields of 
biological studies. 
To further develop the studies here presented, the focus should be the better 
understanding of the physicochemical processes that govern the interaction of these 
compounds with biological membranes, with special focus in selective lipid interaction. 
At the same time, to further explore the selectivity of these compounds, it is 
important to expand the variety of bacterial species to test the susceptibility of compound 
1. The relevance of this study is associated with the fact that lipidic composition of the 
bacterial membranes varies greatly between bacterial species. 
With this in mind, it would be of great importance the susceptibility assessment 
not only of their vegetative cells, but also of the respective spheroplasts and protoplasts, 
since it would be the most direct assessment of the compounds action on the bacterial 
membrane. 
The studies of these interactions should also be continued using model lipid 
bilayers, since their composition can be highly controlled, even if certain structures or 
organizations present in biological membranes are lacking. A similar approach by 
computational methods could also be of importance to the further understanding of this 
phenomena. 
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9 Experimental section 
9.1 Synthesis of antimicrobials 
9.1.1 General methods and materials 
Starting materials and reagents were purchased from Sigma–Aldrich, Fluka and 
Acros. Melting points were determined on an Stuart melting point SPM30 apparatus. 1H 
and 13C NMR spectra as well as additional correlation spectroscopy (COSY and HMQC) 
were obtained on a BRUKER Avance 400 (400.13 MHz for 1H and 100.62 MHz for 13C) 
apparatus for solutions in deuterated acetone (D6) or chloroform (CDCl3) (1% v/v 
Me4Si, Sigma-Aldrich), at room temperature, using tetramethylsilane as an internal 
reference. Chemical shifts are reported in δ (ppm). The values of specific rotation were 
measured in a Perkin Elmer Polarimeter 343, with a temperature stabilizer from P Selecta, 
for solutions in CH2Cl2.  
Reagents for synthetic procedures were purchased to Sigma-Aldrich and the 
reactions performed were controlled by Thin-Layer Chromatography (TLC), using 
aluminum plates with a coating of silica gel Alugram Xtra Sil G/UV F254 (Macherey-
Nagel). The detection of products in TLC was made by observation under UV light (254 
nm) (Camag) and/or by spraying the plate with a solution of sulfuric acid in pure ethanol 
10% (v/v) and heated to 120 ºC with a hot-air pistol. The verification of the neutralization 
processes was made using pH paper (Filterlab, RL911R07).  
The solutions were concentrated in a rotary evaporator (Buchi.V220) at 40 ºC 
under reduced pressure. The separation and purification of products was made by column 
chromatography, using silica gel 60 G (0.040-0.063 mm, SDS). The quantity of stationary 
phase to use was approximately 50 times the mass of the dry residue. All the solvents 
used (Carlo Erba, VWR, Panreac) were previously distilled and maintained in molecular 
sieves 4 Å. Glassware was previously dried in a stove at 100 ºC. 
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9.1.2 General procedures for glycal donor synthesis 
9.1.2.1 Glycal synthesis 
To a solution of the commercial free sugar (6 mmol) in pyridine (10 mL/g), acetic 
anhydride (2 eq./OH, 4.5 mL, 48 mmol) was slowly added and, finally, a catalytic amount 
of DMAP (ca. 20 mg). Reaction mixture was left to stir at room temperature for two 
hours. Then, the solution was diluted with dichloromethane (30 mL) and washed 3 times 
with HCl 2M and finally with brine. The organic phase was dried with anhydrous MgSO4, 
filtered and concentrated under vacuum, affording the peracetylated sugar as a colourless 
oil. This reaction provided quantitative yields of pure products, as verified by TLC and 
NMR, without further purification being necessary. 
Method 1: The resulting product was dissolved in glacial acetic acid (5 mL/g) to 
which acetic anhydride (0.9 mL, 9 mmol, 1.5 eq.) and hydrobromic acid (33%) (3 mL, 
0,018 mmol, 3 eq.) were added. Reaction mixture was kept stirring at room temperature 
protected from light and under nitrogen. After 3h, reaction mixture was diluted with 
dichloromethane and washed 3 times with saturated NaHCO3 and with brine. The organic 
phase was dried with anhydrous MgSO4, filtered and concentrated under vacuum, 
affording the corresponding glycosyl bromide as a translucent yellow oil. 
Method 2: The resulting product was dissolved in glacial acetic acid (5 mL/g) to 
which methanol (0.4 mL, 9 mmol, 1.5 eq.) and acetyl bromide (1.4 mL, 0,018 mmol, 3 
eq.) were added. Reaction mixture was kept stirring at room temperature protected from 
light and under nitrogen. After 3h, reaction mixture was diluted with dichloromethane 
and washed 3 times with saturated NaHCO3 and with brine. Organic phase was dried with 
anhydrous MgSO4, filtered and concentrated under vacuum, affording the corresponding 
glycosyl bromide as a translucent yellow oil. 
The obtained glycosyl bromide was dissolved in acetone (30 mL, 5 mL/mmol), 
sodium dihydrogen phosphate (12.8 g, 132 mmol, 22 eq.) and zinc (5.9 g, 90 mmol, 15 
eq.) were added and mechanically stirred vigorously, at room temperature. After 10 min, 
water (3 mL, 0.5 mL/mmol) was also added and kept stirring for 1h30. Reaction mixture 
was extracted with ethyl acetate, washed twice with saturated NaHCO3 and then brine. 
Organic phase was dried with anhydrous MgSO4, filtered and concentrated under 
vacuum. The resulting residue was purified with column chromatography with 
Hexane/EtOAc, affording the corresponding glycal. 
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3,4-Di-O-acetyl-1,5-anhydro-2,6-dideoxy-L-arabino-hex-1-enitol (2). 
Obtained from L-rhamnose (5.0 g, 30 mmol) as a colourless oil, in 39 % yield according 
to method 1 (2.5 g, 12 mmol) and 74 % yield according to method 2 (4.8 g, 22 mmol). Rf 
=0.31 (EtOAc/Hexane 1:5). 1H RMN (CDCl3) δ 6.43 (br d, 1H, J1,2 = 6.04 Hz, H-1), 5.33 
(m, 1H, H-3), 5.02 (dd, 1H, J3,4=6.22 Hz, J4,5=8.06 Hz, H-4), 4.77 (dd, 1H, J2,3= 2.98 Hz, 
H-2), 4.10 (quint, 1H, J4,5= J5,6=6.93 Hz, H-5), 2.08 (s, 3H, -OAc), 2.04 (s, 3H, -OAc), 
1.31 (d, 3H, H-6). 
 
9.1.3 Procedures for the glycoconjugation reaction and deprotection 
9.1.3.1 General procedure for the synthesis of L-arabino-glycosides 
A solution of the alkyl nucleophile (4,668 mmol, 2 eq.) and TPHB (86,55 mg, 
0.252 mmol, 0.11 eq.) in dry CH2Cl2 (3.0 mL) (or CH3CN for compounds 13-15) was 
added to a solution of 3,4-di-O-acetyl-6-deoxy-L-glucal (2) (500 mg, 2.334 mmol) in dry 
CH2Cl2 (3.0 mL). The mixture was stirred at room temperature for 50 min. After, CH2Cl2 
(6 mL) was added to the reaction mixture and the solution washed with a saturated 
solution of NaHCO3 (for compounds 3,9,10, basic Amberlite IRA-400 is added and the 
solution is filtered). The organic phase is dried with anhydrous MgSO4, filtered, the 
solvent evaporated and column chromatography with EtOAc/n-hexane afforded the two 
anomers of the corresponding 2,6-dideoxy glycosides as well as the Ferrier compound as 
a secondary product. 
 
Tridecyl 3,4-di-O-acetyl-2,6-dideoxy-α-L-arabino-hexopyranoside (3) 
Using the above described protocol, with tridecanol (935 mg, 4.67 mmol) as the 
nucleophile, gave 3 as a white solid (551 mg, 57%); Rf 0.56 (1:5 EtOAc/n-hexane); 
1H NMR (400 MHz, CDCl3): δ = 5.30 (ddd, 1H, H-3, J3,2eq = 5.35 Hz, J3,2ax = 11.42 
Hz, J3,4 = 9.65 Hz), 4.87 (d, 1H, H-1, J1,2ax = 2.80 Hz), 4.75 (t, 1H, H-4, J4,3 = J4,5 = 9.60 
Hz), 3.87 (dq, 1H, H-5, J5,6 = 6.26 Hz), 3.62 (dt, 1H, H-1’a, J1’a,1’b = 9.35 Hz, J1’a,2’ = 6.85 
Hz), 3.36 (dt, 1H, H-1’b, J1’b,2’ = 6.80 Hz), 2.23 (ddd, 1H, H-2eq, J2eq,3 = 5.30 Hz, J2eq,2ax 
= 12.88 Hz, J2eq,1 = 1.01 Hz), 2.07 (s, 3H, CH3CO2), 2.03 (s, 3H, CH3CO2), 1.80 (td, 1H, 
H-2ax, J2ax,2eq = J2ax,3 = 12.29 Hz, J2eq,3 = 3.37 Hz), 1.61 (br. s, 2H, H-2’), 1.38-1.23 (m, 
14H, H-3’-H-12’), 1.19 (d, 3H, H-6, J6,5 = 6.26 Hz), 0.90 (t, 3H, H-13’, J10’,9’ = 6.68 Hz) 
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ppm. 13C NMR (CDCl3) δ = 170.3 (C=O, OAc), 96.6 (C-1), 75.0 (C-4), 69.2 (C-3), 67.6 
(C-1’), 65.4 (C-5), 35.4 (C-2), 31.9, 29.7, 29.6, 29.5, 29.5, 29.4, 29.4, 26.2, 22.7 (C-2' to 
C-12'), 21.1, 20.9 (CH3, -OAc), 17.6 (C-6), 14.1 (C-13'). 
 
Dodecyl 3,4-di-O-acetyl-2,6-dideoxy-α-L-arabino-hexopyranoside (4) 
Using the above described protocol, with dodecanol (870 mg, 4.67 mmol) as the 
nucleophile, gave 4 as a white solid (552 mg, 59%); Rf 0.54 (1:5 EtOAc/n-hexane); 
1H NMR (400 MHz, CDCl3): δ = 5.21 (ddd, 1H, H-3, J3,2eq = 5.41 Hz, J3,2ax = 11.61 
Hz, J3,4 = 9.60 Hz), 4.77 (d, 1H, H-1, J1,2ax = 3.20 Hz), 4.65 (t, 1H, H-4, J4,3 = J4,5 = 9.60 
Hz), 3.78 (dq, 1H, H-5, J5,6 = 6.26 Hz), 3.53 (dt, 1H, H-1’a, J1’a,1’b = 9.58 Hz, J1’a,2’ = 6.75 
Hz), 3.28 (dt, 1H, H-1’b, J1’b,2’ = 6.65 Hz), 2.14 (ddd, 1H, H-2eq, J2eq,3 = 5.43 Hz, J2eq,2ax 
= 12.77 Hz, J2eq,1 = 1.01 Hz), 1.98 (s, 3H, CH3CO2), 1.93 (s, 3H, CH3CO2), 1.70 (ddd, 
1H, H-2ax, J2ax,2eq = 12.66 Hz, J2ax,3 = 11.78 Hz, J2eq,3 = 3.68 Hz), 1.49 (br. s, 2H, H-2’), 
1.27-1.16 (m, 14H, H-3’-H-11’), 1.10 (d, 3H, H-6, J6,5 = 6.28 Hz), 0.81 (t, 3H, H-12’, 
J10’,9’ = 6.82 Hz) ppm. 
13C NMR (CDCl3) δ = 170.3 (C=O, OAc), 96.7 (C-1), 74.5 (C-4), 
69.0 (C-3), 68.0 (C-1’), 65.5 (C-5), 35.5 (C-2), 30.6, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 
26.2, 25.9, 22.9 (C-2' to C-11'), 21.1, 20.9 (CH3, -OAc), 17.6 (C-6), 14.1 (C-12'). 
 
Decyl 3,4-di-O-acetyl-2,6-dideoxy-α-L-arabino-hexopyranoside (5) 
Using the above described protocol, with decanol (740 mg, 4,67 mmol) as the 
nucleophile, gave 5 as a white – pale yellowish solid (529 mg, 61%); 
1H NMR (400 MHz, CDCl3): δ = 4.75 (ddd, 1H, H-3, J3,2eq = 5.46 Hz, J3,2ax = 
11.50 Hz, J3,4 = 9.63 Hz), 4.85 (d, 1H, H-1, J1,2 = 3.85 Hz), 4.73 (t, 1H, H-4, J4,3 = J4,5 = 
9.60 Hz), 3.85 (dq, 1H, H-5, J5,6 = 6.30 Hz), 3.60 (dt, 1H, H-1’a, J1’a,1’b = 9.47 Hz, J1’a,2’ 
= 6.76 Hz), 3.35 (dt, 1H, H-1’b, J1’b,2’ = 6.57 Hz), 2.21 (dd, 1H, H-2eq, J2eq,3 = 5.31 Hz, 
J2eq,2ax = 12.63 Hz), 2.05 (s, 3H, CH3CO2), 2.01 (s, 3H, CH3CO2), 1.78 (td, 1H, H-2ax, 
J2ax,2eq = J2ax,3 = 12.19 Hz, J2eq,3 = 3.66 Hz), 1.57 (m, 2H, H-2’), 1.31 (m, 14H, H-3’-H-
9’), 1.17 (d, 3H, H-6, J6,5 = 6.30 Hz), 0.88 (t, 3H, H-10’, J10’,9’ = 6.69 Hz) ppm. 13C NMR 
(CDCl3) δ = 170.3 (C=O, OAc), 96.6 (C-1), 75.0 (C-4), 69.2 (C-3), 67.6 (C-1’), 65.4 (C-
5), 35.4 (C-2), 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 26.2, 22.7 (C-2' to C-9'), 21.1, 20.9 (CH3, 
-OAc), 17.6 (C-6), 14.1 (C-10'). 
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1H,1H Perfluorodecyl 3,4-di-O-acetyl-2,6-dideoxy-α-L-arabino-
hexopyranoside (13) Using the above described protocol, with 1H,1H Perfluorodecanol 
(2,33 g, 4,67 mmol) as a nucleophile, gave 13 as a white solid (838 mg, 50%); 
1H NMR (400 MHz, CDCl3): δ = 5.25 (dt, 1H, H-3, J3,2ax = 10.48 Hz, J3,2eq = 5.43 
Hz), 4.91 (d, 1H, H-1, J1,2ax = 3.28 Hz ), 4.77 (t, 1H, H-4,  J4,3 = J4,5 = 9.60 Hz,), 4.07 (q, 
1H, H-1’a, J1’a,1’b = J1’a,F2’a = J1’a,F2’b = 13.51 Hz), 3.97 (q, 1H, H-1’b, J1’b,1’a = J1’b,F2’a = 
J1’b,F2’b = 13.51 Hz), 3.85 (dq, 1H, H-5), 2.34 (dd, 1H, H-2eq, J2eq,2ax = 13.26 Hz, J2eq,3 = 
5.43 Hz), 2.07 (s, 3H, CH3CO2), 2.02 (s, 3H, CH3CO2), 1.84 (dt, 1H, H-2ax), 1.20 (d, 1H, 
H-6, J6,5 =6,32) ppm. 
 
9.1.3.2 General procedure for the deacetylation reaction 
A solution of NaOMe in MeOH (1%, 10 mL) was added to a solution of the 
acetylated sugar (1.3 mmol) in MeOH (60 mL) and the mixture was stirred at rt for 1 h. 
Neutralization with Amberlite (IR-120) was followed by filtration and evaporation of the 
solvent, and the resulting residue was submitted to purification by chromatographic 
column, eluted with 1:1 EtOAc–n-hexane affording the corresponding 2,6-dideoxy 
glycosides. 
 
Dodecyl 2,6-dideoxy-α-L-arabino-hexopyranoside (1) 
Using the above described protocol for the anomeric mixture (503 mg), gave 1 as 
a white solid (242 mg, 61%); 
1H NMR (400 MHz, CDCl3): δ = 4.83 (d, 1H, H-1, J1,2 = 3.03 Hz), 3.93 (ddd, 1H, 
H-3, J3,2eq = 5.05 Hz, J3,2ax = 11.56 Hz, J3,4 = 8.91 Hz), 3.70-3.57 (m, 2H, H-5, H-1’a), 
3.35 (dt, 1H, H-1’b, J1’b,1’a = 9.41 Hz, J1’b,2 = 6.51 Hz), 3.11 (t, 1H, H-4, J4,3 = J4,5 = 9.09 
Hz), 2.13 (dd, 1H, H-2eq, J2eq,2ax = 12.76 Hz), 1.69 (td, 1H, H-2ax, J2ax,1 = 3.66 Hz), 1.61-
1.52 (m, 2H, H-2’a, H-2’b), 1.41-1.21 (m, 20H, H-6, H-3’-H-9’), 0.89 (t, 3H, H-10’, J10’,9’ 
= 6.69 Hz) 13C NMR (100 MHz, CDCl3): δ = 97.2 (C-1), 78.1 (C-4), 69.3 (C-5), 67.4 
(C-1’, C-5), 37.9 (C-2), 31.9 (C-1’), [29.6, 29.5, 29.5, 29.4, 29.3, 26.2, 22.7] (C-3’-C-
11’), 17.7 (C-6), 14.1 (C-12’) ppm 
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Dodecyl 2,6-dideoxy-β-L-arabino-hexopyranoside (8) 
Using the above described protocol for the anomeric mixture (503 mg), gave 8 as 
a white solid (103 mg, 26%); 
1H NMR (400 MHz, CDCl3): δ = 4.49 (dd, 1H, H-1, J1,2ax = 9.60 Hz, J1,2eq = 1.77 
Hz), 3.87 (dt, 1H, H-1’a, J1’a,2’ = 6.82 Hz, J1’a,1’b = 9.35 Hz), 3.62 (ddd, 1H, H-3, ), 3.28 
(dq, 1H, H-5, J5,4 = 8.83 Hz), 3.12 (t, 1H, H-4, J4,3 = J4,5 = 8.83 Hz), 2.23 (ddd, 1H, H-
2eq, J2eq,2ax = 12.44 Hz, J2eq,3 = 4.99 Hz), 1.68-1.54 (m, 3H, H-2ax, H-2’a, H-2’b), 1.40-
1.21 (m, 21H, H-6, H-3’-H-11’), 0.88 (t, 3H, H-10’, J10’,9’ = 6.82 Hz) ppm. 
Decyl 2,6-dideoxy-α-L-arabino-hexopyranoside (11) 
Using the above described protocol for the anomeric mixture (506 mg), gave 11 
as syrup (267 mg, 68%); 
1H NMR (400 MHz, CDCl3): δ = 4.75 (d, 1H, H-1, J1,2 = 3.03 Hz), 3.84 (ddd, 1H, 
H-3, J3,2eq = 5.05 Hz, J3,2ax = 12.10 Hz, J3,4 = 9.09 Hz), 3.61-3.49 (m, 2H, H-5, H-1’a), 
3.27 (dt, 1H, H-1’b, J1’b,1’a = 9.41 Hz, J1’b,2 = 6.59 Hz), 3.03 (t, 1H, H-4, J4,3 = J4,5 = 9.09 
Hz), 2.05 (dd, 1H, H-2eq, J2eq,2ax = 12.76 Hz), 1.60 (td, 1H, H-2ax, J2ax,1 = 3.50 Hz), 1.54-
1.43 (m, 2H, H-2’a, H-2’b), 1.40-1.14 (m, 17H, H-6, H-3’-H-9’), 0.81 (t, 3H, H-10’, J10’,9’ 
= 7.04 Hz) ppm. 13C NMR (100 MHz, CDCl3): δ = 97.2 (C-1), 78.1 (C-4), 69.3 (C-5), 
67.4 (C-1’), 67.3 (C-5), 37.9 (C-2), 31.9 (C-1’), [29.6, 29.5, 29.4, 29.3, 26.2, 22.7] (C-3’-
C-9’), 17.7 (C-6), 14.1 (C-10’) ppm. α=-9,3º 
Decyl 2,6-dideoxy-β-L-arabino-hexopyranoside (12) 
Using the above described protocol for the anomeric mixture (506 mg), gave 12 
as a syrup (76 mg, 19%); 
1H NMR (400 MHz, CDCl3): δ = 4.49 (dd, 1H, H-1, J1,2ax = 9.73 Hz, J1,2eq = 1.89 
Hz), 3.87 (ddd, 1H, H-1’a, J1’a,2’ = 6.68 Hz, J1’a,1’b = 9.05 Hz), 3.66-3.57 (m, 1H, H-3), 
3.28 (dq, 1H, H-5, J5,4 = 8.83 Hz), 3.12 (t, 1H, H-4, J4,3 = J4,5 = 8.83 Hz), 2.22 (ddd, 1H, 
H-2eq, J2eq,2ax = 12.39 Hz, J2eq,3 = 4.82 Hz), 1.68-1.55 (m, 3H, H-2ax, H-2’a, H-2’b), 1.47-
1.20 (m, 17H, H-6, H-3’-H-9’), 0.89 (t, 3H, H-10’, J10’,9’ = 6.84 Hz) ppm. 13C NMR (100 
MHz, CDCl3): δ = 99.6 (C-1), 71.8 (C-4), 71.5 (C-5), 69.6 (C-1’, C-5), 39.1 (C-2), 31.9 
(C-1’), [29.6, 29.5, 29.4, 29.3, 26.0, 22.7] (C-3’-C-9’), 17.7 (C-6), 14.1 (C-10’) ppm. 
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1H,1H Perfluorodecyl 2,6-dideoxy-α-L-arabino-hexopyranoside (14) 
Using the above described protocol for the anomeric mixture (1 g), gave 14 as a 
white powder (404 mg, 45%); 
1H NMR (400 MHz, CDCl3): δ = 4.85 (d, 1H, H-1, J1,2ax = 3.54 Hz), 4.00 (q, 1H, 
H-1’a, J1’a,1’b = J1’a,F2’a = J1’a,F2’b = 13.46 Hz), 3.86 (q, 1H, H-1’b, J1’b,1’a = J1’b,F2’a = J1’b,F2’b 
= 13.46 Hz), 3.75 (ddd, 1H, H-3), 3.59 (dq, 1H, H-5, J5,4 = 9.47 Hz, J5,6 = 6.19 Hz), 2.98 
(t, 1H, H-4, J4,3 = 9.22 Hz), 2.13 (ddd, 1H, H-2eq, J2eq,1 = 1.01 Hz, J2eq,3 = 5.18 Hz), 1.62 
(ddd, 1H, H-2ax, J2ax,2eq = 13.19 Hz, J2ax,3 = 11.62 Hz), 1.23 (d, 3H, H-6, J6,5 =6,32 Hz) 
ppm. 13C NMR (100 MHz, CDCl3): δ = 98.4 (C-1), 77.2 (C-4), 68.5 (C-5), 68.1 (C-3), 
63.8 (C-1’), 37.6 (C-2), 17.8 (C-6) ppm. Pf = 73,9 - 76,4  α= - 4,1º 
 
1H,1H Perfluorodecyl 2,6-dideoxy-β-L-arabino-hexopyranoside (15) 
Using the above described protocol for the anomeric mixture (1 g), gave 15 as a 
white powder (109 mg, 12%); 
 
2-Octyldodecyl 2,6-dideoxy-α-L-arabino-hexopyranoside (16) 
Using the above described protocol for the anomeric mixture (1,2 g), gave 16 as 
syrup (518 mg, 51%); 
1H NMR (400 MHz, CDCl3): δ = 4.79 (br. s, 1H, H-1), 3.97-3.81 (m, 1H, H-3), 
3.63 (dq, 1H, H-5, J5,6 = 6.69 Hz), 3.52 (dd, 1H, H-1’a, J1’a,1’b = 8.46 Hz, J1’a,2’ = 5.32 Hz), 
3.21 (dd, 1H, H-1’b, J1’b,2’ = 5.68 Hz), 3.10 (t, 1H, H-4, J4,5 = J4,3 = 9.57 Hz), 2.12 (dd, 
1H, H-2eq, J2eq,2ax = 12.63, J2eq,3 = 4.80), 1.67 (br. t, 1H, H-2ax, J2ax,3 =12,00), 1.56-1.48 
(m, 1H, H-2’), 1.48-1.00 (m, 35H, H-6, H-3’- H-11’, H-1’’- H-8’’) 1.00-0.76 (m, 6H, H-
12’, H-8’’) ppm. 13C NMR (100 MHz, CDCl3): δ = 97.4 (C-1), 78.2 (C-4), 70.4 (C-1’), 
69.4 (C-3), 67.5 (C-5), 38.0 (C-2’), 37.9 (C-2), [31.9, 31.4, 31.3, 30.9, 30.1, 30.0, 29.7, 
29.6, 29.3, 26.9, 26.8, 26.7, 26.6] (C-3’ to C-11’ and C-1’’ to C-7’’), 17.7 (C-6), 14.1 (C-
12’, C-8’’) ppm. 
 
 
2-Octyldodecyl 2,6-dideoxy-β-L-arabino-hexopyranoside (12) 
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Using the above described protocol for the anomeric mixture (1,2 g), gave 12 as a 
syrup (186 mg, 18%); 
 
9.1.4 General procedure for one-pot methodology  
The nucleophile (4,668 mmol, 2 eq.) and a solution of TPHB (86,55 mg, 0.252 
mmol) in dry CH2Cl2 (3.0 mL) (or CH3CN for compounds 7,8) were added to a solution 
of 3,4-diacetyl-6-deoxy-glucal (500 mg, 2.334 mmol) in dry CH2Cl2 (3.0 mL). The 
mixture was stirred at room temperature for 50 min. After, CH2Cl2 (6 mL) was added to 
the reaction mixture and washed with a saturated solution of NaHCO3 (or basic Amberlite 
is added and the solution is filtered, for compounds 7,8). The solvent was evaporated, and 
the resulting residue was re-dissolved in MeOH (60 mL) and a solution of NaOMe in 
MeOH (1%, 10 mL) was added. The mixture was stirred at rt for 1 h. Neutralization with 
Amberlite (IR-120) was followed by filtration and evaporation of the solvent to give a 
residue, which was submitted to CC eluted with 1:1 EtOAc–n-hexane affording the 
corresponding 2,6-dideoxy glycosides. 
 
Tridecyl 2,6-dideoxy-α-L-arabino-hexopyranoside (6) 
Using the above described protocol, gave 6 as a white powder (378 mg, 69%); 
 
Tridecyl 2,6-dideoxy-β-L-arabino-hexopyranoside (7) 
Using the above described protocol, gave 7 as a white powder (154 mg, 23%); 
 
Dodecyl 2,6-dideoxy-α-L-arabino-hexopyranoside (1) 
Using the above described protocol, gave 1 as a white solid (497 mg, 67%); 
 
Dodecyl 2,6-dideoxy-β-L-arabino-hexopyranoside (8) 
Using the above described protocol, gave 8 as a white solid (108 mg, 14%); 
 
Undecyl 2,6-dideoxy-α-L-arabino-hexopyranoside (9) 
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Using the above described protocol, gave 9 as a white solid (418 mg, 56%); 
1H NMR (400 MHz, CDCl3): δ = 4.85 (d, 1H, H-1, J1,2 = 2.94 Hz), 3.94 (ddd, 1H, 
H-3, J3,2eq = 5.05 Hz, J3,2ax = 12.41 Hz, J3,4 = 9.19 Hz), 3.69-3.58 (m, 2H, H-5, H-1’a), 
3.37 (dt, 1H, H-1’b, J1’b,1’a = 9.21 Hz, J1’b,2 = 6.59 Hz), 3.12 (t, 1H, H-4, J4,3 = J4,5 = 9.09 
Hz), 2.14 (dd, 1H, H-2eq, J2eq,2ax = 12.76 Hz), 1.69 (td, 1H, H-2ax, J2ax,1 = 3.32 Hz), 1.60-
1.51 (m, 2H, H-2’a, H-2’b), 1.40-1.14 (m, 17H, H-6, H-3’-H-9’), 0.81 (t, 3H, H-10’, J10’,9’ 
= 7.04 Hz) ppm. 13C NMR (100 MHz, CDCl3): δ = 97.2 (C-1), 78.1 (C-4), 69.3 (C-5), 
67.4 (C-1’), 67.3 (C-5), 37.9 (C-2), 31.9 (C-1’), [29.6, 29.5, 29.4, 29.3, 26.2, 22.7] (C-3’-
C-9’), 17.7 (C-6), 14.1 (C-10’) ppm. 
 
Undecyl 2,6-dideoxy-β-L-arabino-hexopyranoside (10) 
Using the above described protocol, gave 10 as a white solid (107 mg, 15%); 
1H NMR (400 MHz, CDCl3): δ = 4.48 (d, 1H, H-1, J1,2 = 9.66 Hz), 3.87 (ddd, 1H, 
H-3, J3,2eq = 5.05 Hz, J3,2ax = 12.10 Hz, J3,4 = 9.09 Hz), 3.61-3.49 (m, 2H, H-5, H-1’a), 
3.27 (dt, 1H, H-1’b, J1’b,1’a = 9.41 Hz, J1’b,2 = 6.59 Hz), 3.03 (t, 1H, H-4, J4,3 = J4,5 = 9.09 
Hz), 2.05 (dd, 1H, H-2eq, J2eq,2ax = 12.76 Hz), 1.60 (td, 1H, H-2ax, J2ax,1 = 3.50 Hz), 1.54-
1.43 (m, 2H, H-2’a, H-2’b), 1.40-1.14 (m, 17H, H-6, H-3’-H-9’), 0.81 (t, 3H, H-10’, J10’,9’ 
= 7.04 Hz) ppm. 13C NMR (100 MHz, CDCl3): δ = 97.2 (C-1), 78.1 (C-4), 69.3 (C-5), 
67.4 (C-1’), 67.3 (C-5), 37.9 (C-2), 31.9 (C-1’), [29.6, 29.5, 29.4, 29.3, 26.2, 22.7] (C-3’-
C-9’), 17.7 (C-6), 14.1 (C-10’) ppm. 
 
Decyl 2,6-dideoxy-α-L-arabino-hexopyranoside (11) 
Using the above described protocol and 3,4-diacetyl-6-deoxy-glucal (400 mg, 
1.867 mmol), gave 11 as syrup (384 mg, 71%); 
 
Decyl 2,6-dideoxy-β-L-arabino-hexopyranoside (12) 
Using the above described protocol and 3,4-diacetyl-6-deoxy-glucal (400 mg, 
1.867 mmol), gave 12 as a syrup (79 mg, 15%); 
 
1H,1H Perfluorodecyl 2,6-dideoxy-α-L-arabino-hexopyranoside (14) 
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Using the above described protocol, gave 14 as a white powder (863 mg, 59%); 
 
1H,1H Perfluorodecyl 2,6-dideoxy-β-L-arabino-hexopyranoside (15) 
Using the above described protocol, gave 15 as a white powder (250 mg, 17%); 
 
9.1.5 General procedure for the microwave assisted glycosylation and 
one-pot deacetylation. 
A solution of nucleophile (4,668 mmol, 2 eq.) and TPHB (86,55 mg, 0.252 mmol) 
in dry CH2Cl2 (3.0 mL) were added to a solution of 3,4-diacetyl-6-deoxy-glucal (500 
mg, 2.334 mmol) in dry CH2Cl2 (3.0 mL). The mixture was stirred and irradiated with 
micro-waves (400nm) room temperature for 50 min. After, CH2Cl2 (6 mL) was added to 
the reaction mixture and washed with a saturated solution of NaHCO3 (or basic Amberlite 
is added and the solution is filtered, for compounds 14,15). The solvent was evaporated, 
and the resulting residue was re-dissolved in MeOH (60 mL) and a solution of NaOMe 
in MeOH (1%, 10 mL) was added. The mixture was stirred at rt for 1 h. Neutralization 
with Amberlite (IR-120) was followed by filtration and evaporation of the solvent to give 
a residue, which was submitted to CC eluted with 1:1 EtOAc–n-hexane affording the 
corresponding 2,6-dideoxy glycosides. 
Dodecyl 2,6-dideoxy-α-L-arabino-hexopyranoside (1) 
Using the above described protocol, gave 1 as a white solid (63% yield); 
 
Dodecyl 2,6-dideoxy-β-L-arabino-hexopyranoside (8) 
Using the above described protocol, gave 8 as a white solid (24% yield); 
 
Decyl 2,6-dideoxy-α-L-arabino-hexopyranoside (11) 
Using the above described protocol and 3,4-diacetyl-6-deoxy-glucal (200 mg, 
0.934 mmol), gave 11 as syrup (152 mg,56%); 
 
Decyl 2,6-dideoxy-β-L-arabino-hexopyranoside (12) 
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Using the above described protocol and 3,4-diacetyl-6-deoxy-glucal (200 mg, 
0.934 mmol), gave 12 as a syrup (48 mg, 18%); 
9.2 Synthesis of Alzheimer’s therapeutics 
9.2.1 General procedures for glucosyl donor synthesis 
9.2.1.1 Synthesis of D-glucose pentaacetate 
To a solution of the commercial free glucose (6 mmol) in pyridine (10 mL/g), 
acetic anhydride (2 eq./OH, 4.5 mL, 48 mmol) was slowly added and, finally, a catalytic 
amount of DMAP (ca. 20 mg). Reaction mixture was left to stir at room temperature for 
two hours. Then, the solution was diluted with dichloromethane (30 mL) and washed 3 
times with HCl 2M and finally with brine. The organic phase was dried with anhydrous 
MgSO4, filtered and concentrated under vacuum, affording the peracetylated sugar as a 
colourless oil. This reaction provided quantitative yields of pure products, as verified by 
TLC and NMR, without further purification being necessary. 
9.2.1.2 Synthesis of D-glucose bromide 
Method 1: The peracetylated glycoside was then dissolved in glacial acetic acid 
(5 mL/g) to which acetic anhydride (1.5 eq.) and hydrobromic acid (33%) (3 eq.) were 
added. Reaction mixture was kept stirring at room temperature protected from light and 
under nitrogen. After 3h, reaction mixture was diluted with dichloromethane and washed 
3 times with saturated NaHCO3 and with brine. The organic phase was dried with 
anhydrous MgSO4, filtered and concentrated under vacuum, affording the corresponding 
glycosyl bromide in low yields (Table 20) as a translucent yellow oil. Alternatively, 
modifications in the solvent mixture were performed in an attempt to optimize the results: 
Method 2: The peracetylated glycoside was dissolved in dichloromethane, and acetic 
anhydride and hydrobromic acid (33%) were added. Method 3: The peracetylated 
glycoside was dissolved in hydrobromic acid (33%).  
Method 4: The resulting product was then dissolved in glacial acetic acid (5 
mL/g) to which methanol (1.5 eq.) and acetyl bromide (3 eq.) were added. Reaction 
mixture was kept stirring at room temperature protected from light and under nitrogen. 
After 3h, reaction mixture was diluted with dichloromethane and washed 3 times with 
saturated NaHCO3 and with brine. Organic phase was dried with anhydrous MgSO4, 
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filtered and concentrated under vacuum, affording the corresponding glycosyl bromide 
as a translucent yellow oil. 
9.2.2 Procedures for the glycoconjugation reaction and deprotection 
9.2.2.1 Synthesis using D-glucose pentaacetate as a glycosyl donor 
Method 1.1: In a flask, make a solution of per-acetylated glucose (2 eq) and the 
aglycone dissolved in DCM (5 mL/g). Then add trimethylamine (1,1 eq) dissolved in 
DCM and successively boron trifluoride etherate (2,5 eq).  
Method 1.2: In a flask, make a solution of per-acetylated glucose (1,1 eq) and the 
aglycone dissolved in DCM (5 mL/g). Then add trimethylamine (0,5 eq) dissolved in 
DCM and then add also boron trifluoride etherate (2,5 eq) 
Method 1.3: In a flask, make a solution of per-acetylated glucose (5 eq) and the 
aglycone dissolved in DCM (5 mL/g). Then boron trifluoride etherate (2,5 eq) was added. 
The reaction mixture was protected from light and placed under agitation at room 
temperature. It was controlled by TLC and after completion it was added water to the 
reaction, and neutralized, and then extracted with ethyl acetate. 
9.2.2.2 Synthesis using D-glucose bromide as a glycosyl donor 
A solution of glucobromide (2 eq), the aglycone and the phase-transfer catalyst in 
DCM (10 mL/g) was protected from light and placed under agitation at room temperature. 
After, a similar volume of an aqueous solution of the desired base was added. When it is 
complete, dilute with DCM, neutralize the solution, and wash with water. The organic 
phase is then dried with CaSO4 and evaporated. After purification by chromatographic 
column (Ethyl acetate: Hexane), the corresponding glucoconjugate is obtained as a white 
solid. 
9.2.2.3 General procedure for the deacetylation reaction 
A solution of NaOMe in MeOH (1%, 10 mL) was added to a solution of the 
acetylated sugar (1.3 mmol) in MeOH (60 mL) and the mixture was stirred at rt for 1 h. 
Neutralization with Amberlite (IR-120) was followed by filtration and evaporation of the 
solvent, and the resulting residue was submitted to purification by chromatographic 
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column, eluted with 1:1 EtOAc–n-hexane affording the corresponding 2,6-dideoxy 
glycosides. 
Dissolve the acetylated sugar in methanol (100 mL/g) and place under agitation. 
Then add drop by drop a previously prepared solution of 10% NaOMe in MeOH (10 
mL/g). After the reaction is complete, neutralize the solution, and evaporate the solvent. 
For this case, the neutralization was made with HCl solution, which was 
problematic once the product was highly soluble in water. The water was evaporated, and 
the compound dissolved in ethanol, filtered and the product was then obtained pure. 
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9.3 Biological assays 
9.3.1 Bacterial Cultures 
Strains of B. cereus ATCC 11778, B. cereus ATCC 14579, B. subtilis ATCC 
6633, E. coli ATCC 8739 and S. aureus ATCC 29213 were obtained from the American 
Type Culture Collection (Rockville, MD). The bacterial cultures were maintained at 
lyophilized state or stored at -80ºC in Muller-Hinton broth (MH) supplemented with 20% 
glycerol (Sigma Aldrich). Overnight cultures of bacteria were grown in 50 mL 
Erlenmeyer flasks, with orbital shake at 200 rpm at 30 ºC. 
9.3.2 MIC and MBC determination 
MIC determination was made by a modified micro-dilution method according to 
CLSI guidelines214.  Briefly, overnight culture (17 h) of all bacterial strains were diluted 
to 0,5 McFarland units in Muller-Hinton broth. In sterile 96-well plates (Sarstedt, 
Germary), 150 μL of culture media were added and then supplemented with the 
compound in study by serial dilution. Finally, the desired wells were inoculated with 10 
μL of a 1/10 dilution of the 0,5 McFarland bacterial suspension. Microplates were 
incubated at 35 °C, with orbital shaking, taking absorbance readings is all wells at 
intervals of 10 minutes, for up to 24 h (Anthos Zenith 3100 Microplate Multimode 
Detector). The lowest concentration at which no bacterial growth was observed is 
considered the minimal inhibitory concentration. Aliquots of 5 μL from every well were 
transferred to Muller-Hinton Agar (MHA) for determination of minimum bactericidal 
concentration (MBC). Bacterial growth was assessed at 17 h, MBC was considered the 
lowest concentration of compound where no bacterial growth was observed. All 
measurements are the average of a minimum of 3 independent experiments. 
9.3.3 Cytotoxicity evaluation in Caco-2 cells 
9.3.3.1 Cell cultures  
Caco-2 cells were grown in DMEM high glucose supplemented with 10% fetal 
bovine serum, 2 mM glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin, in a 
humidified incubator at 37 °C with a 5 % CO2 atmosphere. The cells were trypsinized 
twice a week with trypsin/EDTA (0.05%/0.02%) and the medium was also changed twice 
a week. 
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9.3.3.2 Cell viability assay 
Determination of cell growth was performed using the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay. On day 1, 20,000 
cells/well were seeded into 96-well plates in a volume of 100 µL. On day 2, the different 
drugs concentration (0.1–100 µM) were added to the plate. In all the experiments, the 
various drug-solvents (EtOH, DMSO) were added in each control to evaluate a possible 
solvent cytotoxicity. After the established incubation time with drugs, MTT (0.5 mg/mL) 
was added to each well, and after 3-4 h incubation at 37 °C, the supernatant was removed. 
The formazan crystals were solubilized using 100 µL of DMSO/EtOH (1:1) and the 
absorbance values at 570 nm and 630 nm were determined on the microplate reader 
Victor3 from Perkin Elmer Life Sciences. 
9.3.4 In vitro Time-Killing curves:  
Inoculum preparation: The initial cellular concentration was standardized in MH 
by OD600nm in order to obtain 10
8, 107 and 106 cells per microplate well, as needed. 
Microplate preparation: Stock solution of compound 1 dissolved in DMSO (2.4 
µl) was serial diluted (2-0,25X MIC) in 150 µl of sterile MH. The plate inoculation is 
performed by adding 10 µl of the inoculum previously prepared. 
Time-kill assay conditions: All the microplates prepared were incubated at 35ºC, 
with orbital shaking at 200rpm, the OD readings were performed at 600 nm (Anthos 
Zenith 3100 Microplate Multimode Detector). After each OD reading, the plate is 
retrieved, and 5 µl are taken and added to a premade plate containing 95 µl of sterile 
medium followed by 7 steps of 1/10 serial dilution. 
Colony Forming Units (CFU) counting: After the serial dilution step, a 10 µl drop 
from every well is placed in MHA solid media plates. After inoculation, the plates are 
incubated for 17 h at 30ºC for later CFU counting. 
The compounds were added to an exponential phase culture of B. cereus in 
Muller-Hinton containing about 106, 107, and 108 cells/mL. Bacteria were then incubated 
at 35 ºC, and 5 μL aliquots were withdrawn at different intervals and diluted in a 
previously premade microplate. The samples were serial diluted in 1/10 of the previous 
concentration, and then, a 10 μL droplet was transferred to MHA and bacterial growth 
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was evaluated. The number of surviving bacteria, expressed as the number of colony 
forming units (CFU), were counted after an overnight incubation at 30 ºC. 
For all the experiments, sample homogeneity and methodology validation was 
performed by OD600nm, as a measure of cellular density, for all sixteen replicates. 
9.3.5 Compound 1 bioactivity against bacterial strains resistant to 
conventional antibiotics 
Resistant mutants to the major families of antibiotics were created. This was 
accomplished using a variant of the gradient plate methodology for the following 
antibiotics of diverse classes: erythromycin (macrolide), penicillin, vancomycin 
(glycopeptide), ciprofloxacin (quinolone), tetracycline (Sigma Aldrich). The plates were 
inoculated with 100 µL of 0.5 McFarland bacterial suspension of B. cereus ATCC 14579 
strain, carefully dispersed on the agar surface using spreading spheres. The plates were 
incubated at 30 ºC during 24 hours. After, the colony closest to the higher concentration 
in the gradient was collected, re-suspended and re-inoculated in new fresh gradient plates. 
This procedure was repeated for 15 days.  
9.3.6 Susceptibility of Bacillus spores to compound 1 
Production of spores from B. cereus ATCC 14579 was carried out by incubation 
at 37 ºC in sporulation medium (CCY – Bacillus Sporulation media217: 1g/L acid casein 
hydrolysate, 1 g/L  bacto casitone (pancreatic casein hydrolysate), 0.4 g/L  yeast extract, 
20 mg/L L-glutamine, 0.06% (v/v) glycerol, 1.77 g/L KH2PO4, 4.53 g/L K2HPO4, 0.5mM  
MgCl2.6H2O, 0.01mM MnCl2.4H2O, 0.05 mM ZnCl2 , 0.2 mM CaCl2.6H2O, 0.05 mM  
FeCl3.6H20.) for 96 hours. Purification of the spores was achieved by centrifugation at 4 
ºC, 15000 g and wash 10 times with Milli RO water. As preparation for the susceptibility 
assays, the spores were suspended in 1 mM PBS and 0,01 % tween 20, then submitted to 
heat treatment at 70 ºC for 30 minutes. Germination was achieved in AGFK buffer (30 
mM L-asparagine, 5,6 mM D-Glucose, 5,6 mM D-Fructose, 20 mM KCl and 50 mM Tris-
HCl, pH 8,4) at 37 ºC.  Susceptibility to compound 1 was assessed at all the preparation 
steps, 20 minutes and 2 hours after the germination process. 
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9.3.7 Differential metabolomics analysis 
The study of bacterial metabolic response to compound 1, was performed using 
Phenotype MicroArrays (Biolog). The impact of compound 1 was assessed in the 
metabolism of 95 different carbon sources by B. cereus ATCC 14579 strain. All the 
solutions used were supplied by the manufacturer. The PM solutions B-F were sterilized 
in autoclave at 121 ºC during 15 minutes, and afterwards stored at 4 ºC until use. The PM 
additive solution was prepared by mixing these solutions (10 mL of solutions B, C, E and 
F and 30 mL of solution D and water). The bacterial growth media was used according 
to instructions provided by the manufacturer. The bacterial suspension, for PM 
Inoculating Fluid, was prepared by centrifuging the overnight pre-inoculum (at 3000g, 4 
ºC for 5 minutes) collecting and resuspending the cells in IF-0a, and finally adjusting the 
bacterial suspension to 0.5 McFarland Units. 
Finally, 100 μL of the PM inoculating fluid, was added to each well of 4 PM1 
microplates (Compound 1 at the final concentrations of 16, 8, 4 and 0 μg/mL). The 
microplates were sealed with parafilm, shielded from light and incubated at 35 ºC with 
orbital shaking. The compound was added at 1 hour of incubation, in order to stabilize 
and allow bacterial cells to adapt to the new media. 
The reduction of tetrazolim violet associated to NADH produced by the 
consumption of each tested carbon source, was monitored by OD590nm at time 0’, at 30’, 
at 60’ after incubation, and then, hourly for 27 hours. (Anthos Zenith 3100 Microplate 
Multimode Detector). 
9.3.7.1 Data Analysis 
The time-dependent series for each tested carbon source was classified by the 
acquisition periods, corresponding to: 1) initial phase of response to the compound 1 
(from 0 to 5 hours of incubation); 2) late phase of response (from 16 to 27 hours of 
incubation). 
After data normalization, results were divided into five categories depending on 
the effect shown: 1) highly inhibitory effect, when the difference between the effect of 
the compound 1 and control was higher than 5σ (OD590nm>5σ); 2) inhibitory effect, when 
the difference observed was between 5σ and 2σ (5σ>OD590nm>2σ); 3) no effect, when 
bacterial growth was observed in the absence of compound (OD590nm>2σ) and the 
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difference between absence and presence of compound was less than 2σ; 4) no growth, 
when value with and without the presence of compound was less than 2σ (OD590nm<2σ); 
5) potentiation effect, when value without the compound was less than 2σ (OD590nm<2σ) 
and the difference of value between the presence and absence of compound was superior 
to σ. 
The hits classified as category 1, 2 or 5, were correlated to the biological pathways 
described at "Kyoto Encyclopedia of Genes and Genomes" (KEGG) database (33). The 
biological pathways were then ordered by the number of inhibitory hits per pathway. The 
metabolic reconstruction was performed using graph theory for hierarchical 
superimposition of the pathways based at the nonparametric Spearman’s rank association 
coefficients (edges) between hits (nodes – according to KO classification system). The 
SPSS (SPSS Statistics for Windows, SPSS Inc.) software was used for data normatization 
and determination of nonparametric association coefficients and Cytoscape (Cytoscape, 
U.S. NIGMS) for the hierarquical representation (Fig. S3). 
9.3.8 Mutant libraries 
9.3.8.1 Preparation of electro-competent cells 
B. cereus ATCC 14579 cells were grown in a Erlenmeyer flask containing tryptic 
soy broth (TSB, Difco Laboratories), and placed in an incubator at 37ºC and 200 rpm, 
until the bacterial suspension reaches a maximum OD of 0.45 – 0.46 measured at 600 nm. 
The suspension was then incubated during 1 h in 5% glycine or DL-threonine and 250 
mM sucrose at 37 °C at 200 rpm. Cells were washed five times in electroporation buffer 
(250 mM sucrose, 1 mM Hepes, 1 mM MgCl2, 10% glycerol, pH 7.0) and concentrated 
150-fold.  
9.3.8.2 Electroporation 
 Electroporation was performed at 25 μF using a Bio-Rad Gene Pulser X-cell 
apparatus (Bio-Rad laboratories, U.S.). Electroporation was carried out in 1 mm 
electroporation cuvettes, at 4ºC, with 50 μl cells combined with 500 ng of plasmid, in 
order to respect cells/DNA proportions. It was used voltage of 20kV/cm-1 with 200 ohms 
of resistance. After electroporation, cell suspensions were immediately diluted with 1 ml 
of TSB supplemented with 250 mM sucrose, 5 mM MgCl2, 5 mM MgSO4 and incubated 
for 2 h at 37 °C, 200 rpm to allow expression of antibiotic resistance markers. Aliquots 
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were spread onto tryptic soy agar (TSA, Difco Laboratories) supplemented with 
appropriate antibiotic. Transformants harbouring antibiotic resistance were counted 
following overnight incubation. 
9.3.8.3 Construction of in vivo mutant library by random insertion of 
transposon Tn917 in B. cereus ATCC 14579 
 Transposon mutagenesis was performed by obtaining a stationary-phase culture 
of modified B. cereus (pLTV1) cultured overnight at 28°C in Lysogeny broth (LB) 
containing tetracycline (50 µg/ml), erythromycin (1 µg/ml), and chloramphenicol (10 
µg/ml) (Sigma Aldrich). This culture was diluted 1:800 in prewarmed (43°C) LB broth 
that contained erythromycin (1 µg/ml) and chloramphenicol (5 µg/ml). Then, it was 
incubated at 43°C for 24 h with shaking at 200 rpm. The above procedure was repeated 
one more time. Transposon mutants were subsequently selected on LB agar containing 
erythromycin (1 µg/ml) and chloramphenicol (5 µg/ml) and incubated at 37°C, resulting 
in two libraries of 106 mutants each. 
9.3.8.4 Southern Blotting 
The validation of insertion site of Tn917 carried by plasmid pLVT1 was 
performed in the two pool of mutants. Briefly, chromosomal DNA from both B. cereus 
ATCC 14579 wild and modified strains, as well as from both generated mutant libraries, 
were isolated using the CTAB method (34). After digestion with EcoRI the DNA of the 
mutant libraries and control strains were resolved in an agarose gel 0.8 %. The DNA 
transfer proceeded overnight and hybridization was performed at 40 ºC with DNA probe 
(5.1 kb EcoRI restriction fragment of Tn917), labelled with digoxigenin-dUTP, at a 
concentration of 25 ng/mL. The membrane was revealed with NBT-BCIP. 
9.3.8.5 Transporter systems knockout mutant library 
Twenty-eight knockout mutants based in the isogenic system B. subtilis 168 on 
main ABC and PTS systems were purchased from National BioResource Project (NIG, 
Japan): Bacillus subtilis.  Table 18 identifies the individual mutants and respective MIC 
and MBC values obtained for compound 1. 
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9.3.9 Susceptibility of bacterial protoplasts and spheroplasts to 
compound 1 
In order to understand the role of the ultrastructure of cellular envelope, the 
susceptibility of Gram-negative E. coli K12 spheroplasts, Gram positive B. cereus ATCC 
14579 and S. aureus ATCC 29213 protoplasts were evaluated. Bacterial spheroplasts and 
protoplasts [LPS and peptidoglycan-free bacteria] were prepared by harvesting bacterial 
cells by centrifugation (10, 000 g during 10 minutes at 4 ºC), and washing with 10 mM 
Tris-HCl (pH 8) at 4 ºC. Cells were resuspended, supplemented with sucrose (0.6 M) at 
room temperature. Lysozyme (0.5 mg/mL) (Sigma Aldrich) was added, very slowly 
aiming to decrease the aggregation of plasts, after 30 min of incubation. The plasts (used 
at the same concentration as in the biological activity assay) were incubated with the 
desired compound and with polymixin B as a positive control, at various concentrations. 
9.3.10 Morphologic evaluation by atomic force microscopy  
Samples containing B. cereus ATCC 14579 (106 CFU/mL) in MH medium were 
incubated with compound 1 at various concentrations (0, 8 and 16 µg/mL) and after 2 
hours aliquots were taken. A drop (40 µL) containing the bacteria was deposited onto 
freshly cleaved mica surfaces for 30 minutes, gently washed with Milli-Q water and dried 
under mild nitrogen flux. The surface was examined ex-situ, at ambient temperature 
(21ºC), using Nanoscope IIIa multimode atomic force microscope (Digital Instruments, 
Veeco, Santa Barbara, CA) and etched silicon tips (TESP-V2, Bruker) with a resonance 
frequency of ca. 300 kHz. Images were acquired with scan rates between 1.2 and 1.5 Hz. 
It is worth to note that washing and drying steps, as wells as tip repetitive scanning did 
not influence the results presented in this work. 
9.3.11 Methodologies used in surface disinfection assays 
For all methodological variations, the bacterial strain in study was B. cereus 
ATCC 14579, the liquid growth media used was Muller-Hinton (MH) and the solid 
growth media was Muller-Hinton Agar (MHA). Concentrations tested for compound 1 
were 8 mg/L, 16 mg/L, 32 mg/L, 256 mg/L and 1000 mg/L. 
Method 1: according to NP1040 from OECD "Guidelines for the Testing of 
Chemicals" - "Quantitative Method for Evaluating Bactericidal Efficacy of Biocides Used 
on Hard Surfaces", a 10 μL drop of standardized bacterial suspension was placed in a 
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sterile surface and allowed to dry. After, a 15-20 μL drop of compound 1 solution in water 
(at the desired concentration) was added to the surface, in such a way that completely 
covers the inoculated surface. After the desired time period, the surface is washed with 
growth media as means of neutralizing the compound in action. The media used in the 
wash was recovered and aliquots were plated in solid growth media (MHA) and further 
incubated. Results obtained by observation at 24 hours proved to be inconsistent and of 
low reproducibility. For this reason, results presented were obtained by growth 
observation at 48 hours. 
*results defined as not determined (nd) were inconclusive results for lack of 
reproducibility. 
Method 2: A variation to the standard methodology was deemed necessary since, 
while tuning the method, it was concluded that the surface washing and sampling steps 
lead to low reproducible results. So, instead, the smaller surfaces, after the desired time 
for the action of compound 1, were submerged in liquid growth media and vortexed. 
Then, samples of this media were plated in solid growth media, and incubated for 48h.  
Method 3: Since method 2 could not be applied to all surfaces, the assessment of 
the efficacy of compound 1 was performed by direct transfer: the surfaces were placed in 
contact with solid growth media and removed after a short period of time, and the media 
was incubated for 48h.  
Method 4: As a more practical alternative to method 3, after the desired time 
period for the compounds action, a swab sampling was performed and the swab was 
placed on solid growth media and dampened with sterile media if needed for complete 
adhesion. Alternatively, the swabs were also immersed in liquid growth media. Both 
methodologies provided similar results after 48h incubation period. 
Method 5: since the obtained results were not expected, the dry, contaminated 
surfaces were completely submerged in growth media supplemented with compound 1, 
as an attempt at approximate the conditions to the ones known to be optimal for the 
compounds action. After submersion, the results were obtained by direct transfer 
methodology. 
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Annex 1. Summary of similar compounds found in the literature, as well as similar aglycones, and their biological activity in the 
most relevant microorganisms, for comparison (MIC [mM]) 
 
Structure 
S. 
aureus 
B. 
subtilis E. coli 
P. 
aeruginosa 
C. 
albicans 
S. 
cerevisiae 
A. 
Niger 
P. 
chrysogenum 
 
0,029 0,072 0,574 1,148 1,148 1,148 0,574 0,574 
 
0,072 0,143 >1,148 >1,148 0,143 0,072 0,574 0,574 
 
0,072 0,072 >1,148 >1,148 0,574 0,029 1,148 0,574 
 
0,574 0,574 >1,148 >1,148 >1,148 0,574 >1,148 >1,148 
 1,256 0,628 >1,256 >1,256 >1,256  1,256 1,256 
 
0,029 0,029 0,144 0,029 0,576 0,029 1,151 0,576 
 
0,029 0,029 0,144 0,072 1,151 0,072 1,151 0,576 
 
>1,027 >1,027 >1,027 >1,027 >1,027 >1,027 >1,027 >1,027 
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>1,027 >1,027 1,027 >1,027 >1,027 >1,027 >1,027 1,027 
 
>1,95 >1,95 >1,95 >15,6 0,243  0,1221  
 
0,111 0,111 0,888 0,888 0,222  0,222 0,222 
 
0,089 0,178 0,178 >1,42 0,355  0,3551  
 
>0,686 0,686 >0,686 >0,686 >0,686  >0,686 0,686 
 
0,312 0,312 0,624 0,624 >1,248 0,312 >1,248 >1,248 
 
0,312 0,312 0,624 0,624 0,624 0,312 1,248 1,248 
 
0,156 0,156 0,624 0,624 0,624 0,156 >1,248 1,248 
 
0,312 0,312 1,248 1,248 0,624 0,312 1,248 0,624 
 >1,377 >1,377 >1,377 >1,377 >1,377  >1,377 1,377 
 
0,313 0,313 0,626 0,157 1,252 0,313 1,252 1,252 
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0,157 0,313 0,626 0,157 1,252 0,313 >1,252 1,252 
 0,473 0,473 >0,947 >0,947 >0,947  0,947 0,947 
 
>0,721 >0,721 >0,721 >0,721 >0,721  >0,721 >0,721 
 
1,368 1,368 1,368 1,368 >1,368 >1,368 >1,368 1,368 
 
0,342 >1,368 >1,368 1,368 1,368 1,368 >1,368 1,368 
 
0,684 1,368 1,368 1,368 >1,368 >1,368 >1,368 1,368 
 >1,525 >1,525 >1,525 >1,525 >1,525  >1,525 >1,525 
 >1,014 >1,014 >1,014 >1,014 >1,014  >1,014 >1,014 
 
0,717 0,7172 0,717 0,717     
 
0,297 0,0742 0,149 0,149     
 
0,150 0,0192 0,150 0,150     
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0,274 0,1372 0,137 0,137     
 
0,780 0,7802 0,780 0,780     
 
0,318 0,1592 0,159 0,159     
 
0,322 0,1612 0,161 0,322     
 
0,292 0,1462 0,146 0,292     
 
0,277 0,277 0,014 0,028 0,553 0,138 >1,106 0,138 
 
0,138 0,138 0,069 0,028 0,277 0,138 1,106 0,138 
 
0,271    0,135    
 
0,272    0,135    
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2,490    2,490    
 
>4,6    4,6    
 
>4,3    >4,3    
 
0,112    0,112    
 0,109    0,109    
 
>4,94    >4,94    
 
>3,732 >3,732 >3,732 >3,732  >3,732 >3,732 >3,732 
 
>3,993 0,031 >3,993 >3,993  >3,993 >3,993 3,993 
 
0,067 0,067 >4,293 >4,293  >4,293 >4,293 0,067 
 
0,145 0,145 >4,643 >4,643  0,290 0,145 0,073 
 
0,316 0,316 >5,054 >5,054  0,316 0,316 0,158 
 
1,386 1,386 >5,546 >5,546  0,693 1,386 0,347 
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1 Different fungal strain: Aspergillus brasiliensis 
2 Different bacterial strain: Bacillus stearothermophilus 
 
 
 
6,143 3,072 >6,143 3,072  3,072 3,072 1,536 
 
>6,885 >6,885 >6,885 6,885  6,885 6,885 3,442 
 
>7,830 >7,830 >7,830 >7,830  >7,830 >7,830 7,830 
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Annex 2. NMR comparison of reactional mixtures and corresponding α:β ratios.  
Annex 2. A - NMR from reactional system a, in CH2Cl2 
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Annex 2. B - NMR from reactional system a, in CH3CN 
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Annex 2. C - NMR from reactional system b, in CH2Cl2 
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Annex 2. D - NMR from reactional system c, in CH3CN 
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Annex 3. Bacterial growth curves for B. cereus ATCC 14579 in the presence of compounds 
1, 4 and 8, respectively 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 148 | P a g e  
 
 
 
 
 
 
  
 149 | P a g e  
 
Annex 4. Bacterial growth curves for B. cereus ATCC 14579 in the presence of compounds 
11, 13 and 14, respectively 
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Annex 5. Images obtained from different temporal points, in 3 experimental conditions: 
a) Bacterial culture 
b) Bacterial culture with DMSO 6% 
c) Bacterial culture with compound 1 [256 µg/mL] 
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Annex 6. Carbon sources of PM1 plate used for phenotypic assay 
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Annex 7. Impact of compound 1 in the metabolism of B. cereus ATCC 14579 with diverse single carbon sources 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A1 A4 A3 A5 A2 A6 A7 A8 A9 A10 A11 A12 
B1 B2
 
B3 B4 B5 B6 B7 
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H8
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H10
 
H11
 
H12
 
C2
 
D2
 
E2
 
F2
 
G2
 
C3 
D3 
E3 
F3 
G3 
C4 
D4 
E4 
F4 
G4 
C5 C6 C7 C8 C9 
D5
 
D6 D7
 
D8 D9 
E5 E6 E7 E8 E9 
F5 F6 F7 F8 F9 F10 
G5 G6 G7 G8 G9 G10 G11
 
 
G10 
G12
V
 
F12
11
 
F11
 
 
G10 
E10 E11 E12 
D10 D11 D12 
C10 C11 C12 
B10 B11 B12 B8 B9 
Control condition   Compound 1 - 4 µg/mL   Compound 1 - 8 µg/mL   Compound 1 - 16 µg/mL 
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Annex 8. Complete metabolic reconstruction map 
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Annex 9. Comparison of sample microscopy images of GFP fluorescence in a control 
condition (top) and after 4 hours of exposure to compound 1 [256 µg/mL] (bottom) 
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Annex 10. NMR data relative to the compounds sinthesized and isolated. 
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